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1. INTRODUCTION  
1.1. Hepatitis B virus infection 
1.1.1. Epidemiology, transmission and prevention 
Epidemiology 
Hepatitis B virus (HBV) infection is one of the major public health problems affecting 
approximately two billion people worldwide. HBV infection causes a range of clinical 
manifestations that include asymptomatic carriers, acute hepatitis (AHB), chronic 
hepatitis (CHB), liver cirrhosis (LC), and hepatocellular carcinoma (HCC) (Lozano et 
al. 2012; Schweitzer et al. 2015; Trepo et al. 2014; WHO. 2017). An estimated 257 
million people were reported to be chronically infected and approximately 887 000 
deaths were reported in 2015 due to the complications of HBV infection (WHO. 
2017). The infection gathers pace from CHB to LC and HCC over years and the 
current five-year cumulative risk for the development of HBV-related LC ranges 
between 10% and 20% (Liu et al. 2007). Furthermore, chronic HBV infection largely 
contributes to 50% of the HCC cases caused by a multitude of factors including 
hepatitis B and among those HCC cases, 70%-80% are reported in patients with 
HBV-related LC (El-Serag. 2011).  
Taking into consideration global HBV prevalence, distinct geographical distribution 
can be observed that ranges between 0.1 and > 20% (Lok. 2002; Ott et al. 2012). 
The global endemicity of hepatitis B surface antigen (HBsAg) is classified in four 
specific groups, namely the low prevalence (<2%), low-intermediate (2-5%), high–
intermediate (5-8%) and the high endemic (>8%) (Ott et al. 2012).  A high burden of 
HBV infection is documented particularly in Asia, sub-Saharan Africa, and in 
countries of the Western Pacific (Ott et al. 2012; Schweitzer et al. 2015). Few 
countries in the Middle East, Eastern and Southern Europe, Southern America are 
with high-intermediate HBV prevalence, whereas low endemic zones include 
countries from Western and Northern Europe, North America, Central America, and 
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the Caribbean (Lok et al. 2001a; Lok et al. 2007). Vietnam is one of the South-East 
Asian countries, where HBV is highly endemic. The prevalence of chronic HBV 
infections ranges between 10% and 15% (Nguyen. 2012). HBV-related liver 
diseases are foreseen to become a significant public health burden in the next 
decades.
Figure 1: Geographic distribution of chronic HBV infection.             
Source: https://www.cdc.gov/hepatitis/hbv/pdfs/hbv_figure3map_08-27-08.pdf   
Transmission and prevention 
HBV is a contagious virus that remains viable in the environment and can survive on 
inanimate surfaces for at least a week. Thus, transmission may occur even in the 
absence of visible blood or residue (Lok and McMahon. 2007; Stroffolini et al. 2007). 
HBV is spread predominantly by exposure to infected blood and other body fluids 
from infected persons. The frequency of infection and transmission vary in different 
regions of the world. For instance, in a HBV endemic area, the most common route 
of vertical transmission is perinatal (from mother to infant) and horizontal 
transmission occurs by person-to-person contact (CDC. 2015). Other modes of 







and occupational exposure, blood transfusions, tattooing, and by acupuncture 
therapy. So far, there is no direct evidence that HBV can be spread through 
breastfeeding (WHO. 2001).  
Although HBV infection remains highly endemic in certain parts of the world, global 
expansion of universal hepatitis B vaccination programs has effectively reduced the 
rates of acute and chronic HBV infections as well as related complications (Chang. 
2006). The development of HBV vaccine using purified HBsAg protein as an 
immunogen to induce the protective antibody (anti-HBs), has paved the way for 
eliminating HBV infection. Active immunization with three to four regimens of HBV 
vaccine is 95% effective in preventing infection (WHO. 2015) and the incidence of 
HCC has been reduced to approximately 25%, since the launch of the vaccination 
program  (Chang. 2006). Active HBV vaccine plus passive immunization with HBIG 
(hepatitis B immune globulin) showhigh effectiveness in infants and in HBeAg 
positive mothers (94% and 71% respectively) (Lo et al. 1985). Other measures to 
prevent horizontal transmission include screening among the donated blood, proper 
sterilization of injection needles and syringes, and any potential risk avoidance 
(tattoo, skin piercing). 
1.1.2. Hepatitis B virus: structure, genome organization and viral proteins 
HBV structure 
HBV belongs to the genus Orthohepadnavirus, of the Hepadnaviridae family 
(Schaefer. 2007). HBV was first described in an Australian Aborigine in 1967 
(Blumberg et al. 1967). Prior to the discovery of HBV, the hepatitis B surface antigen 
(HBsAg) known as the Australian antigen was isolated in patients who received large 
number of transfusions for the treatment of anemia (Blumberg et al. 1965). 
Subsequently, this antigen was linked to the particulate form of the so-called Dane 
particle (Cossart et al. 1970; Dane et al. 1970), which is the complete form of the 
HBV virion (H.C.Thomas et al. 2013; Sherlock. 1970). In addition to Dane particles, 
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sera of HBV-infected persons contain 1000-fold excessive amounts of sub-viral 
particles that are either 22 nm spheres or 22 nm-diameter filaments with variable 
lengths. These sub-viral particles do not contain genomic material and are therefore 
non-infectious.  
Dane particles, spheres, and filaments consist of hepatitis B surface antigen 
(HBsAg). The hepatitis B surface protein comprises of three different protein 
domains, namely the S domain, the preS1, and the PreS2.  The S domain encodes 
the small HBs protein (HBSs), whereas the preS1 and preS2 encode the large and 
middle HBs protein (LHBs and MHBs), respectively. Dane particle has an inner 
capsid, which includes the 3.2kb of the viral dsDNA. Each virion also contains kinase 
and heat shock proteins hsp70 and hsp90.  
Genome organization and viral proteins  
The HBV genome is composed of partial double-stranded DNA, also known as 
relaxed-circular DNA. Neither of the two strands of this relaxed circular DNA is 
covalently closed. The minus strand which is complementary to pre-genomic RNA, 
has a short terminal redundancy and carries the whole genome (3.2kb). The 
incomplete noncoding positive strand is heterogeneous in length with 3’ end 
terminating hundreds of nucleotides (H.C.Thomas et al. 2013). The 5’ end of the 
minus strand is located in the DR1 (direct repeats), while the positive strand starts 
at the DR2. The repeats are involved in priming the synthesis of the respective DNA 
strands. On the genome, six start codons, four promoters, and two transcription 
elements were identified. The four distinct open reading frames (ORF) are PreS/S, 
Precore/core, P and X. The ORF preS/S encodes the three viral surface proteins 
(LHBs, MHBs and SHBs or HBsAg), depending on the usage of one of the three 
translational start codons. HBsAg is the main target of host immune response during 
HBV infection. The ORF precore/core encodes core protein known as HBcAg and 
non-structural precore protein known as HBeAg. The ORF P is the longest HBV ORF 
and overlaps, at least partially, with all other HBV ORFs. It encodes a multifunctional 
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viral DNA polymerase (Pol, 90 kd) with RNAase H activities and terminal protein 
(TP). The ORF X codes for the small regulatory X protein, which has been shown to 
be essential in vivo for viral replication and is capable of transactivating numerous 
cellular and viral genes (Lucifora et al. 2011). The two enhancer elements (Enh I and 
Enh II) control the four defined overlapping open reading frames (pre-S/S, core/e, X, 
and P gene), which promote transcription and expression of the seven different 
hepatitis B virus proteins.  
 
Figure 2. HBV-DNA structure and genome organization. The HBV genome is ∼3.2 kb in 
size with a circular partially double-stranded DNA composed of a complete coding minus 
strand (–) and an incomplete noncoding positive strand (+) with variable 3 ′end size. Two 
direct repeats (DRs) of 11 nucleotides (DR1 and DR2) are located at the 5 ′ends of both 
strands. The viral genome contains four promoters and two transcription enhancers (Enh1 
and Eh2), which control the transcription of four genes (preC/C, P, preS/S, and X). This 
figure is redrawn and adapted from the original picture (Kao. 2011). 
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1.1.3. HBV life cycle 
During the last 30 years, the HBV replication in hepatocytes has been extensively 
studied to understand the mechanism of infection (Allweiss et al. 2016; Schultz et al. 
2004). The viral replication takes place entirely in the hepatocytes and is illustrated 
in Figure 3. The virus entry is initiated by the interaction of surface lipoproteins with 
the host specific receptors on the liver cells. HBV uses the carbohydrate side chains 
of hepatocyte-associated heparan sulfate proteoglycans as receptors (Leistner et al. 
2008; Schulze et al. 2007). This interaction requires the integrity of LHBs protein 
(Engelke et al. 2006; Gripon et al. 2005; Meier et al. 2013). Studies have 
demonstrated that HBV and HDV (hepatitis D virus) can be blocked by the 
competition of a small protein (Myrcludex-B; described as HBVpreS/2-48myr), which 
contains the same amino acid sequences as LHBs (Glebe et al. 2007; Lutgehetmann 
et al. 2012; Petersen et al. 2008). Recently, the sodium taurocholate co-transporting 
polypeptide (NTCP) has been identified as a cellular entry receptor for HBV (Yan et 
al. 2012, 2014). This entry mechanism is inhibited by myrcludex-B, cyclosporin A 
and NTCP inhibitors (Watashi et al. 2014) 
Following entry into hepatocytes, HBV undergoes uncoating of its capsid and 
releases its relaxed circular-DNA. The relaxed circular-DNA is then translocated to 
the nucleus, where it is converted to covalently close circular DNA (cccDNA). This 
intra-nuclear and episomal form of the viral genome serves as a transcriptional 
template for viral RNAs and subsequent generation as virions. Thus, the cccDNA is 
crucial for HBV replication and persistence of HBV infection (Levrero et al. 2009a). 
In short, cccDNA functions as the template for the transcription of four viral RNAs (of 
0.7 kb, 2.1 kb, 2.4 kb and 3.5 kb), which are exported to the cytoplasm and used as 
mRNAs for the translation of the seven HBV proteins. The longest pre-genomic RNA 
(3.5 kb) functions as the template for replication, which occurs within nucleocapsids 
in the cytoplasm. Nucleocapsids are enveloped to become the complete viral 
particles. The mature HBV virions will be released from the cells  through the 
endoplasmic reticulum and/or golgi complex (Rehermann et al. 2005). 
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Figure 3. The replication cycle of hepatitis B virus in the hepatocytes and the inhibitors of 
HBV attachment to the cell membrane. This picture is adapted and used with the permission 
from (Rehermann et al. 2005). 
1.1.4. Natural course of HBV infection 
Children are at greater risk of being infected with HBV. Over 90% of infants were 
infected from mothers and 30–50% of children were infected before the age of 6 
years and develop chronic HBV infections. In contrast, ~5% of immunocompetent 
adults will progress to chronic infection. (Dandri et al. 2012; Fattovich. 2003; Ganem 
et al. 2004; WHO. 2015). HBV infection can lead to inflammation of the liver with 
variable severity, in both acute and chronic phases. During the acute phase, clinical 
manifestations vary from a self-limiting, transient liver disease to an anicteric and 
icteric hepatitis, and fulminant hepatitis in some cases. During the chronic phase, 
clinical manifestations range from an asymptomatic carrier state to chronic hepatitis, 
cirrhosis and HCC (Fattovich. 2003; Fattovich et al. 2008; Hadziyannis. 2011; Lok et 













































Acute hepatitis: After exposure, the incubation of HBV lasts from 1 to 4 months. 
During this period, flu-like syndrome develop. Fever, skin rash, fatigue, typically 
arthralgia occur and usually cease with the onset of hepatitis. At least 70% of patients 
have subclinical or anicteric hepatitis and less than 30% will develop an icteric 
hepatitis (S.Mauss et al. 2015). In typical cases of acute hepatitis, abnormal 
elevation of liver enzymes (alanine and aspartate aminotransferases: ALT and AST) 
and bilirubin were detected in the serum. In addition, HBV-DNA levels are usually 
high and several HBV-related markers were also present in the serum including 
HBsAg, HBeAg, followed by anti-HBe and anti-HBc antibodies (Figure 4A). In acute 
self-limiting hepatitis, sero-conversion of HBeAg and HBsAg to anti-HBe and anti-
HBs as well as absence of HBV DNA from the serum occur within about six months 
after exposure. Fulminant hepatic failure is an unusual event that occurs in 0.1-0.5% 
of patients with acute hepatitis. The pathology of fulminant hepatitis is not well 
understood. However, it is believed to be immune-mediated that might be a result of 
interaction between the virus and host immune response (S.Mauss et al. 2015).  
Chronic hepatitis: The natural course of chronic hepatitis B is age dependent and 
varies between individuals, depending on the interaction between the virus and host 
responses. In general, chronic hepatitis B has been well characterized into four 
different phases in parentally acquired infections namely; the immune-tolerant, 
immune clearance, inactive carrier state, and an immune-reactive phase (Figure 4B).  
The immune-tolerant phase lasts between 10 and 30 years with high levels of HBV 
replication (HBeAg positive and HBV-DNA >107-108 copies/ml), low levels of liver 
necroinflammation (biopsies are without signs of significant inflammation or fibrosis), 
and with no evidence of active liver disease (normal ALT concentration) (Fattovich. 
2003; Fattovich et al. 2008; Ganem and Prince. 2004; Sarin et al. 2016; Terrault et 
al. 2016).  During this phase, the spontaneous clearance rate of HBeAg is expected 
to occur between 15-20% (S.Mauss et al. 2015).  
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The HBeAg-positive immune-active phase or immune clearance is characterized by 
irregular HBV-DNA levels and ALT levels in the serum (Figure 4B) and hepatic 
necroinflammation (Fattovich. 2003; Fattovich et al. 2008; Ganem and Prince. 2004; 
S.Mauss et al. 2015; Sarin et al. 2016; Terrault et al. 2016). During this phase, 
HBeAg sero-conversion may occur. The rate of seroconversion is less than 2% per 
year in children < 3 years of age and among adults this may range between 8% to 
12% per year (Terrault et al. 2016). Some patients will develop acute hepatitis or 
fulminant hepatic failure as a result of the high levels of immune-mediated lysis of 
infected hepatocytes (Elgouhari et al. 2008). Also in this phase, periodic loss of 
serum HBV-DNA and HBeAg also occur (S.Mauss et al. 2015).  
The inactive carrier state is an outcome of the immune-active phase, marked by 
sero-conversion from HBe antigenemia to anti-HBe antibody positivity. During this 
phase, one may observe low and/or undetectable HBV-DNA with normal ALT levels, 
and minimal necro-inflammation with variable fibrosis, reflecting previous liver injury 
during the immune-active phase (Fattovich. 2003; Ganem and Prince. 2004; 
S.Mauss et al. 2015; Sarin et al. 2016). Approximately  between 4% and 20% of 
inactive carriers have one or more reversions back to HBeAg positivity (Terrault et 
al. 2016). However, a few clinical-based cross-sectional studies have demonstrated 
that relatively few patients in the inactive HBV phase have experiencedmoderate to 
severe liver fibrosis (Kumar et al. 2008a; McMahon. 2009). 
The HBeAg-negative immune-reactive phase is characterized by elevated ALT 
levels from moderate to severe necroinflammation with HBeAg negativity, anti-HBe 
positivity and detectable HBV-DNA (Sarin et al. 2016). As HBV cccDNA persists in 
hepatocytes, reactivation of HBV can be spontaneously triggered during or after 
inactive carrier state (Fattovich et al. 2008). Reactivation of viral replication may 
occur due to reactivation with the wild type virus or much more frequently with HBV 
variants that prevent HBeAg expression. The precore mutation produces a stop 
codon in a region of the HBV genome that prevents the formation of HBeAg, whereas 
the basal core promoter mutation affects HBeAg transcription (Chen et al. 2011; 
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Jammeh et al. 2008; Tong et al. 2016). These mutations allow HBV replication in the 
absence of HBeAg. 
Figure 4. Clinical, serological and virological course of HBV infection. This picture is 
adapted and used with the permission from (Rehermann et al. 2005). 
New nomenclature redefined for the chronic hepatitis B infection 
A recent guideline for the nomenclature for the chronic states (European Association 
for the Study of the Liver. Electronic address et al. 2017) has been released. The 
natural course of chronic HBV infection is now classified into five distinct phases, 
considering the presence of HBeAg, HBV DNA levels, ALT values and eventually 
the presence or absence of liver inflammation. The new nomenclature is based on 
the description of the two main characteristics: infection versus hepatitis. The phases 
of chronic HBV infection are not necessarily sequential but includes: Phase 1: 
HBeAg-positive chronic HBV infection, previously termed ‘‘immune tolerant’’; Phase 
2: HBeAg-positive chronic hepatitis B; Phase 3: HBeAg-negative chronic HBV 
infection, previously termed ‘inactive carrier’; Phase 4: HBeAg-negative chronic 
hepatitis B; Phase 5: HBsAg-negative phase is characterized by the absence of 
HBsAg and presence of antibodies to HBcAg (anti-HBc) in the serum, with or without 
A. Acute hepatitis B. Chronic hepatitis
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detectable antibodies to HBsAg (anti-HBs). This phase is also known as ‘‘occult HBV 
infection”. 
1.1.5. Host immune responses to HBV infection 
Innate immune responses to HBV infection 
HBV is a noncytopathic virus as seen in a number of asymptomatic HBV carriers 
who have minimal hepatocellular injury as well as liver necroinflammation, despite 
high levels of HBV replication. Most of the clinical syndromes are as a result of 
interaction between the virus and the host defense (Chang et al. 2007; Guidotti et al. 
2006). Following HBV infection, pathogens are recognized by a subset of immune 
receptors so-called pattern recognition receptors (PRRs) e.g. toll-like receptors 
(TLRs) (Akira et al. 2006; Boehme et al. 2004) initiating the process of antiviral 
responses of innate immune system, which functions as the first line of defense. 
Innate immune system consists of several components including epithelial barriers, 
innate immune host cells [phagocytes: granulocytes, monocytes, macrophages; 
natural killer (NK) cells, natural killer T (NKT) cells, dendritic cells (DC), kupffer cells, 
the complement system, and cytokines released as cellular responses.  
Cytokines play a key role in cell to cell communication and are required for the 
defense against hepatitis viruses and determines liver disease progression (Dunn et 
al. 2007; Koziel. 1999a; Larrubia et al. 2009). It is widely believed that 
interferons (IFNs) are the most important cytokines, which are produced by 
interferon-producing cells in response to viral infections (Colonna et al. 2002). These 
cells were primarily termed “plasmacytoid T cells” because of their location and 
abundance in the lymph nodes and in their expression of CD4 (Kadowaki et al. 2002; 
Vollenweider et al. 1983). Today, many host cells (innate and adaptive immune cells) 
were shown to induce IFNs. Interferons are divided into type I (IFN-α/β), type II (IFN-
γ), and type III (IFN-λ). Type I IFNs are produced by most innate cells and affect 
most phases of cycle including entry/uncoating, transcription, RNA stability, 
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translation, maturation, assembly, and release. Type II interferon (IFN-γ) is 
exclusively produced by T cells and NK cells and is often considered in the context 
of adaptive immune response as a key antiviral T-cell cytokine (Koyama et al. 2008). 
Type III IFNs bind to receptors distinct from type I IFNs and activate intracellular 
signals, which overlap with IFN-α/β in downstream JAK/STAT signaling pathway 
(Donnelly et al. 2010).  
During HBV infection, the secretion of IFNs and other cytokines (such as IL-2, IL-6, 
IL-10 and IL-12) is controlled by suppressors of cytokine signaling (SOCS) family 
proteins (CISH and SOCS1 to SOCS7). These SOCS proteins belong to a classical 
negative feedback system that regulates cytokine transduction via JAK/STAT 
signaling pathway (Carow et al. 2014; Yoshimura et al. 2007a). Of these, SOCS 
family proteins, suppressor of cytokine SOCS3 was shown as a key regulator in 
regulating various intracellular activities. Subsequently, SOCS3 can inhibit the 
process of cell proliferation and cell survival through inhibition of STAT3, which is an 
oncogene by itself (Levy et al. 2006; Wake et al. 2015; Yasukawa et al. 2003; 
Yoshimura et al. 2007a; Yu et al. 2007; Yu et al. 2009). In chronic HBV infection, the 
persistent activation of STAT3 mediated by JAK/STAT signaling pathway was shown 
to induce inflammation and subsequent carcinogenesis (Jiang et al. 2011; Yang et 
al. 2016; Yu et al. 2007).  
IFNs mediate their signal transduction by binding to their cell surface receptors 
(IFNAR) activating the downstream IFN-signaling pathway. This process leads to the 
induction of numerous IFN-stimulated genes (ISGs) that activate a wide biologic 
responses (e.g. antiviral, immune modulatory, antiproliferative, antiangiogenic, and 
antitumor effects) (Platanias. 2005). Among these ISGs, the ubiquitin-like molecule, 
ISG15, is one of the most strongly induced proteins linked to a variety of cellular 
proteins, suggesting regulation of different cellular processes.  
ISG15 is a major effector molecule of the innate immune responses (Estrabaud et 
al. 2010). Although ISG15 was discovered early, the anti-viral effects of ISG15 were 
 13 
 
only extensively studied in recent years. ISG15 induces type I interferon responses 
and exert responses against many viruses including Influenza, HIV-1, Ebola and 
HPV (Campbell et al. 2013b). ISG15 also plays an important role in several 
immunomodulatory activities, including induction of natural killer (NK) cell 
proliferation, triggering the T-cell reaction, augmentation of lymphokine-activated 
killer activity, stimulating IFN-γ production, inducing dendritic cell maturation and 
also functions as a chemotactic factor for neutrophils (Lenschow. 2010). Although 
ISG15 is a 15 kDa protein with a sequence homology and immune-cross reactivity 
to ubiquitin (Ub), limited knowledge still exists on the role of ISG15 and its conjugates 
towards antiviral activities and on carcinogenesis (Campbell and Lenschow. 2013b; 
Desai. 2015a; Jeon et al. 2010a; Skaug et al. 2010).  
 
Figure 5. Innate immune response to HBV infection through JAK/STAT signaling 
pathway. During HBV infection, type I interferons (IFN α/β/γ) bind to specific surface 
receptors and induce antiviral effects by activating the JAK/STAT signaling pathway. In brief: 
the binding of IFNs to receptors activate both janus kinase 1 (JAK1) and tyrosine kinase 2 
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(TYK2). The activated JAK1 and TYK2 phosphorylate tyrosine residues remain as the 
binding site for STAT proteins. Two activated STATs form hetero-or homodimer complexes, 
which then translocates into the nucleus and acts as an active transcription factor. Generally, 
IFN regulatory factor 9 binds to STAT1/STAT2 heterodimers to form the transcription 
complex. This complex translocates into nucleus and binds to IFN stimulatory response 
elements (ISREs) within the promoters of ISGs to produce hundreds of ISG proteins. In 
addition, the homo and heterodimers of STAT1 and STAT3 bind to gamma activated 
response elements. These ISG proteins play key roles in the induction of innate and adaptive 
immune responses. This figure was redrawn and adapted from (Gao et al. 2012). 
Adaptive immune response to HBV infection 
Adaptive immunity is mediated by humoral B cell and cellular T cell responses that 
are activated by antigen-presenting cells including Kupffer cells and, in particular, 
the dendritic cells.  
T-cell response 
The cellular immune response is believed to play a role in disease pathogenesis 
during HBV infection which is mediated by CD8+ and CD4+ T cell activity. (Chang 
and Lewin. 2007; Chisari et al. 1995; Guidotti et al. 1999; Rehermann and 
Nascimbeni. 2005; Shuai et al. 2016). The naive T cells are usually activated by 
antigen-presenting cells in the lymph nodes and other lymphoid organs however, 
these T cells can readily be detected in peripheral blood (Maini et al. 2000; Maini et 
al. 1999; Shuai et al. 2016) and can also be activated locally in the liver during acute 
HBV infection (Sprengers et al. 2006). HBV clearance is mediated by the destruction 
of infected hepatocytes by the antiviral effects (cytopathic and perhaps more 
importantly by noncytolytic) of HBV-specific cytotoxic T lymphocytes (CTLs) (Guidotti 
and Chisari. 2006; Guidotti et al. 1999; Schuch et al. 2014).  
HBV-specific CTLs are associated with HBV resolution by producing several anti-
viral cytokines during acute infection (Guidotti et al. 1996; Kakimi et al. 2000; Phillips 
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et al. 2010; Webster et al. 2000). These cytokines can suppress HBV gene 
expression and replication. In contrast, the HBV-specific CTL responses are weak 
during chronic HBV infection (Bertoletti et al. 2003; Chang and Lewin. 2007; Phillips 
et al. 2010; Webster et al. 2000; Yang et al. 2010). The liver injuries are associated 
with the activity of CTLs (Guidotti et al. 1999; Thimme et al. 2003). The dysfunction 
of HBV-specific CTL responses can aggravate the liver damage (Kakimi et al. 2001) 
and subsequent liver disease progression in patients with chronic hepatitis B 
(Thimme et al. 2003).  
Increasing knowledge on immune regulation contributes to HBV chronic infection 
and disease progression. One such immune regulation is the involvement of the 
regulatory T cells (CD4+, CD25+ Treg cells) which suppresses the HBV-specific T cell 
responses. In chronic HBV patients, these regulatory T cells are observed to be in 
increased numbers in peripheral blood. The presence of HBV-specific Tregs could 
lead to an inadequate immune response against the virus, and thus establishment 
of a chronic infection (Peng et al. 2008; Stoop et al. 2005; Xu et al. 2006).  
B-cell response 
B cells mediate the humoral adaptive immune responses by producing antibodies 
that are antigen-specific. Therefore, the production of anti-HBs antibodies is key in 
in the clearance of HBV and protection against reinfection. The anti-HBs antibodies 
can limit the viral load, spread, andresolve infections either by direct binding to the 
virions or by blocking viral entry. Protection by neutralizing anti-HBs antibodies 
remains a basis for successful vaccine implementation and passive immunization by 
HBIG (hepatitis B immune globulins) for newborns from HBV infected mothers. It has 
been demonstrated that lack of HBsAg-specific B cells and anti-HBsAg antibodies 
are associated with HBV persistence (Barnaba et al. 1985; Bocher et al. 1996) and 
that the restoration of B-cell hyperactivation and HBsAg-specific B-cell impairment 
was associated with HBsAg seroconversion in chronic HBV infection (Oliviero et al. 
2011; Xu et al. 2015). 
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1.1.6. Host genetic/epigenetics on HBV-related liver diseases 
The clinical outcome HBV infection is markedly heterogeneous and is a 
consequence of the complex interaction between viral and host factors in patients 
with persistent HBV infection. The factors influencing the progression are age of the 
patient, the duration of the HBV infection, HBV genotypes, and various host and viral 
factors. It has been widely accepted that host genetic factors influence the outcome 
of a given disease. Substantial evidences from the twin study (Lin et al. 1989) and  
genome wide association studies (GWASs) (Al-Qahtani et al. 2013; Chang et al. 
2014; Hu et al. 2013; Jiang et al. 2013; Kim et al. 2013; Li et al. 2012; Mbarek et al. 
2011; Nishida et al. 2014; Nishida et al. 2012) were documented. The GWASs 
examined the association of large number of genetic variants across the entire 
human genome with a specific disease phenotype (Thursz et al. 2011). Recently, 
many candidate genes were identified, which are significantly associated with the 
susceptibility to HBV infection, persistence of the viruses, liver diseases, and HCC 
development.  
HCC is believed to develop from chronic liver injury, inflammation, and cirrhosis and 
is considered to be multifactorial. Transformation of normal hepatocytes to 
malignancy is associated with altered gene expression and accumulated genetic 
alterations. Among genetic alterations, DNA methylation is of particular interest and 
can aid in early detection of carcinogenesis (Mikeska et al. 2014). DNA methylation 
is a multistep event, which occurs at the early stage of HBV infection (Zhao et al. 
2014). As a normal process, methylation of DNA cytosine residues at the carbon 5 
position (5 mC) in cytosine-guanine dinucleotides (CpG sites) is believed to be 
essential for cell differentiation and embryonic development, playing important roles 
in regulation of gene expression. In carcinogenesis, tumor suppressor genes (TSGs) 
are often silenced following hypermethylation of CpG islands located in the promoter 
regions (Herman et al. 2003). There is increasing evidence that support the notion 
that hypermethylation in the CpG islands of TSG promoter region can be a 
prognostic indicator in many cancers (Mikeska and Craig. 2014; Ozen et al. 2013; 
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Rakyan et al. 2011; Tischoff et al. 2007). Studies on DNA hypermethylation in HCC 
tumor and adjacent tissues have identified several candidate genes involvement, 
including GSTP1, RASSF1A, APC, SOCS1, E-cadherin, and EDKN2A (Gao et al. 
2008; Hernandez-Vargas et al. 2010; Li et al. 2010; Lou et al. 2009; Moribe et al. 
2009; Shen et al. 2012; Um et al. 2011; Yong et al. 2016; Zhong et al. 2002).  
Figure 6. The contribution of host genetic/epigenetic factors to the clinical course in 
patients with HBV infection. The human genes presented in the boxes have been 
identified as associated with susceptibility to persistent HBV infection, disease progression, 
and hepatocarcinogenesis by GWAS (genome-wide association studies). In addition, 
mutations in HBV genome, HBV genotypes, coinfection with other viruses such as HIV, 
HCV, HDV, and HEV are the crucial factors that significantly contribute to the HBV 
replication, immune response escape and subsequently the progression of liver diseases. 
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1.2. Hepatitis E Virus infection 
1.2.1. Epidemiology and transmission routes  
Hepatitis E virus infection is a significant public health problem worldwide. It is 
estimated that one third of the world population lives in areas endemic for HEV and 
are at risk. Each year approximately 20 million HEV infections were documented, 
with an estimated 3.3 million hepatitis E symptomatic cases, and 56,600 hepatitis E-
related deaths (WHO. 2016). HEV is considered to be the most common etiology of 
acute viral hepatitis and several outbreaks were reported, especially in resource-
limited countries. Limited access to clean water, poor sanitation, hygiene, and 
inadequate health care services are the major contributing factors in resource-limited 
countries. HEV occurs as sporadic outbreaks (Kamar et al. 2012; Kamar et al. 2014) 
and more than 60% of infections and 65% of deaths occur in Asia, where 
seroprevalence exceed 25% in certain age groups (WHO. 2016). 
Although HEV infection is sporadic in industrialized countries, it is described as an 
emerging disease and the transmission also occurs by zoonoses. In particular, 
intake of raw or undercooked meat from wild boar, pigs, and deer increases the risk 
of being infected (Arends et al. 2014). Studies have reported on a high HEV 
seroprevalence (5 to 20%) among general populations in developed countries 
(Emerson et al. 2003; Mansuy et al. 2011; Mansuy et al. 2008). Seroprevalence 
might be even higher, if high sensitive tests are utilized for anti-HEV antibody 
detection. This is substantiated by a seroprevalence study conducted in Toulose, 
France where the HEV seroprevalence rose from 16 to 52% (Dalton et al. 2008; 
Dalton et al. 2013; Kamar et al. 2012).  
In the new nomenclature, HEV belongs to the family of Hepeviridae, divided into the 
two genera: members of Piscihepevirus and Orthohepevirus. The genus of 
Orthohepevirus can infect several mammalian and avian species and comprises four 
species (Orthohepevirus A-D). In which, Orthohepevirus A is the most important 
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species and consists of eight HEV genotypes (HEV-1 to HEV-8) that are identified 
based on the phylogeny of entire viral genomes (Smith et al. 2016; van Tong et al. 
2016a; Woo et al. 2016). In high endemic areas, HEV-1 and -2 are responsible for 
most epidemics and is usually transmitted by the fecal-oral route and outbreaks 
occur particularly during monsoons and floods (Bile et al. 1994; Teshale et al. 2010). 
HEV-3 and -4 can cause sporadic infections in both humans and animals and are 
associated with zoonotic transmission in developed countries (Kamar et al., 2012; 
Kamar et al., 2014; WHO, 2016). HEV isolated from wild boars in Japan are 
designated as HEV-5 and HEV-6 (Smith et al. 2014; Takahashi et al. 2011). Very 
recently, two novel HEV strains isolated from camel were classified as HEV-7 and 
HEV-8 (Lee et al. 2016; Sridhar et al. 2017; Woo et al. 2016). Of which, HEV-7 was 
shown to cause chronic hepatitis in a liver transplanted patient (Lee et al. 2016; 
Sridhar et al. 2017).  
Waterborne transmission is the key mode in many outbreaks, which are related to 
poor sanitation and hygiene, whereas the zoonotic transmission is associated with 
sporadic cases in developed countries. Phylogenetic evidence reveals homology 
between the human and swine strains isolated in different geographic areas (Banks 
et al. 2004; Lu et al. 2006; Meng. 2010; Wenzel et al. 2011). Other transmission 
routes through blood transfusion and vertical transmission from mother to child have 
been documented, however, there is no direct evidence by sexual transmission 
(Bose et al. 2011; Kamar et al. 2012; Scobie et al. 2013).  
1.2.2. Hepatitis E virus: structure and genome organization  
HEV is a small, non-envelope Hepevirus of 27-34 nm in size.  The virus consists of 
a 7.2 kb single-stranded, positive-sense RNA genome harboring three open reading 
frames (ORF1, 2, 3), 5´- and 3´-untranslated regions (UTRs), and a polyA-tail at the 
3´-end (Kamar et al. 2012). ORF1 encodes enzymes for RNA replication; ORF2 
encodes the viral capsid and ORF3 encodes a multifunctional protein that can 
modulate cellular signaling and is related to particle secretion (Parvez et al. 2015). 
 20 
 
Recently, a novel ORF4 of 158 amino acids within ORF1 has been described for 
HEV-1. ORF4 is involved in HEV replication by interacting with multiple viral proteins 
and host factors such as eEF1α1 (eukaryotic elongation factor 1 isoform-1) and β-
tubulin (Nair et al. 2016; van Tong et al. 2016b). 
 
Figure 7. HEV genome structure and viral proteins. HEV is a single-stranded RNA virus. 
Its genome is about 7.2kb and is composed of 3 open reading frames. ORF1 encodes the 
nonstructural polyprotein, including methyltransferase (Met), Y-domain (Y), papain-like 
cysteine protease (PCP), hypervariable region (HVR), macro-domain (X), RNA helicase 
(Hel) and RNA-dependent RNA polymerase (RdRp). ORF2 encodes the capsid protein 
(CP), containing S domain (S), M domain (M) and P domain (P). ORF3 encodes a small 
multifunctional protein (MFP) including hydrophobic regions (D1, D2) and proline-rich 
regions (P1, P2). JR is ORF2 and ORF3 overlapping/intergenic-junction region; CRE is cis-
reactive element; SP is signal peptide. Nucleotide positions are relative to the HEV-1 
Burmese strain (Acc. No. M73218)/HEV-3 47832 strain (Acc. No. KC618402). Asterisk (*) 
indicates the hot spot region for clinical mutations (this figure was used with the permission 
from Dr. Hoang van Tong (van Tong et al. 2016a).  
1.2.3. Clinical pathology 
HEV can cause both acute and chronic hepatitis. Among acute cases, HEV 
infections are mainly asymptomatic or self-limited. In rare cases, HEV infection can 
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be symptomatic and sometime results in severe acute and fulminant hepatitis (acute 
liver failure), which may lead to life-threatening conditions (Dalton et al. 2013; Kamar 
et al. 2012; WHO. 2016). Acute Hepatitis E is usually a self-limiting disease and last 
less than 6-10 weeks showing symptoms typically presented also for other viral 
hepatitis such as HAV and HBV. Notably, HEV3 (and HEV4) infections are more 
frequent in males with a median age of 65 years while HEV1 and HEV2 infections in 
endemic countries affect young adults from 10-40 years (Aggarwal. 2013). These 
differences may be due to different routes of transmission of the HEV genotypes 
(zoonotic or waterborne) or other yet unknown environmental, host, and viral factors. 
Alcohol consumption, pre-existing liver diseases, pregnancy, and co-infection with 
other hepatitis viruses (e.g. HBV) are considered risk factors. However, knowledge 
of interference mechanisms in co-infection with other hepatitis viruses is poor and 
needs further investigation.  
Hepatitis E infection during the third trimester of pregnancy is associated with 
increased risk of stillbirth and mortality. The case fatality rate is as high as 20–23% 
among pregnant women in their third trimester (Bose et al. 2011; Lhomme et al. 
2016; Navaneethan et al. 2008; WHO. 2016). In addition, abortion and stillbirth are 
common. This can be explained by the evidence of HEV replication in the human 
placenta and thus an increased neonatal risk (Bose et al. 2014; Bose et al. 2011; 
Khuroo et al. 2009).  
Chronic hepatitis E is defined by HEV genome persistence (RNA) and/or anti-HEV 
IgM for more than 6 months. To date, HEV genotype 3 is reported to cause chronic 
hepatitis in patients who were immune compromised, such as those with organ 
transplant, stem cell recipients, hematological patients receiving chemotherapy and 
immunotherapy (Donnelly et al. 2017; Kamar et al. 2008; Pischke et al. 2012). Very 
recently, HEV genotype 4 was also reported to cause chronic HEV infection (Wu et 
al. 2017). The chronicity of HEV infection largely depends on host immune 
responses. However, also few cases with chronic or persistent HEV infection are 
also reported in healthy and in immune competent individuals (Gonzalez Tallon et 
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al. 2011; Grewal et al. 2014). Until to-date, there were no studies carried out to 
understand, whether viral factors esp. the genetic variability is associated with HEV 
chronic infection.   
1.2.4. Treatment and prevention 
Prevention of HEV infection is largely associated with appropriate hygiene and 
sanitary measures, thereby, avoidance of fecal-oral transmission. In regions where 
HEV infection is sporadic, the consumption of raw meat products shall be avoided. 
HEV infection can be prevented with an effective immunization program. Although 
HEV has become a significant health problem worldwide, to date, vaccine against 
HEV infection is not available globally. The first vaccine for HEV was licensed in 
2011 for use only in China and recently a recombinant HEV vaccine (Hecolin) 
sustained protection against HEV for up to 4.5 years in a Chinese population (Zhang 
et al. 2015a). 
Both these HEV vaccines (recombinant ORF2 and HEV 293) based on the viral 
capsid protein have shown protective efficacy (Zhang et al. 2015a). However, there 
is no direct evidence of these vaccine usees among pregnant women, patients with 
pre-existing liver damage, and protective efficacy across HEV genotypes (HEV1-
HEV4). There are no specific drugs that are approved for HEV treatment. In 2010, 
an initial case study demonstrated the effectiveness of PEG-interferon-α in 
combination with ribavirin for HEV infection. This finding was further confirmed by a 
larger multi-center study (Pischke et al. 2013; Wedemeyer et al. 2012). The data 
from these studies revealed that antiviral resistance mutations can occur in HEV 
genome (RdRp-domain) under treatment with PEG-IFN/ribavirin (Debing et al. 
2014).  
1.3. Scope and specific objectives 
The present thesis describes the contribution of host candidate genes in the 
JAK/STAT signaling pathway to HBV susceptibility and its clinical course. The 
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association of SOCS3 hypermethylation, ISG15 genetic variants with HBV disease 
susceptibility and its clinical outcome was studied. Also, this thesis describes how 
HEV superinfection in HBV patients may influence HBV disease and its course in 
liver disease progression. This study especially on HEV epidemiology is first of its 
kind in the Vietnamese population, where HBV is epidemic. Based on the objectives, 
the thesis is structured as two independent chapters, which are published as three 
full length original articles in peer reviewed journals. In particular, I investigated the 
1. Clinical significance of hepatitis E virus superinfection in hepatitis B virus infected 
patients. 
2. Role of SOCS3 genetic variants and promoter hypermethylation in patients with 
chronic hepatitis B. 
3. Association of ISG15 variants, ISG15 expression with outcomes of HBV infection 
and progression of HBV-related diseases.  
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HBV-related liver diseasesHepatitis E virus (HEV) infection may cause acute hepatitis and lead to hepatic failure in developing and devel-
oped countries.We studiedHEV seroprevalences in patients with hepatitis B virus (HBV) infection to understand
the consequences of HEV superinfection in a Vietnamese population. This cross-sectional study was conducted
from 2012 to 2013 and included 1318 Vietnamese patients with HBV-related liver diseases and 340 healthy
controls. The case group included patients with acute (n = 26) and chronic hepatitis B (n = 744), liver cir-
rhosis (n = 160), hepatocellular carcinoma (n= 166) and patients with both liver cirrhosis and hepatocel-
lular carcinoma (n = 222). Anti-HEV IgG and IgM antibodies were assessed in patients and controls by
ELISA. HEV-RNAwas identified by PCR assays and sequencing. Seroprevalences of anti-HEV IgG among hep-
atitis B patients and controls were 45% and 31%, respectively (adjusted P = 0.034). Anti-HEV IgM
seroprevalences were 11.6% and 4.7% in patients and controls, respectively (adjusted P = 0.005).
Seroprevalences were higher among the elder individuals. When stratifying for patient groups, those
with liver cirrhosis had the highest anti-HEV IgG (52%) and anti-HEV IgM (19%) seroprevalences. Hepatitis
B patients with current HEV infection had abnormal liver function tests compared to patients with past or
without HEV infection. One HEV isolate was retrieved from a patient with both liver cirrhosis and hepato-
cellular carcinoma and identified as HEV genotype 3. This study indicates high prevalences of HEV infection
in Vietnamese HBV patients and among healthy individuals and shows that HEV superinfection may influ-
ence the outcome and progression of HBV-related liver disease.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Hepatitis E virus (HEV) may cause acute hepatitis. Pregnant women
are vulnerable to fulminant courses (Boccia et al., 2006; Hamid et al.,
2002). Chronic HEV infectionmay occur mainly in immunocompromised
patients with HIV, organ transplants and during cancer chemotherapyB virus; AHB, acute hepatitis B;
llular carcinoma; IgG, immuno-
frame; WBC, white blood cells;
transferase; ALT, alanine amino
cine, Wilhelmstraße 27, 72074
.P. Velavan).
. This is an open access article under(Dalton et al., 2009; Kamar et al., 2008). Large hepatitis E outbreaks
with 120,000 cases occurred in China in 1986–1988 (Dalton et al.,
2013), followed by N30,000 cases in India in 1956 (Shukla et al., 2011).
Global annual incidences are 20 million asymptomatic infections and
3.4 million acute cases with 70,000 deaths (Rein et al., 2012).
Seroprevalences of 16 to 52% and incidences between 0.2 to 1.7% are
reported from regions with poor sanitation (Dalton et al., 2013). More
than 60% of infections and 65% of deaths occur in Asia, where
seroprevalences exceed 25% in certain age groups (WHO, 2014). The
first vaccine for HEVwas licensed in China in 2011 and very recently a re-
combinant HEV vaccine (Hecolin) sustained protection against HEV for
up to 4.5 years after first vaccination tested in a Chinese population
(Zhang et al., 2015).
HEV is a hepevirus of 27–34 nm in size (Kamar et al., 2012). Its ge-
nome consists of ssRNA of 7.2 kb, containing three open reading framesthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
2081N.X. Hoan et al. / EBioMedicine 2 (2015) 2080–2086(ORF1, 2, 3) (Kamar et al., 2012). ORF1 encodes enzymes for RNA repli-
cation while ORF2 and ORF3 encode the capsid and a multifunctional
protein, respectively. However, viral replication in hepatocytes is not
fully understood (Cao and Meng, 2012). Four HEV genotypes have
been identified. Genotypes 1 and 2 (HEV1, HEV2) only infect humans,
and HEV genotypes 3 and 4 (HEV3, HEV4) can cause human and animal
disease (Kamar et al., 2012, 2014). HEV1 is widely distributed in Asia
and HEV2 predominates in Africa and Mexico. HEV3 and HEV4 are dis-
tributed globally. HEV1, HEV2 and HEV4 are transmitted fecal–orally,
while HEV3 infections occur also by consumption of undercooked
meat (Kamar et al., 2012).
Hepatitis B virus (HBV) infections are frequent in sub-Saharan Africa
and Asia with infection rates between 8% and 20% (WHO, 2013). In
Vietnam, approximately 10 million (10%) individuals live with chronic
hepatitis B (Dunford et al., 2012; Nguyen, 2012). HEV superinfection
in patients with chronic HBV or HCV infections and autoimmune
hepatitis has been found associated with clinical outcomes in several
geographical settings (Atiq et al., 2009; Bayram et al., 2007; Cheng
et al., 2013; Marion-Audibert et al., 2010; Monga et al., 2004; Pischke
et al., 2014). This study aims to assess prevalences and consequences
of HEV infection in patients with HBV-related liver diseases and to com-
pare it to uninfected Vietnamese controls.
2. Materials and Methods
2.1. Study Design and Sample Collection
A cross-sectional study was implemented between June 2012 and
December 2013. A total of 1318 HBV patients and 340 healthy controls
were recruited (108 Military Central Hospital and 103 Hospital of the
VietnamMilitary Medical University, Hanoi). Based on clinical manifes-
tations and laboratory parameters, patients were assigned to the differ-
ent clinical subgroups as previously described (Song et al., 2003).
Briefly, the acute hepatitis B (AHB, n = 26) are patients who presented
with the prodromal symptoms preceded the onset of jaundice (e.g.
fever, anorexia, nausea, vomiting, and fatigue), an onset of clinical jaun-
dice, the constitutional prodromal symptomswere diminished, hepato-
megaly, jaundice, hyperbilirubinemia, serum ALT, and AST at least 5-
fold higher than normal range, HBsAg positive, anti-HBc IgM positive,
anti-HBc IgG negative. The chronic hepatitis B (CHB, n = 744) were
characterized based upon clinical syndromes such as fatigue, anorexia,
jaundice, hepatomegaly, hard density of the liver, splenomegaly,
hyperbilirubinemia, elevated levels of AST and ALT, HBsAg positive for
longer than 6 months. The HBV-related liver cirrhosis (LC, n = 160)
were characterized as patients infected with HBV (HBsAg positive)
showing the clinical manifestations such as anorexia, nausea, vomiting,
malaise, weight loss, abdominal distress, jaundice, edema, cutaneous
arterial “Spider” angiomas, palma erythema, ascites, shrunken liver,
splenomegaly, hyperbilirubinemia, elevated levels of AST and ALT,
prolonged serum prothrombin time, and decreased serum albumin.
The HBV-related hepatocellular carcinoma (HCC, n = 166) were
characterized as patients infected with chronically HBV (HBsAg pos-
itive), abdominal pain, an abdominal mass in the right upper quad-
rant, blood-tinged ascites, weight loss, anorexia, fatigue, jaundice,
prolonged serum prothrombin time, hyperbilirubinemia, elevated
levels of AST, ALT and serum a-fetoprotein (AFP), ultrasound showed
tumor, liver biopsy and histopathology showing tumor cells. The pa-
tients with liver cirrhosis and hepatocellular carcinoma (LC + HCC,
n= 222) were characterized if the patients showed clinical manifes-
tations and laboratory tests of both LC and HCC. In addition, the pa-
tients with LC were also categorized as Child-A, Child-B and Child-C
based on Child–Pugh scores (Cholongitas et al., 2005). We also in-
cluded 340 healthy individuals without any history of alcohol or
drug use as healthy controls (HC). Biochemical and serological tests
were performed for all participants. HBV viral loads were measured
by quantitative real-time PCR as described previously (Song et al.,2003). Five milliliters of venous blood was collected from all partic-
ipants. Serum or plasma was used for biochemical and laboratory
assays.2.2. Ethics Statement
Informed consent was obtained at sampling from all participants or
from parents if subjects were b18 years. The studywas approved by the
institutional review board of the 108 Military Central Hospital and the
103 Military Hospital, Hanoi, Vietnam.2.3. Serology Testing for HEV Infection
Anti-HEV IgG and IgM levels were determined in serum from
patients and healthy controls through ELISA kits (MP Biomedicals,
Santa Ana, California, USA). The MP HEV IgG and IgM EIA test system
was chosen for our analysis on the basis of own round robin test and
due to recently reported comparative analysis of commercial available
HEV IgG/IgMEIA assays showing no inconsistent performances of sensi-
tivity and specificity among different assays including the MP EIA
(Avellon et al., 2015; Wu et al., 2013).2.4. HEV-RNA Detection
Viral RNAwas isolated from serum obtained from patients and con-
trols (QIAamp Viral RNA Mini Kit; Qiagen GmbH, Hilden, Germany).
HEV-RNA was reverse transcribed into cDNA (QuantiTect Reverse
Transcription Kit; Qiagen GmbH, Hilden, Germany). Presence of
HEV-RNA was examined in all the patients and controls using a
nested PCR assay. Primers were designed based on conserved re-
gions of the overlapping HEV ORF1 region. Outer primer pairs were
HEV-38 (sense) 5′-GAGGCYATGGTSGAGAARG-3′ and HEV-39 (anti-
sense) 5′-GCCATGTTCCAGACRGTRTTCC-3′; inner primers were HEV-
37 (sense) 5′-GGTTCCGYGCTATTGARAARG-3′ and HEV-27 (antisense)
5′-TCRCCAGAGTGYTTCTTCC-3′.
PCR amplification was carried out in 25 μl volumes [5 ng viral cDNA,
1× PCR buffer (20 mM Tris–HCl, 50 mM KCl, 2 mM MgCl2), 0.2 mM
dNTPs, 0.4 mMMgCl2, 0.6 μM specific primer pairs, 1 unit Taq polymer-
ase (Qiagen GmbH, Hilden, Germany)]. Cycling parameters were dena-
turation (94 °C, 5 min), 35 cycles of 30 s at 94 °C denaturation, 30 s at
54 °C annealing, 30 s at 72 °C extension, followed by final extension of
10 min (72 °C). Parameters for nested PCR were: denaturation (94 °C
5 min), followed by 40 cycles of 30 s at 94 °C denaturation, 30 s at
56 °C annealing temperature, 30 s at 72 °C extension, followed by
10 min extension (72 °C). A plasmid containing HEV cDNA served as
positive control. Amplicons (306 bp) were visualized on 1.5% agarose
gels stained with SYBR green.
In addition, the HBV patients were confirmed for the presence of
HEV-RNA by applying the same PCR conditions by, however, using
other set of primers which amplified a 497 bp ORF2 fragment. Outer
primers were HEV-34 (sense) 5′-CCGACGTCYGTYGAYATGAA-3′ and
HEV-36 (antisense) 5′-TTRTCCTGCTGAGCRTTCTC-3′; inner primers
were HEV-35 (sense) 5′- AAGTGAGCGCCTACAYTAYCG-3′ and HEV-29
(antisense) 5′-CTCGCCATTGGCTGAGAC-3′.2.5. HEV Genotyping
PCR products were purified (Exo-SAP-IT kit; USB, Affymetrix, USA)
and used as sequencing templates (BigDye terminator v.1.1 sequencing
kit; Applied Biosystems, USA, ABI 3130XL sequencer). HEV genotyping
was performed by phylogenetic analyses based on the amplified ORF2
sequences using the MEGA 5 software (www.megasoftware.net). HEV
reference sequences were obtained from the NCBI GenBank database.
2082 N.X. Hoan et al. / EBioMedicine 2 (2015) 2080–20862.6. Statistical Analysis
Analyses were performed using the SPSS software (SPSS Statistics,
IBM, Armonk, NY) and Intercooled Stata (Stata Corporation, College
Station, TX, USA). Prevalences and quantitative variables are given as
percentages and medians with ranges. Categorical variables were com-
pared applying Chi square or Fisher's exact tests. Kruskal–Wallis or
Mann–Whitney U tests were used to compare quantitative
variables. A logistic regression model was used to compare HEV
seroprevalences between groups and to analyze associations of
HEV seroprevalences with disease progression. Odds ratios (OR) and
95% confidence intervals (CI) were calculated. The level of significance
was P b 0.05.
3. Results
3.1. Demographic and Clinical Characteristics of Hepatitis B Patients and
Controls
The baseline characteristics of the 1318 Vietnamese hepatitis B
patients and 340 healthy controls are provided in Table 1. The pro-
gression of liver disease increased according to median age of pa-
tients. Most patients were male (82%). Differences of means were
observed for several clinical parameters, including white and red
blood cell counts, platelets, AST/ALT, total and direct bilirubin, albu-
min, prothrombin, AFP and HBV viral loads. Platelet counts were
lower in patients with LC compared to non-LC patients (P b 0.001).
Levels of AST, ALT and total and direct bilirubin were higher in AHB
patients compared to other subgroups (P b 0.001). Albumin and
prothrombin levels were lower in patients with LC and/or with
HCC (P b 0.001). As expected, AFP levels were higher in HCC com-
pared to non-HCC patients (P b 0.001). HBV viral loads were higher
in chronic hepatitis B patients without LC and/or HCC than in chronic
hepatitis B patients with LC and/or HCC (Table 1).
3.2. Seroprevalence of HEV Infection in Patients With HBV Infection and in
Healthy Population
Seroprevalence rates of anti-HEV IgG were higher in patients (45%)
compared to controls (31%) (P=0.034).When stratified for the clinical
subgroups of HBV infection, the anti-HEV IgG seroprevalence was 42%
(11/26) in AHB, 41% (305/744) in CHB, 52% (83/160) in LC, 48%
(79/166) in HCC and 49% (108/222) in patients with LC and HCCTable 1
Demographic and clinical characteristics of the studied HBV patients and controls.
Characteristics AHB (n = 26) CHB (n = 744) LC (n =
Age (years) 34 [20–49] 41 [9–84] 57 [15–
Gender (M/F) 21/5 557/187 135/25
WBC⁎ (103/ml) NA 6.5 [4–17] 5.6 [1.7–
RBC⁎ (106/ml) NA 4.9 [3–6.8] 4.2 [1.9–
PLT⁎ (103/ml) NA 223 [19–401] 90 [3.7–
AST⁎ (IU/l) 1064.5 [316–4425] 44 [14–1600] 76.5 [15
ALT⁎ (IU/l) 1125.5 [309–3328] 48 [8–2924] 58.5 [8–
Total bilirubin⁎ (μmol/l) 184.8 [21.8–558] 15 [4.9–452] 31 [4.1–
Direct bilirubin⁎ (μmol/l) 137.9 [15–353] 5 [1–298] 12 [0.4–
Albumin⁎ (g/l) 36 [27–42] 41.8 [26–48] 34 [20–
Prothrombin⁎
(% of standard)











NA 4.3 [1–200] 7.3 [1.18
AHB: acute hepatitis B; CHB: chronic hepatitis B; LC: liver cirrhosis; HCC: hepatocellular carcinom
alanine amino transferase; IU: international unit; NA: not available. Values given are medians
⁎ P b 0.001 for comparison with all other groups.(Fig. 1A, Supplementary Table 1). Anti-HEV IgM was observed in
19% (30/160) of LC patients, followed by 15% (4/26) of AHB patients,
15% (33/222) of patients with both LC and HCC, 12% (20/166) of HCC
patients, 9% (65/744) of CHB patients and 5% (16/340) of controls.
The seroprevalence rate of anti-HEV IgM was also higher among pa-
tients with HBV infection (11.6%) compared to the controls (4.7%; ad-
justed P= 0.005) (Fig. 1A, Supplementary Table 1). In the HBV group
positive for anti-HEV IgG, we observed a higher positivity of anti-
HEV IgM in the AHB (36%) and LC (36%) subgroups, followed by
patients with both LC and HCC (29%), HCC (20%) and CHB (20%)
(Fig. 1B).
3.3. Association of Higher HEV Seroprevalence With Increasing Age
Seroprevalences of anti-HEV IgG and IgMwere higher in elder com-
pared to younger subgroups of HBV patients and controls. In the HBV
group, the mean age of patients positive for anti-HEV antibodies was
higher than that in HBV patients negative for anti-HEV antibodies
(P b 0.001 and P=0.002 for anti-HEV IgG and IgM). A similar trend ap-
plied to the controls (P b 0.001 and P=0.022 for anti-HEV IgG and IgM).
A prevalence of 51% and 46% of anti-HEV IgG was observed in HBV
patients and controls N40 years of age, respectively. The anti-HEV IgG
prevalence in HBV patients between 30 to 40 years was higher com-
pared to that in controls of the same age group (P=0.03). No difference
was seen between HBV patients and controls b30 years of age (Fig. 1C
and Supplementary Table 2). The prevalence of anti-HEV IgM in HBV
patients and in controls N40 years of age was 13.7% and 9.2%, respec-
tively. When stratified for age groups and sex, no differences of anti-
HEV IgM prevalence was observed between HBV patients and controls
(Fig. 1D and Supplementary Table 2).
3.4. HEV Seroprevalence and Progression of HBV-Related Liver Diseases
We found higher anti-HEV IgM prevalences in LC patients (16.8%)
compared to patients without LC (9.5%) (OR = 1.64; 95% CI = 1.1–
2.4; adjusted P = 0.01), indicating that anti-HEV IgM was associated
with LC in chronic hepatitis B patients (Table 2). Significance did not
apply to anti-HEV IgG seroprevalences. A similar trend was found
when comparing anti-HEV IgG and IgM prevalences between HCC and
non-HCC patients (Supplementary Table 3).
To analyze associations of HEV seroprevalences with underlying LC
and its prognosis, we categorized LC patients into three subgroups
based on Child–Pugh scores. Anti-HEV IgG prevalences in Child-B and160) HCC (n = 166) LC and HCC (n = 222) Healthy controls
(n = 340)
84] 55 [15–81] 59 [26–81] 33 [15–69]
159/7 210/12 223/117
20.5] 6.3 [3–16] 6 [2.5–17] Normal
9.2] 4.7 [2.1–6.8] 4.3 [2.2–6.2] Normal
441] 208 [68.6–389] 122 [34–361] Normal
–1221] 48.5 [17–2158] 72 [14–670] b30
1426] 40.5 [10–832] 54.5 [10–805] b30
690] 14 [5–160] 22 [7–419] b17
440] 4.9 [1–80] 8.2 [0.4–214] b5
47] 39 [27–49] 37 [24–47] N35








–300] 196 [1.1–305] 170 [1.6–880] NA
a;WBC:white blood cells; RBC: red blood cells; PLT: platelets; AST andALT: aspartate and
and range.
Fig. 1. Seroprevalence of HEV infection in patients with HBV infection and in healthy population. (A): Anti-HEV IgG and anti-HEV IgM in healthy controls (HC) and in HBV patients includ-
ing acute hepatitis B (AHB), chronic hepatitis B (CHB), patients with only liver cirrhosis (LC), patients with only hepatocellular carcinoma (HCC) and patients with both LC and HCC; (B):
Anti-HEV IgM positivity in individuals positive for anti-HEV IgG; (C): Anti-HEV IgG seroprevalence increasing with age; (D): Anti-HEV IgM prevalence in different age groups. P values
were calculated by Chi square or Fisher's exact tests for comparisons of the seroprevalence among different groups.
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(adjusted P b 0.001 and P = 0.002, respectively). A similar result was
observed for anti-HEV IgM (adjusted P= 0.007 and P b 0.001, respec-
tively) (Table 2), indicating that higher seroprevalences of anti-HEV
IgG and IgM are associated with an increase of LC severity.3.5. Significance of HEV Coinfection in the Outcome of HBV Patients
To analyze the significance of HEV superinfection in HBV pa-
tients, we categorized HBV patients into three subgroups based
on HEV serology results. Patients negative for anti-HEV IgG and
IgM were categorized as “no HEV infection”. Patients who were
positive for anti-HEV IgG and negative for IgM were categorized
as “past HEV infection”. “Current HEV infection” was defined as
HBV patients positive for anti-HEV IgM (anti-HEV IgG positive or
negative). Levels of AST, total and direct bilirubin and HBV-DNA
viral loads were elevated in the “current HEV infection” group com-
pared to the “no HEV infection” and “past HEV infection” groups
(P = 0.023 for AST, P = 0.01 for total bilirubin, P = 0.005 for direct
bilirubin, P = 0.026 for HBV-DNA viral loads) (Fig. 2). In contrast,
levels of albumin, prothrombin and platelet counts in the “current
HEV infection” group were lower compared to the “no HEVTable 2
Association of HEV seroprevalence with liver cirrhosis (LC) and prognosis of LC in HBV patient
Patient group
Anti-HEV IgG
Total n Positive n (%) OR (95% CI) P val
Cirrhosis status
Non-cirrhosis 936 395 (42.2) 1 Refer
Cirrhosis 382 191 (50) 0.94 (0.7–1.22) 0.65
Child–Pugh
Child A 235 91 (38.7) 1 Refer
Child B 117 79 (67.5) 3.3 (2.05–5.2) b0.00
Child C 30 9 (70) 1.9 (1.3–2.9) 0.002
Non-cirrhosis: HBV patients without liver cirrhosis; Cirrhosis: hepatitis B patients with liver cir
culated by using logistic regression model and adjusted for age and gender.infection” and “past HEV infection” groups (P b 0.001 for albumin
and prothrombin, P = 0.018 for platelets) (Fig. 2).
We formed three subgroups of patients with “no HEV infection”,
“past HEV infection” and “current HEV infection” for each patient
group including AHB, CHB, LC, HCC and patients with both LC and
HCC. We observed that AST levels were increased, while prothrombin
levels were decreased in the “current HEV infection” patients in CHB
group (P = 0.01) and for other clinical parameters no differences
were observed (Fig. 3).
3.6. Prevalence of HEV-RNA and Sequencing Analysis of HEV Isolates
HEV-RNA was detected in only one serum sample from a patient
with both LC and HCC. The phylogenetic analysis revealed that the
HEV isolate was close to a HEV genotype 3 (NCBI #ssID 1825526)
(Supplementary Fig. 1). The patient was negative for both anti-HEV
IgG and IgM, indicating that he was in the early phase of HEV infection.
4. Discussion
HEV superinfection in HIV-infected patients, but also in patients
with chronic HBV and HCV infections may aggravate the course of un-
derlying conditions (Dalton, 2012; Pischke et al., 2014). We describes.
Anti-HEV IgM
ue Total n Positive n (%) OR (95% CI) P value
ence 936 98 (9.5) 1 Reference
382 64 (16.8) 1.64 (1.1–2.4) 0.01
ence 235 25 (10.6) 1 Reference
01 117 31 (21.4) 2.3 (1.3–4.3) 0.007
30 14 (46.4) 2.7 (1.8–4.2) b0.0001
rhosis (with or without hepatocellular carcinoma); odds ratio (OR) and P values were cal-
Fig. 2. Clinical outcomes of HEV superinfection inHBV patients. Based on the positivity of anti-HEV IgG and anti-HEV IgM, HBV patients were categorized into three different groups as “no
HEV infection”, “past HEV infection” and “current HEV infection”. Different clinical and biochemical parameters including AST (A), ALT (B), albumin (C), total bilirubin (D), direct bilirubin
(E), prothrombin (F), platelets (G) and HBV-DNA viral loads (H) were compared. Box-plots illustrate medians with 25 and 75 percentiles and P values were calculated by using Kruskal–
Wallis test. The number in parenthesis indicates number of samples analyzed and those numbers in the respective groups vary for the clinical parameters because some patients were not
tested for all the clinical parameters.
Fig. 3. Clinical outcomes of HEV superinfection in patients with chronic HBV. HBV patients were categorized into three different groups as “no HEV infection”, “past HEV infection” and
“current HEV infection” based on the positivity of anti-HEV IgG and anti-HEV IgM. The levels of aspartate aminotransferase (AST) (A) and prothrombin (B) were compared. Box-plots il-
lustrated medians with 25 and 75 percentiles and P values were calculated by using Kruskal–Wallis test. The number in parenthesis indicates number of analyzed subject samples.
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2085N.X. Hoan et al. / EBioMedicine 2 (2015) 2080–2086higher HEV seroprevalences in patients with HBV-related liver disease
compared to healthy individuals. The frequency of HEV superinfection
in HBV patients was differentially distributed among progressive stages
of HBV infection. HEV infection was independently associated with the
prognosis of HBV-related LC and the clinical outcome of HBV infection.
HEV seroprevalences have previously been determined in general
populations and blood donors from various geographical settings
(Boutrouille et al., 2007; Cleland et al., 2013; Gallian et al., 2014; Guo
et al., 2010; Hau et al., 1999; Pittaras et al., 2014; Ren et al., 2014). Our
study shows prevalences of 31% and 5%of anti-HEV IgGand IgM, respec-
tively, in healthy Vietnamese individuals. Anti-HEV IgG seropositivity
was considerably higher than previously reported in rural areas of
Vietnam (Hau et al., 1999). This differencemight result from the sen-
sitivity and specificity of ELISA tests applied (Abravanel et al., 2014;
Mansuy et al., 2011). Comparative analysis of the sensitivity and
specificity of commercial test systems have been described in recent
reports showing comparable performance in terms of negative pre-
dictive value and slightly variable performance in relation to sensi-
tivity and specificity (Avellon et al., 2015; Pas et al., 2013; Wenzel
et al., 2013; Wu et al., 2014). In our study, the used MP HEV EIA
showed minor limitation with regard to sensitivity (IgM and IgG,
approx. 80% and approx. 75%, respectively) in agreement to recent
reports. However, the MP HEV EIA assay seemed to be robust and
suitable for our analysis generating a feasible and true number of
positive HEV IgM and IgG samples. Social and demographic charac-
teristics may also cause differences of seroprevalences (Hau et al.,
1999; Mansuy et al., 2011). Our results support studies in Chinese
blood donors, where anti-HEV IgG and IgM prevalences were approxi-
mately 30% and 1%, respectively (Guo et al., 2010; Ren et al., 2014).
Somewhat lower anti-HEV IgG prevalences of 3% to 17% occur among
most European populations (Beale et al., 2011; Boutrouille et al., 2007;
Cleland et al., 2013; Gallian et al., 2014; Juhl et al., 2014; Pittaras et al.,
2014; Ren et al., 2014). HEV seroprevalenceswere, however, exception-
ally high in southern France (53%) and Denmark (21%) (Christensen
et al., 2008; Mansuy et al., 2011).
This is the first study on HEV superinfection in Vietnamese HBV pa-
tients. Prevalences of anti-HEV IgG and IgM in patients were 45% and
12%, respectively. The HEV seroprevalence in our patient group differed
from other studies on HBV, HCV and HIV infections (Atiq et al., 2009;
Bayram et al., 2007; Feldt et al., 2013; Hamid et al., 2002). Anti-HEV
IgG prevalences in chronic HBV Turkish and American patients were
14% and 8% (Atiq et al., 2009; Bayram et al., 2007). In agreement with
other findings (Atiq et al., 2009), our results indicate that the HEV sero-
prevalence was higher in patients with HBV-related liver diseases com-
pared to healthy individuals, suggesting patients with HBV-related liver
diseases might have a higher risk for HEV infection (Hamid et al., 2002).
Nevertheless, similar findings were not observed in other studies
(Bayram et al., 2007; Hamid et al., 2002). A probable explanation
could be the sample size utilized in these studies and the study area.
These both factors may largely contribute for such dissimilarities in se-
roprevalence rates. In Europe, HEV infection was observed to be higher
in autoimmune hepatitis patients and not in patients with either chron-
ic hepatitis B or C (Pischke et al., 2014), whereas in endemic areas like
Vietnam, individuals usually acquire the HBV early in their life and
HEV infection subsequently through the fecal–oral transmission later.
A plausible explanation is that the patients primarily infected with
HBV may show an altered immune response and thus likely to be
more susceptible for HEV as a secondary infection. In addition, HEV su-
perinfection in HIV patients and development of chronic hepatitis E has
also been described (Dalton et al., 2009). Recently, a study has found a
seroprevalence of anti-HEV IgG in Ghana (45%) and Cameroon (14%)
(Feldt et al., 2013). However, no contribution of HEV infection to liver
pathology was observed. The HEV seroprevalence in our study group
was significantly associatedwith age, both in HBV patients and controls,
indicating cumulative exposure to HEV. Aging of the immune system
might also favor acquisition of HEV infection.Althoughmost HEV-infected individuals are asymptomatic, the out-
come of HEV superinfection in HBV patients appears more severe
(Cheng et al., 2013; Marion-Audibert et al., 2010; Monga et al., 2004).
Our results show increased levels of liver enzymes and total and direct
bilirubin and decreased levels of albumin, prothrombin and platelet
counts in HBV patients with concomitant HEV infection. In contrast to
an earlier study suggesting that chronic HBV infections may be inactive
during HEV–HBV coinfections (Cheng et al., 2013), we found higher
HBV-DNA loads in coinfections. Biochemical and serological tests sug-
gest that HEV superinfection contributes to inflammation and liver fail-
ure. HBV-DNA loadswere lower inHBVpatientswith past HEV infection
compared to thosewith no or patentHEV infection, suggesting that host
immune responses contribute to control HBV replication. HBsAg posi-
tive individuals had a poorer prognosis after HEV superinfection
(Chow et al., 2014; Wu et al., 2013).
Although associations of HEV infection with development and pro-
gression of LC were reported (Gerolami et al., 2008; Kumar et al.,
2007; Marion-Audibert et al., 2010), the mechanisms of LC induction
are unclear. According to previous studies, we show that HEV infections
were independently associated with underlying LC and progression in
chronic hepatitis B. Hepatocyte damage and immune responses during
HEV superinfection that leads to increased liver inflammation can
progress to LC. The severity of LC is classified based on the Child–
Pugh score, determined by a number of clinical and laboratory pa-
rameters such as bilirubin, albumin, and prothrombin levels. The as-
sociation of HEV superinfection with increased abnormalities of
bilirubin, albumin, and prothrombin levels supports that HEV super-
infection contributes to severity of HBV infection. Although the dif-
ference was not significant, the prevalence of anti-HEV antibodies
was increased among patients with HBV-related HCC. Therefore, tu-
morigenesis of HEV cannot be excluded.
In this study, we detected the presence of HEV-RNA in only one
serum sample from patient with both LC and HCC (negative for both
anti-HEV IgG and IgM) showing that this patient was in the early
stage of HEV infection. However, we could not follow up longitudinally
the patient confirmed positive for HEV-RNA to verify the chronicity of
HEV infection. HEV-RNA can persist longer in the stool than in the
blood (Kamar et al., 2012), therefore another limitation of the study is
that the nested PCR for detection of HEV-RNA from stool of the HBV pa-
tients and controls had not been performed due to the unavailability of
stool samples.
In conclusion, this study indicates high HEV seroprevalences in
Vietnamese patients with HBV-related liver diseases and in healthy
individuals. HEV infection may aggravate the clinical outcome of HBV
infection, especially in liver cirrhosis.
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Supplementary data 
Supplementary table 1: HEV seroprevalence in patients with HBV-related liver diseases 
Groups Total n Positive n (%) OR (95% CI) P value 
anti-HEV IgG         
HC 340 105 (30.9) 1 Reference 
AHB 26 11 (42.3) 1.97 (0.9-4.5) 0.11 
CHB 744 305 (41.0) 1.2 (1-1.34) 0.043 
LC 160 83 (51.9) 1.14 (0.98-1.3) 0.091 
HCC 166 79 (47.6) 1.05 (0.9-1.2) 0.4 
LC+HCC 222 108 (48.6) 1.05 (0.96-1.15) 0.25 
HBV patients 1318 586 (44.5) 1.34 (1.02-1.75) 0.034 
anti-HEV IgM 
    HC 340 16 (4.7) 1 Reference 
AHB 26 4 (15.4) 4.7 (1.37-16) 0.014 
CHB 744 65 (8.7) 1.3 (1-1.76) 0.056 
LC 160 30 (18.8) 1.7 (1.3-2.1) <0.0001 
HCC 166 20 (12) 1.2 (0.97-1.5) 0.089 
LC+HCC 222 33 (14.9) 1.15 (0.99-1.35) 0.074 
HBV patients 1318 153 (11.6) 2.2 (1.3-3.75) 0.005 
HC: healthy controls; AHB: acute hepatitis B; CHB: chronic hepatitis B; LC: patients with only liver 
cirrhosis; HCC: patients with only hepatocellular carcinoma; LC+HCC: patients with both liver cirrhosis 
and hepatocellular carcinoma; Odds ratio (OR) and P values were calculated by using logistic regression 
model and adjusted for age and gender. 
  
Supplementary table 2: HEV seroprevalence in patients with HBV-related liver diseases and in healthy controls according to age groups 
Age Group 





























Anti-HEV IgG  
             
<20 3/12 25.0 0/0 0.0 2/28 7.1 1/2 50.0 1/2 50.0 0/0 0.0 4/32 12.5 
20-29  26/118 22.0 2/8 25.0 29/137 21.2 1/4 25.0 0/6 0.0 0/1 0.0 32/156 20.5 
30-39 19/87 21.8 7/12 58.3 67/176 38.1 5/15 33.3 5/15 33.3 7/12 58.3 91/230 39.6 
40-49 12/33 36.4 2/6 33.3 82/173 47.4 19/29 65.5 16/34 47.1 25/41 61.0 144/283 50.9 
50-59 29/53 54.7 0/0 0.0 69/144 47.9 24/52 46.2 32/54 59.3 30/70 42.9 155/320 48.4 
≥60 16/37 43.2 0/0 0.0 56/86 65.1 33/58 56.9 25/55 45.5 40/98 40.8 160/297 53.9 
Total 105/340 30.9 11/26 42.3 305/744 41.0 83/160 51.9 79/166 47.6 108/222 48.6 586/1318 44.5 
Anti-HEV IgM  
             
<20 0/12 0.0 0/0 0.0 0/28 0.0 0/2 0.0 0/2 0.0 0/0 0.0 0/32 0.0 
20-29  1/118 0.0 0/8 0.0 11/137 8.0 0/4 0.0 0/6 0.0 0/1 0.0 11/156 7.1 
30-39 5/87 5.7 3/12 25.0 6/176 3.4 5/15 33.3 3/15 20.0 2/12 16.7 19/230 8.3 
40-49 6/18 33.3 1/6 16.7 20/173 11.6 10/29 34.9 3/34 8.8 6/41 14.6 40/283 14.1 
50-59 0/53 0.0 0/0 0.0 16/144 11.1 8/52 15.4 7/54 13.0 7/70 10.0 38/320 11.9 
≥60 4/37 10.8 0/0 0.0 12/86 14.0 8/58 13.8 7/55 12.7 18/98 18.4 45/297 15.2 
Total 16/340 4.7 4/26 15.4 65/744 8.7 31/160 19.4 20/166 12.0 33/222 14.9 153/1318 11.6 
HC: healthy controls; AHB: acute hepatitis B; CHB: chronic hepatitis B; LC: patients with only liver cirrhosis; HCC: patients with only hepatocellular 
carcinoma; LC+HCC: patients with both liver cirrhosis and hepatocellular carcinoma. 
  
Supplementary table 3: Association of HEV seroprevalence with HCC  
Patient Group Total n Positive n(%) OR (95% CI) P value 
anti-HEV IgG 
    
Non-HCC 930 399 (42.9) 1 Reference 
HCC 388 187 (48.2) 0.8 (0.6-1.1) 0.17 
anti-HEV IgM 
    Non-HCC 930 100 (10.8) 1 Reference 
HCC 388 53 (13.7) 1.06 (0.7-1.56) 0.78 
Non-HCC: Hepatitis B patients without hepatocellular carcinoma; HCC: patients with hepatocellular 
carcinoma (with or without LC); Odds ratio (OR) and P values were calculated by using logistic regression 




Supplementary figure 1: Phylogenetic analysis of HEV RNA sequence 
Phylogenetic tree was reconstructed from amplicons representing the overlapping ORF2/3 region of the 
identified HEV genome. The reference sequences were obtained from NCBI database along with 
GenBank accession numbers. A neighbor-joining tree was reconstructed with a bootstrap of 1,000 
replicates. The scale indicates the number of nucleotide substitutions per position. 
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ABSTRACT
The clinical manifestations of hepatitis B viral infection (HBV) include chronic 
hepatitis B (CHB), liver cirrhosis (LC) and hepatocellular carcinoma (HCC). The 
contribution of negative regulator suppressor of cytokine signaling-3 (SOCS3) 
promoter variants in HBV disease and SOCS3 hypermethylation in tumor tissues 
were investigated. The SOCS3 promoter region was screened for polymorphisms in 
878 HBV patients and in 272 healthy individuals. SOCS3 promoter methylation was 
examined by bisulfite sequencing. SOCS3 mRNA expression was quantified in 37 tumor 
and adjacent non-tumor liver tissue specimens. The minor allele rs12953258A was 
associated with increased susceptibility to HBV infection (OR=1.3, 95%CI=1.1-1.6, 
adjusted P=0.03). The minor allele rs111033850C and rs12953258A were observed in 
increased frequencies in HCC and LC patients compared to CHB patients (HCC: OR=1.7, 
95%CI=1.1-2.9, adjusted P=0.046; LC: OR=1.4, 95%CI=1.1-1.9, adjusted P=0.017, 
respectively). HBV patients with rs111033850CC major genotype had decreased viral 
load (P=0.034), whereas the rs12953258AA major genotype contributed towards 
increased viral load (P=0.029). Tumor tissues revealed increased hypermethylation 
compared to adjacent non-tumor tissues (OR=5.4; 95%CI= 1.9-17.1; P=0.001). 
Increased SOCS3 expression was observed in HBV infested tumor tissues than non-
HBV related tumor tissues (P=0.0048). SOCS3 promoter hypermethylation was 
associated with relatively low mRNA expression in tumor tissues (P=0.0023). In 
conclusion, SOCS3 promoter variants are associated with HBV susceptibility and 
SOCS3 hypermethylation stimulates HCC development.
INTRODUCTION
Hepatitis B virus (HBV) infection is a major health 
problem affecting approximately two billion people 
worldwide. Approximately 240 million individuals are 
chronically infected with 780,000 annually reported 
deaths due to HBV infection [1]. HBV infection causes a 
wide spectrum of clinical manifestations of liver diseases. 
Besides asymptomatic carriers, HBV causes chronic 
hepatitis B (CHB), liver cirrhosis (LC) and hepatocellular 
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carcinoma (HCC). The five-year cumulative risk for the 
development of HBV-related LC ranges between 10% and 
20% [2]. In addition, chronic HBV infection accounts for 
50% of all HCC cases and most HCC cases (70%-80%) 
occur in patients with HBV-related LC [3].
During the course of HBV infection, the mechanism 
of liver injury is dependent on the host immune responses 
[4]. The innate immune responses play a major role in 
suppression of viral replication and in inflammatory 
activity during the early stage of HBV infection. These 
responses include the secretion of interferons (IFNs) 
and cytokines, which are regulated by Janus kinase/
Signal Transducer and Activator of Transcription (JAK/
STAT) signaling [5, 6] and involvement of JAK/STAT 
pathway in HBV infection had been well documented 
[7, 8]. Suppressors of cytokine signaling (SOCS) 
family proteins (CISH and SOCS1 to SOCS7) belong 
to a classical negative feedback system that regulates 
cytokine transduction via JAK/STAT signaling pathway 
[9]. Of these SOCS family, SOCS3 is a key regulator of 
interleukin (IL)-6 and IL-10, which are activated by Toll-
like receptor stimulation. SOCS3 can inhibit the process 
of cell proliferation and cell survival through inhibition of 
STAT3 activation [6, 10]. STAT3, an oncogene, is largely 
correlated with NF-kβ activation [11, 12]. The activation 
of STAT3 by cytokines (e.g. IL-6 and IL-22) mediated 
by JAK/STAT signaling pathway was shown earlier to 
induce inflammation and subsequent carcinogenesis [10–
12]. SOCS3 functionally suppresses STAT3 activation 
and negatively regulate tumor development. Therefore, 
SOCS3 is a vital regulator of several diseases including 
atopic, autoimmune and infectious diseases, inflammation, 
and cancer development [13, 14].
SOCS3 overexpression has been shown in the liver 
tissue of CHB patients and is associated with the severity 
of inflammation suggesting that JAK/STAT signaling 
pathway is dysregulated in HBV-infected hepatocytes 
[15]. The hypermethylation in the CpG (5'-Cytosine-
phosphate-Guanine-3') islands of the SOCS3 promoter 
can be a prognostic indicator in cancer development [16]. 
In addition, SOCS3 expression is further influenced by 
SOCS3 polymorphisms, especially in the SOCS3 promoter. 
To date, SOCS3 polymorphisms were documented in 
several diseases including HCV infection and colorectal 
cancer [14, 17–20]. However, there are so far no 
available data on association of SOCS3 promoter variants 
with susceptibility to HBV infection and the clinical 
course of HBV-related liver diseases. In addition, the 
involvement of epigenetics during the clinical course of 
HBV infection needs to be studied. Therefore, this study 
aims to investigate whether SOCS3 promoter variants are 
associated with HBV infection and HBV-related liver 
diseases and to investigate the hypermethylation in the 
SOCS3 promoter region and corresponding SOCS3 mRNA 
expression in HBV-related HCC.
RESULTS
Baseline characteristics of study participants
The baseline characteristics of the 878 HBV-
infected patients and 272 healthy controls (HC) are 
shown in Table 1. Most HBV patients and HCs were male 
(86% and 66%, respectively). The median age of patients 
increased according to the clinical progression of the liver 
disease. HCs were younger than patient groups (P<0.05). 
The levels of liver enzymes ALT, AST and HBV loads 
were higher in CHB patients compared to other subgroups 
(P<0.01). As expected, albumin and prothrombin levels 
and platelet counts were lower in LC patients compared 
to the other patient groups (P<0.001). AFP levels were 
higher in HCC patients compared to CHB and LC patients 
(P<0.001). The clinical profile of the 37 HCC patients who 
underwent surgery and corresponding data of their liver 
specimens are described in Table 2. Most patients were 
male (89%) and were between 40-60 years of age (73%). 
The HCC patients were in early and/or at intermediate 
stage of liver cancer according to the Barcelona clinic liver 
cancer (BCLC) staging criteria (stage A: 70% and stage 
B: 30%). All the patients were Child-Pugh class A group 
according to Child-Pugh classification. HBV was the 
common etiology of the liver cancer in this study (46%), 
while 8% suffered from HCV infection, and 46% showed 
non-HBV/non-HCV related HCC.
SOCS3 promoter variants and HBV-related liver 
diseases
The genotype and allele frequencies of two SOCS3 
promoter SNPs (rs111033850T/C, rs12953258C/A) 
in clinically classified 878 HBV patients and 272 HCs 
are described in Table 3 and Supplementary Table 2. 
The analyzed SNPs in healthy controls were in Hardy-
Weinberg equilibrium (P>0.05). We compared the 
genotype and allele frequencies between HBV patients 
and HCs. We observed that heterozygous genotype 
rs111033850TC and minor allele rs111033850C were 
less frequent in HBV patients compared to HCs (OR=0.4, 
95%CI=0.3-0.6, adjusted P<0.0001 and OR=0.6, 
95%CI=0.4-0.8, adjusted P<0.0001; respectively). In 
contrast, the homozygous genotype rs12953258AA and 
the minor allele rs12953258A were more frequent in 
patients compared to HCs (OR=2.0, 95%CI=1.3-3.2, 
adjusted P<0.0001 and OR=1.3, 95%CI=1.1-1.6, adjusted 
P=0.03; respectively). A similar trend was observed for 
the SNP rs111033850T/C in the dominant genetic model 
and for the SNP rs12953258C/A in the recessive genetic 
model. These results indicated that the rs111033850TC 
contributes to a decreased risk of HBV infection while 
the genotype rs12953258AA contributes to increased 
susceptibility to HBV infection.
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Subsequently, we compared the genotype and 
allele frequencies between different subgroups of HBV 
patients. The genotype rs12953258AA was significantly 
more frequent in LC patients compared to CHB patients 
(OR=1.7, 95%CI=1.02-2.8; adjusted P=0.036). The 
genotype rs111033850TC was also significantly more 
frequent in LC, HCC and HCC+LC groups compared 
to CHB patients (LC vs. CHB: OR=2.6, 95%CI=1.4-
5.0, adjusted P=0.002; HCC vs. CHB: OR=2.6, 
95%CI=1.3-5.0, adjusted P=0.005; LC+HCC vs. 
CHB: OR=2.0, 95%CI=1-4.4, adjusted P=0.048). The 
alleles rs111033850C and rs12953258A were more 
frequent in HCC and in LC patients compared to 
CHB patients, respectively (OR=1.7, 95%CI=1.1-2.9, 
adjusted P=0.046 and OR=1.4, 95%CI=1.1-1.9, adjusted 
P=0.017).
We also observed the gene dose effect of the 
allele rs111033850C when compared CHB with HCC 
and HCC+LC groups (P for trend =0.046 and 0.026, 
respectively). This indicate that the allele rs111033850C 
was associated with an increased risk of HCC and that the 
allele rs12953258A was associated an increased risk of 
LC in CHB patients. There were no significant differences 
when comparing the genotype and allele frequencies of the 
two SOCS3 SNPs in LC and HCC groups with HCC+LC 
group.
Table 1: Clinical profiles of 878 HBV-infected patients and 272 healthy controls
Characteristics CHB (n=212) LC (n=243) HCC (n=220) LC + HCC (n=203) HC (n= 272)
Age (years) 43 [18-82] 55 [18-84] 55 [18-81] 50 [19-81] 36 [18-69] ‡α
Male (%) 74 84.4 92.7 94.1 66 †α
Child-Pugh 
classification (n)
Child A NA 117/236 101/173 93/164 NA
Child B NA 81/236 56/173 52/164 NA
Child C NA 38/236 16/173 19/164 NA
Missing NA 7 47 39 NA
Clinical 
parameters
AST (IU/L) 72 [15-3253] ‡β 52 [15-1221] 50 [17-2158] 49 [21-737] NR
ALT (IU/L) 69 [9-3382] ‡β 46 [8-1426] 46 [10-832] 44 [10-1095] NR
Total bilirubin 
(µmol/l)
17 [8-788] 29 [3-752] 14 [5-235] 22 [7-419] NR
Direct bilirubin 
(µmol/l)
7 [1-472] 12 [1-450] 5 [1.2-167] 8 [1-214] NR
Albumin (g/L) 42 [23-48] 30 [20-47]‡β 39 [27-49] 38 [23-47] NR
Prothrombin  
(% of standard)
87 [30-180] 53.5 [15-101]§β 80 [31-115] 74 [19.6-118] NR













4.3 [1.5-300] 7.4 [1.2-400] 196 [1.1- 438] §β 168 [1.6-489] §β NR
Abbreviations: CHB: chronic hepatitis B; LC: liver cirrhosis; HCC: hepatocellular carcinoma; HC: healthy control; PLT: 
platelets. AST and ALT: aspartate and alanine amino transferase; IU: international unit; NR: Normal range, NA: not 
applicable. Values given are medians and range. P values were calculated by student's t-test, Fisher exact test, and Mann-
Whitney- Wilcoxon test where appropriate. (†) P<0.05, (‡) P<0.01 and (§) P<0.001. (α) for comparison with LC, HCC and 
LC+HCC group; (β) for comparison with all other groups.
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SOCS3 promoter haplotypes and HBV-related 
liver diseases
The haplotypes were reconstructed based on the 
two SNPs (rs111033850T/C, rs12953258C/A) and the 
frequencies were presented in Table 4. Haplotype CC was 
found more frequently in HCs compared to HBV patients 
(OR=0.5, 95%CI=0.4-0.75, adjusted P=0.001) indicating 
that this haplotype contributes to a decreased risk of HBV 
infection. We further compared haplotype frequencies 
between different subgroups of HBV patients and 
observed that the frequencies of haplotypes TA and CC 
were significantly higher in LC, HCC and patients with 
both LC and HCC compared to CHB patients (P<0.01) 
(Table 4). This result indicates that the haplotypes TA 
and CC contribute to an increased risk of progression to 
Table 2: Characteristics of 37 HCC patients
Characteristics n (%)
Age (years)
< 40 4/37 (10.8)
40 - 60 27/37 (73)









Child A 37/37 (100)
BCLC staging Classification
Stage A 26/37 (70.3)
Stage B 11/37 (29.7)
Stage C and D 0/ 37 (0)
Clinical parameters Median (Range)
AFP (IU/ml) 240 [4.6 - 300]
HBV-DNA NA
PLT (103/ml) 211 [153 - 461]
AST (IU/ml) 52 [21 - 415]
ALT (IU/ml) 66.5 [17 - 242]
Total Bilirubin (µmol/l) 27.8 [8.9 - 315]
Direct Bilirubin (µmol/l) 6.7 [1 - 178]
Prothrombin (% of standard) 93 [75 - 125]
Protein (g/l) 73 [62 - 78]
Allbumin (g/l) 40 [32 - 48]
Abbreviations: BCLC: Barcelona Clinic Liver Cancer; HCC: hepatocellular carcinoma; AFP: Alpha feto protein; PLT: 
platelets; AST and ALT: aspartate and alanine amino transferase; IU: international unit; NA: not applicable.
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Cases vs. HC LC vs. CHB HCC vs. CHB HCC+LC vs. CHB














TT 190 (89.6) 198 (81.5) 178 (80.9) 162 (79.8) 191 (70.3) Reference Reference Reference Reference
TC 16 (7.5) 43 (17.7) 36 (16.4) 35 (17.2) 76 (27.9) 0.4 (0.3-0.6) <0.0001 2.6 (1.4-5.0) 0.002 2.6 (1.3-5.0) 0.005 2.0 (1- 4.4) 0.048
CC 6 (2.9) 2 (0.8) 6 (2.7) 6 (3.0) 5 (1.8) 1.1 (0.4 -3.0) 0.89 0.4 (0.1-2.0) 0.2 0.9 (0.2-3.1) 0.8 1.2 (0.3 - 
5.3)
0.8
P for trend 1.99 0.12 0.046 0.026
Allele
T 396 (93.4) 439 (90.3) 392 (89) 359 (88.4) 458 (84.2) Reference Reference Reference Reference
C 28 (6.6) 47 (9.7) 48 (11) 47 (11.6) 86 (15.8) 0.6 (0.4-0.8) <0.0001 1.6 (0.9-2.6) 0.07 1.7 (1.1-2.9) 0.046 1.7 (0.9-3.0) 0.09
Dominant
TT 190 (89.6) 198 (81.5) 178 (80.9) 162 (79.8) 191 (70.3) Reference Reference Reference Reference
TC & CC 22 (10.4) 45 (18.5) 42 (19.1) 41 (20.2) 81 (29.7) 0.5 (0.3-0.7) <0.0001 2.0 (1.1-3.7) 0.014 2.0 (1.1-3.8) 0.017 1.9 (1.1-3.7) 0.046
Recessive
TT & TC 206 (97.2) 241 (99.2) 214 (97.3) 197 (79.8) 267 (98.2) Reference Reference Reference Reference
CC 6 (2.9) 2 (0.8) 6 (2.7) 6 (3.0) 5 (1.8) 1.3 (0.5-3.7) 0.64 0.3 (0.1-1.8) 0.2 0.8 (0.2-2.8) 0.7 1.1 (0.3-5.3) 0.8
P for trend 0.058 0.059 0.55 0.33
rs12953258
CC 94 (44.3) 88 (36.2) 86 (39.1) 75 (36.9) 101 (37.1) Reference Reference Reference Reference
AC 72 (34) 88 (36.2) 88 (40) 84 (41.4) 140 (51.5) 0.7 (0.5-0.98) <0.0001 1.3 (0.8-2.0) 0.27 1.34 (0.8-2.2) 0.21 1.4 (0.8-2.4) 0.22
AA 46 (21.7) 67 (27.6) 46 (20.9) 44 (21.7) 31 (11.4) 2.0 (1.3-3.2) <0.0001 1.7 (1.02-2.8) 0.036 1.0 (0.6-1.7) 0.96 1.4 (0.7-2.7) 0.26
Allele
C 260 (61.3) 264 (54.3) 260 (59.1) 172 (42.4) 342 (62.9) Reference Reference Reference Reference
A 164 (38.7) 222 (45.7) 180 (40.9) 234 (57.6) 202 (37.1) 1.3 (1.1-1.6) 0.03 1.4 (1.1-1.9) 0.017 0.9 (0.7 - 1.2) 0.87 1.3 (0.9-1.8) 0.15
Dominant
CC 94 (44.3) 88 (36.2) 86 (39.1) 75 (36.9) 101 (37.1) Reference Reference Reference Reference
AC & AA 118 (55.7) 155 (63.8) 134 (60.9) 128 (63.1) 171 (62.9) 1.0 (0.7-1.3) 0.72 1.45 (0.9-2.2) 0.07 1.2 ( 0.8-1.8) 0.38 1.4 (0.8-2.3) 0.16
Recessive
CC & AC 166 (78.3) 176 (72.4) 174 (79.1) 159 (78.3) 241 (88.6) Reference Reference Reference Reference
AA 46 (21.7) 67 (27.6) 46 (20.9) 44 (21.7) 31 (11.4) 2.4 (1.6-3.7) <0.0001 1.5 (0.9-2.4) 0.08 0.9 (0.5-1.5) 0.61 1.2 (0.7-2.1) 0.47
Abbreviations: CHB: Chronic hepatitis B; LC: Liver cirrhosis; HCC: Hepatocellular carcinoma; HC: Healthy control;  
Cases = all HBV infected patients; n= Number of chromosomes; OR: adjusted Odd Ratio; ORs and P values were 
calculated by using binary logistic regression model adjusted for age and gender. P for trend was calculated by Cochran-
Armitage test. Bold values present the statistical significance.
LC and HCC in HBV patients. However, no significant 
difference was observed when haplotype frequencies of 
LC and HCC patients were compared.
SOCS3 promoter variants and clinical 
parameters
The HBV loads were lower in HBV patients with 
rs111033850CC compared to those with rs111033850TT 
and rs111033850TC (P=0.034). In contrast, viral loads 
were higher in HBV patients with rs12953258AA 
compared to those with rs12953258CC and rs12953258AC 
(P=0.029) (Figure 1A and 1C). To further examine this 
possible association, we compared HBV loads according 
to different genotypes for each SNP in the subgroups of 
HBV patients. A similar trend of HBV loads was observed 
in HCC+LC group for rs111033850 (P=0.045) and in LC 
group for rs12953258 (P=0.039) (Figure 1B and 1D). 
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Table 4: Association of SOCS3 haplotypes with HBV-related liver diseases
SOCS3
Haplotype 
HC CHB LC HCC HCC+LC Cases vs. HC LC vs. CHB HCC vs. CHB HCC+LC vs. CHB
































CC 92 (16.9) 24 (5.7) 42 (8.7) 46 (10.5) 46 (11.3)













Abbreviations: CHB: Chronic hepatitis B; LC: Liver cirrhosis; HCC: Hepatocellular carcinoma; HC: Healthy control;  
Cases = all HBV infected patients; n= Number of chromosomes; NA: not applicable; OR: Adjusted Odd Ratio; ORs and 
P values were calculated by using binary logistic regression model adjusted for age and gender. Bold values present the 
statistical significance.
Figure 1: Association of HBV loads with SOCS3 SNPs. A. and B. HBV viral loads according to different genotypes of SNP 
rs111033850T/C in all HBV patients and in patients with both liver cirrhosis and hepatocellular carcinoma, respectively. C. and D. HBV 
loads according to different genotypes of SNP rs12953258C/A in all HBV patients and in patients with liver cirrhosis, respectively. Box-
plots illustrate medians with 25 and 75 percentiles with whiskers to 10 and 90 percentiles; P values were calculated by Krusskal-Wallis test.
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However, there was no significant association of these 
SNPs with clinical parameters: ALT, AST, total and direct 
bilirubin, albumin, prothrombin, platelet counts and AFP 
(P>0.05) (Supplementary Figure 1 and 2). In addition, we 
also compared clinical parameters according to different 
haplotypes however we did not observe any significant 
association of SOCS3 promoter haplotypes with laboratory 
parameters.
Methylation status of SOCS3 promoter region in 
primary HCCs
In total, 127 CpG islands in the fragment of 1150 
bp (-1091 through +60) in the SOCS3 promoter region 
were investigated. We found that CpG islands were 
unmethylated in the fragment 1 (-1091 through -679) 
while were hypermethylated in the fragment 2 (-425 
through -217) and in the fragment 3 (-140 through 
-28) (Figure 2 and 3A). Subsequently, we analyzed 
methylation status in the SOCS3 promoter in 37 pairs 
of tissue samples (tumor and adjacent non-tumor 
tissues). We observed that the SOCS3 promoter region 
was methylated in 26/37 (70.3%) liver tumor tissues 
while only in 11/37 (29.7%) adjacent non-tumor tissues 
showed methylation patterns (OR=5.4, 95%CI=1.9-17.1, 
P=0.0011) (Figure 3A). This result indicates that SOCS3 
promoter methylation occurs more frequently in tumor 
tissues compared to adjacent non-tumor tissues. In 
addition, we analyzed the intensity of SOCS3 promoter 
methylation in 11 pairs of tissue samples, in which 
SOCS3 promoter methylation was detected in both 
tumor and adjacent non-tumor tissues. We observed that 
the methylation intensity was higher in tumor tissues 
compared to adjacent non-tumor tissues (P=0.012) 
(Figure 3B). In addition, we compared the status and 
intensity of SOCS3 promoter methylation between 
tissue samples (tumor and non-tumor) with and without 
HBV infection. However, no statistical significance was 
observed.
SOCS3 mRNA expression in primary HCCs
The mean levels of SOCS3 mRNA expression did 
not differ significantly between tumor and non-tumor 
tissues (Figure 4A and Supplementary Figure 3). The 
hypermethylated tumor tissues had significantly decreased 
SOCS3 mRNA expression than non hypermethylated 
tumor tissues (P=0.0023). However, there were no 
significant differences in SOCS3 mRNA expression 
between hypermethylated tumor and non-tumor liver 
tissues. (Figure 4B and Supplementary Figure 3). Our data 
demonstrate that the hypermethylation status in the SOCS3 
promoter is associated with downregulation of the SOCS3 
mRNA expression in tumor tissues.
SOCS3 mRNA expression discriminating between 
HCC and non-HCC tissue samples showed that SOCS3 
mRNA expression was significantly higher in HBV-related 
HCC tissues compared to non-HBV-related HCC tissues 
(P=0.0048) (Figure 4C and Supplementary Figure 3). 
In order to examine whether SOCS3 mRNA expression 
was associated with the development of liver cancer, 
we analyzed SOCS3 mRNA expression according to the 
BCLC staging classification. However, SOCS3 mRNA 
expression was not different between stage A and B HCC 
tissues (Figure 4D and Supplementary Figure 3).
DISCUSSION
The negative regulator SOCS3 is a key player in 
the modulation of the JAK/STAT signaling that control 
a number of inflammatory cytokines such as IL6 and 
IL16 [6] and is involved in infectious diseases and 
cancers [13, 14]. In addition, gene silencing mediated 
by aberrant methylation of CpG islands in the SOCS3 
promoter frequently occurs in malignancies [16, 21]. 
In this study, we investigated the possible association 
of SOCS3 promoter variants with the progression of 
HBV-related liver diseases and SOCS3 methylation 
with HBV-induced HCC. We showed that the SOCS3 
Figure 2: Schematic structure of SOCS3 gene presenting the location of CpG island. Methylation status of SOCS3 promoter 
region was analyzed by bisulfite sequencing (BS). The start codon site for SOCS3 gene is defined as +1. The shaded boxes depict the 
exons of the SOCS3 gene and open box represents the reported STAT3-binding site and the black boxes represent the region with aberrant 
methylation in the fragments 2 and 3.
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promoter variants are associated with HBV infection 
and HBV-related liver diseases. SOCS3 mRNA 
expression was higher in tumor tissues infected with 
HBV than non-infected tumor tissues. The aberrant 
methylation of the CpG islands in the SOCS3 promoter 
is associated with relatively low mRNA expression in 
tumor tissues.
This first study reports on the association of SOCS3 
variants with HBV susceptibility and progression of HBV-
related liver diseases. We have shown that the variants 
rs111033850T/C and rs12953258C/A are associated 
with HBV infection and the progression of HBV-related 
liver diseases. Particularly, the variant rs111033850T/C 
shows a heterozygous advantage in HBV susceptibility 
but might be a risk factor for the disease progression. 
The contribution of the minor allele rs111033850C to 
the increased risk of HCC in CHB patients is through 
the gene dose manner. In studies on hepatitis C, the 
rs4969170AA genotype was associated with antiviral 
IFN-α resistance with increased SOCS3 expression in 
HCV patients [14, 18]. The rs4969170A/G polymorphism 
was associated with HCV treatment-induced neutropenia 
Figure 3: Methylation status of the SOCS3 CpG islands in the promoter region. A. Methylation status of HCC tumor and 
non-tumor tissues. We randomly sequenced five to eight clones of PCR products amplified from Bisulfite treated genomic DNA for each 
liver tissue sample. The highly methylated CpG islands were found in two regions (from positions -425 to -217 and from positions -140 
to -28). Each square shape presents one CpG island, black color shows CpG islands with methylation and white color shows CpG islands 
without methylation. B. Methylation intensity of the 11 HCC tumor and 11 adjacent non-tumor tissue samples. P values were calculated 
by Mann-Whitney test.
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and thrombocytopenia in antiviral therapy with pegylated 
interferon alpha [17]. The rs4969170A/G polymorphism 
was associated with clinical features and prognosis of 
HCC after surgical treatment [22]. Our results support 
earlier findings that SOCS3 polymorphisms influence 
liver disease progression by modulating the SOCS3 
protein expression and thus down-regulate the JAK/STAT 
signaling.
In this study, we showed that HBV-DNA loads were 
associated with the SOCS3 promoter polymorphisms 
rs111033850T/C and rs12953258C/A. The HBV-DNA 
loads are an important and independent risk factor for 
liver disease progression in CHB patients [23, 24]. The 
effects of HBV replication during HBV persistence were 
regulated by many host factors [25]. Previous studies have 
shown that the control of HBV replication was regulated 
by JAK/STAT signaling, which is activated by IFNs 
[15, 26, 27]. IFNs play a central role in control of viral 
replication including HBV [28] and IFNs are controlled 
by JAK/STAT signaling, which is regulated by SOCS3 
protein [9]. Therefore, SOCS3 promoter variants might 
have contributed to control of HBV replication through 
IFN signaling, which is also regulated by JAK/STAT 
signaling. However, the effects of SOCS3 and its variants 
on the cytokine signaling that subsequently influence the 
HBV replication are required further studies.
Cytokines are involved in cell communication and 
are required for the defense against hepatitis viruses [28]. 
Previous study has shown that the HCV core protein 
impairs IFN-α-induced signal transduction via induction 
of SOCS3 expression [29] and therefore influences 
the outcome of antiviral therapy [30]. SOCS3 was 
Figure 4: Expression of SOCS3 mRNA in liver specimens from HCC patients. Quantitative real-time PCR (qRT-PCR) 
analysis presents comparison of SOSC3 mRNA level. A. The SOSC3 mRNA level in the tumor tissues and adjacent non-tumor tissues. 
B. The SOSC3 mRNA level in the tumor and in non-tumor tissues with methylation (M) and in the tumor and in non-tumore tissues with 
un-methylation (UM). C. The SOSC3 mRNA level in patients positive for HBV and in patients negative for both HBV and HCV. D. The 
SOSC3 mRNA level in patients at early HCC stage (Stage A) and in patients at intermediate HCC stage (Stage B). The GAPDH gene was 
used as a reference gene. The data are shown as the medians with inter-quartile range. P values were calculated by Mann-Whitney test.
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overexpressed in liver tissues and was strongly associated 
with severity of hepatic inflammation in CHB patients [15, 
27]. In accordance, SOCS3 overexpression was observed 
in liver tissues from HBV-infected patients rather than 
non-HBV patients. These results may indicate that HBV 
can induce SOCS3 expression, which in turn inhibits IFN 
signaling transduction resulting in the progression of liver 
diseases and failure of IFN treatment of HBV infection 
[27].
HCC development is often due to chronic liver 
injury, inflammation, and cirrhosis caused by the 
persistence of HBV infection. However, the interaction 
between HBV and SOCS3 in infected hepatocytes has not 
been clearly understood. DNA hypermethylation in the 
promoter region can lead to the silence of SOCS3 in HCC 
[16, 31]. SOCS3 silencing by promoter methylation is 
possibly involved in the progression of HBV-related liver 
cancer. In line with previous studies, our results showed 
that aberrant methylation in the SOCS3 promoter region 
was observed more frequently in tumor tissues compared 
to adjacent non-tumor tissues. Hypermethylation status 
in the SOCS3 promoter region may be a crucial factor 
for HCC development. However, SOCS3 expression 
in tumor and adjacent non-tumor tissues was not 
significantly different, suggesting that other factors such 
as phosphorylation, acetylation and microRNAs may also 
involve in the regulation of SOCS3 expression during 
progression of liver diseases [32]. In addition, both SOCS3 
methylation status and intensity were not significantly 
different between tissue samples (tumor and non-tumor) 
from patients with and without HBV infection. This 
indicates that HBV may not promote DNA methylation 
of host genes in infected hepatocytes. However, further 
studies are needed to verify this preliminary observation 
since the number of samples used for this analysis was 
rather small.
Although our data indicate that SOCS3 expression 
is associated with HBV infection and may involve in the 
progression of HBV-related liver diseases, the study has 
several limitations. A limited number of HCC tumor and 
non-tumor tissues were utilized. Due to the study design 
as a case-control study, SOCS3 expression over the 
course of HBV infection were not assessed longitudinally 
and therefore the causative effect of SOCS3 expression 
on progression of HBV-related liver diseases could not 
conclusively be determined. The insufficiency of some 
clinical and laboratory parameters such as HBV serology 
tests and HBV genotypes may weaken the findings 
indicating the crucial role of SOCS3 in the immune 
response to HBV infection and the disease outcomes.
In conclusion, the SOCS3 promoter variants 
rs111033850 and rs12953258 are associated with 
HBV infection and HBV-related liver diseases. DNA 
methylation in the SOCS3 promoter region is related to the 
regulation of SOCS3 expression and occurs frequently in 
HCC tumors of HBV-infected patients. Our study suggests 
that SOCS3 polymorphisms and methylation play an 
important role in regulation of SOCS3 expression and thus 
influences the progression of HBV-related liver diseases.
MATERIALS AND METHODS
Patients and liver specimens
878 unrelated Vietnamese HBV-infected patients 
were randomly recruited in a case-control design at 108 
Military Central Hospital and 103 Military Hospital 
of the Vietnam Military Medical University, Hanoi, 
Vietnam, between 2012 and 2013. With this sample size, 
we can detect the significance of common studied SOCS3 
variants according to the sample size estimation based on 
the 95% confidence interval, the lowest detection rate of 
minor allele set at the lowest value of 5%, a significance 
level of 5% and a power >90%. Patients were assigned 
to subgroups of disease based on clinical manifestations 
and liver function tests. Subgroups included chronic 
hepatitis (CHB, n=212), liver cirrhosis (LC, n=243), 
hepatocellular carcinoma (HCC, n=220) and patients 
with LC and HCC (LC+HCC, n=203). The diagnostic 
criteria for the CHB patients and the HBV-related LC 
were previously described [33]. The HBV-related HCC 
group was characterized as patients infected with HBV 
and was diagnosed based on the American Association 
for the Study of Liver Diseases (AASLD) practice 
guideline for HCC [34]. The patients with LC and 
HCC were characterized if the patients showed clinical 
manifestations and laboratory tests of both LC and HCC. 
The patients with LC were also categorized as Child-A, 
Child-B and Child-C based on Child-Pugh scores [35]. 
None of these HBV-infected patients had a history of 
alcohol or drug abuse. All participants were confirmed 
negative for anti-HCV and anti-HIV by ELISA assays. 
HBV-DNA loads and liver function tests including alanine 
transaminase (ALT), aspartate transaminase (AST), total 
bilirubin and direct bilirubin, albumin, prothrombin were 
quantified. 272 blood samples from healthy individuals 
were collected from blood bank as the control group. In 
addition, we analyzed 37 dyads of liver specimens (tumor 
and adjacent non-tumor) collected from HCC patients 
who underwent surgery at the 108 Military Central 
Hospital between 2013 and 2014. The HCC patients who 
underwent surgery were independent from 878 HBV 
patients. HCC was confirmed by histology and classified 
based on the BCLC classification [36]. All specimens 
were frozen at -80°C until use.
Ethics statement
Informed written consent was obtained after 
explanation of the study at the time of sampling from all 
participants. The study was approved by the institutional 
review board of the 108 Military Central Hospital and the 
Oncotarget17137www.impactjournals.com/oncotarget
103 Military Hospital of the Vietnam Military Medical 
University, Hanoi, Vietnam.
Genotyping of SOCS3 promoter variants
Genomic DNA was isolated from blood using DNA 
purification kits (Qiagen, Hilden, Germany). The SOCS3 
promoter region (nucleotides -1109 to -772) including 
two pre-described SNPs (rs111033850 and rs12953258) 
were amplified by PCR using primer pair SOCS3_PrF and 
SOCS3_PrR (Supplementary Table 1). PCR components, 
thermal conditions and sequencing procedures are 
presented in the Supplementary Materials.
SOCS3 promoter methylation analysis
Liver tissues were grounded using liquid nitrogen. 
Genomic DNA was extracted from liver powder using 
DNA purification kit (Qiagen, Hilden, Germany). 
Extracted DNA (2μg) was subjected to bisulfite 
conversion using EZ DNA Methylation-Direct™ Kit 
(Zymo Research Corp, the USA), according to the 
manufacturer’s protocol. Three different fragments were 
amplified from bisulfite-treated genomic DNA using three 
specific primer sets (Figure 2 and Supplementary Table 1). 
The PCR products were subsequently cloned into TOPO-
TA pCR2.1 vector (Life Technologies, the USA). Eight 
clones were randomly picked from each transformation 
(each tissue sample) and were analyzed for methylation 
by direct sequencing.
SOCS3 mRNA expression
Total RNA was extracted from 37 dyads of liver 
biopsy tissues with Trizol reagent (Life Technologies, 
the USA). RNA was reverse transcribed into cDNA using 
QuantiTect Reverse Transcription Kit (Qiagen GmbH, 
Hilden, Germany). cDNA quantification was performed 
by qRT-PCR and GAPDH (glyceraldehyde-3-phosphate 
dehydrogenase) gene was used as a reference gene. 
The specific primers used for evaluating SOCS3 mRNA 
expression as well as the PCR components and thermal 
conditions of qRT-PCR are presented in the Supplementary 
Materials. Calculation of normalized gene expression was 
based upon the ΔΔCT method.
Statistical and genetic analysis
All statistical analysis was performed using R 
version 3.1.2 (http://www.r-project.org) and GraphPad 
Prism 6 (http://www.graphpad.com). Genotype and allelic 
frequencies were determined by simple gene counting 
and the haplotype frequency was estimated using the 
expectation-maximum algorithm method implemented 
in the Arlequin v.3.5.2.2. The deviations from Hardy-
Weinberg equilibrium were calculated for each group. 
We used a binary logistic regression adjusted for age 
and gender to analyze association of SOCS3 variants 
with HBV-related liver diseases applying for different 
genetic models. In the binary logistic regression model, 
the disease subgroups and control group are considered 
as dependent variables. The genetic data are considered 
as independent variables (predictors) while age (treated 
as a continuous variable) and gender (treated as a binary 
variable) are independent confounding factors. In addition, 
the Cochran-Armitage test for trend was used to examine 
the gene dose effect of risk allele. Fisher’s exact test 
was used to test the difference of categorical variables 
between two groups. Student's t-test and Mann Whitney 
Wilcoxon test were used to compare the parametric and 
non-parametric data of quantitative variables between 
two groups, respectively. Kruskal-Wallis test was used 
to compare non-parametric data of quantitative variables 
among more than two groups. The level of significance 
was set at a value of P< 0.05.
Abbreviations
CHB, chronic hepatitis B; HBV, hepatitis B virus; 
HC, healthy control; HCC, hepatocellular carcinoma; LC, 
liver cirrhosis; SNP, single nucleotide polymorphism; 
SOCS3, suppressor of cytokine signaling-3.
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SOCS3 genetic variants and promoter hypermethylation in 
patients with chronic hepatitis B
SUPPLEMENTARY DATA
SUPPLEMENTARY MATERIALS AND 
METHODS
Genotyping of SOCS3 promoter variants
Genomic DNA was isolated from whole blood 
using a DNA purification kit (Qiagen, Hilden, Germany). 
The SOCS3 promoter region (nucleotides -1109 to -772) 
including two pre-described SNPs (rs111033850 and 
rs12953258) were amplified by PCR using primer pair 
SOCS3_PrF and SOCS3_PrR (Supplementary Table 1). 
PCR amplifications were carried out in a 25μl reaction 
volume containing (Qiagen): 1X PCR buffer, 0.2mM 
dNTPs, 1mM MgCl2, 0.15mM of each primer, 1unit of 
Taq polymerase and 50ng of genomic DNA. The cycling 
conditions were as follows: denaturation at 95°C for 
5min, followed by 40 cycles of three-step cycling with 
denaturation at 94°C for 30s, annealing at 63°C for 35s, 
and extension at 72°C for 45s and a final extension at 72°C 
for 7min. PCR products were purified using Exo-SAP-IT 
(USB, Affymetrix, USA). 5μl of purified PCR products 
were used as templates. The sequencing was performed 
using the BigDye terminator v.1.1 cycle sequencing 
kit (Applied Biosystems, Foster city, USA) on an ABI 
3130XL DNA sequencer according to the manufacturer’s 
instructions. Sequencing results were finally analysed 
using vector NTI v.10 software.
SOCS3 mRNA expression
Total RNA was extracted from 37 dyads of liver 
biopsy tissues with Trizol reagent (Life Technologies). 
RNA was reverse transcribed into cDNA using QuantiTect 
Reverse Transcription Kit (Qiagen GmbH, Hilden, 
Germany). Quantification of cDNA was performed 
by qRT-PCR using SYBR Green PCR mix (Bioline, 
Germany). All reactions were performed in triplicate 
using the LightCycler®480 real-time PCR system (Roche, 
Switzerland). The GAPDH (glyceraldehyde-3-phosphate 
dehydrogenase) gene was used as a reference gene. In 
addition, the TGFBRAP-1 gene (transforming growth 
factor, beta receptor associated protein 1) was selected as 
an additional reference gene using Genevestigator (https://
genevestigator.com/gv/). The specific primers used for 
evaluating the SOCS3 mRNA expression were presented 
in the Supplementary Table 1. The thermal cycling 
conditions were as follows: 2min at 95°C followed by 
45 cycles of denaturation at 95°C for 5s and annealing at 
58°C for 10s and extension at 72°C for 20s. The specificity 
of each reaction was confirmed by melting curve analysis. 
Calculation of normalized gene expression was based upon 
the ΔΔCT method. The fold change in SOCS3 expression 
was normalized to the expressed reference genes and 
then compared to the mean level expression in non-tumor 
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Supplementary Figure 1: Association of clinical parameters with SOCS3 rs111033850T/C variants. Box-plots illustrate 
medians with 25 and 75 percentiles with whiskers to 10 and 90 percentiles; P values were calculated by Krusskal - Wallis test.
SUPPLEMENTARY FIGURES AND TABLES
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Supplementary Figure 2: Association of clinical parameters with SOCS3 rs12953258C/A variants. Box-plots illustrate 
medians with 25 and 75 percentiles with whiskers to 10 and 90 percentiles; P values were calculated by Krusskal - Wallis test.
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Supplementary Figure 3: Expression of SOCS3 mRNA in liver specimens from HCC patients. Quantitative real-time PCR 
(qRT-PCR) analysis presents comparison of SOSC3 mRNA level. A. The SOSC3 mRNA level in the tumor tissues and adjacent non-tumor 
tissues. B, C. The SOSC3 mRNA level in the tumor and in non-tumor tissues with methylation (M) and in the tumor and in non-tumore 
tissues with un-methylation (UM). D. The SOSC3 mRNA level in patients positive for HBV and in patients negative for both HBV and 
HCV. E. The SOSC3 mRNA level in patients at early HCC stage (Stage A) and in patients at intermediate HCC stage (Stage B). The 
TGFBRAP-1 gene was used as a reference gene. The data are shown as the medians with inter-quartile range. P values were calculated by 
Mann-Whitney test.
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Supplementary Table 1: Primers used in this study
Primer Sequence Application
SOCS3_PrF 5'- CCG CGC TCA GCC TTT CTC TGC TGC GA-3' SOCS3 genotyping
SOCS3_PrR 5'-AGT CCA CAA AGG AGC CTT CGC GCG CG-3' SOCS3 genotyping
SOCS3_Fr1_F 5'-GTG TAG AGT AGT GAT TAA ATA-3' SOCS3 promoter methylation
SOCS3_Fr1_R 5'-TCC TTA AAA CTA AAC CCC CTC-3' SOCS3 promoter methylation
SOCS3_Fr2_F 5'-GAT TYG AGG GGG TTT AGT TTT AAG GA-3' SOCS3 promoter methylation
SOCS3_Fr2_R 5'-CCA CTA CCC CAA AAA CCC TCT CCT AA-3' SOCS3 promoter methylation
SOCS3_Fr3_F 5'- GGG AAG GGG TTG TTY GGG GTT ATT TTG -3' SOCS3 promoter methylation
SOCS3_Fr3_R 5'- CAA ACT AAT ATC CAA AAA ACA ACT CAT CC -3' SOCS3 promoter methylation
SOCS3_Exp_F 5'- CCC TCG CCA CCT ACT GAA -3' SOCS3 mRNA expression
SOCS3_Exp_R 5'- TCC GAC AGA GAT GCT GAA GA -3' SOCS3 mRNA expression
GAPDH_F 5'-TGCACCACCAACTGCTTAGC-3' SOCS3 mRNA expression
GAPDH_R 5'-GGCATGGACTGTGGTCATGAG-3' SOCS3 mRNA expression
TGFBRAP-1_F 5'-GCG GCT GTG TCC TTT CCA TA-3' SOCS3 mRNA expression
TGFBRAP-1_R 5'-GCG TCT GCT TCT GTT GCT GAT-3' SOCS3 mRNA expression
The specific primer pair SOCS3_PrF and SOCS3_PrR were designed to amplify nucleotides -1109 to -772 from start codon 
and were used for amplification and sequencing of the SOCS3 promoter region. Primers for fragment 1 were SOCS3_Fr1_F 
and SOCS3_Fr1_R [2], primers for fragment 2 were SOCS3_Fr2_F and SOCS3_Fr2_R [3], and primers for fragment 
3 were SOCS3_Fr3_F and SOCS3_Fr3_R. These primers were designed to amplify nucleotides -1091 to -679; - 704 to 
-186, and -295 to +60, respectively. The PCR amplification of the three fragments were performed as described previously 
(2;3). The specific primers used for evaluating the expression of SOCS3 mRNA were SOCS3_Exp_F and SOCS3_Exp_R 
[4]. Primers used for the reference genes were GAPDH_F and GAPDH_R (GAPDH) [5] and were TGFBRAP-1_F and 
TGFBRAP-1_R (TGFBRAP-1).
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Supplementary Table 2: Allelic and genotypic frequencies of SOCS3 variants in sub-HBV patient groups and healthy 
controls 
SOCS3 variants
CHB (%) LC (%) HCC (%)
HCC+LC 
(%) HC (%) CHB vs. HC LC vs. HC HCC vs. HC HCC+LC vs. HC















TT 190(89.6) 198(81.5) 178(80.9) 162(79.8) 191(70.3) Reference Reference Reference Reference
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CHB: Chronic hepatitis B; LC: Liver cirrhosis; HCC: Hepatocellular carcinoma; HC: Healthy control; Cases = all HBV 
infected patients; n= Number of chromosomes; OR: adjusted Odd Ratio; ORs and P values were calculated by using binary 
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ABSTRACT
This study investigates the association of Interferon-stimulated gene 15 (ISG15) 
polymorphisms, ISG15 serum levels and expression with HBV-related liver diseases. 
The ISG15 promoter and the two exons of the gene were screened for polymorphisms 
in 766 HBV-infected patients and in 223 controls. Soluble ISG15 levels were measured 
by ELISA. ISG15 mRNA expression was quantified by qRT-PCR in 36 tumor and 
adjacent non-tumor tissues. The exon 2 allele rs1921A was found associated with 
decreased progression of HBV-related liver diseases (LC vs. CHB: OR = 0.6, 95%CI = 
0.4-0.8, adjusted P = 0.003; HCC vs. CHB: OR = 0.6, 95%CI = 0.4-0.9, adjusted P = 
0.005). The rs1921AA genotype was associated with low levels of AST, ALT and total 
bilirubin, but with high prothrombin levels (P < 0.05). ISG15 serum levels were higher 
among HBV patients compared to controls (P < 0.0001) and positively associated with 
HBV-related liver diseases, with highest levels among LC patients. ISG15 levels were 
correlated with HBV-DNA loads (P = 0.001). In non-tumor tissues from HCC patients, 
ISG15 mRNA expression was increased in HBV compared to non-HBV infection (P = 
0.016). The ISG15 rs1921 variant and ISG15 expression are associated with HBV-
related liver diseases. Taken together, ISG15 appears to be a proviral factor involved 
in HBV replication and triggering progression of HBV-related liver diseases.
INTRODUCTION
Although effective vaccines for hepatitis B virus 
(HBV) infections are available, HBV-related liver diseases 
remain a health problem of considerable concern with 
250 million chronic carriers globally [1]. In Vietnam, the 
prevalence of HBV infection currently ranges from 10% to 
20% in general population and HBV-related liver diseases 
are foreseen and predicted to be a notable public health 
burden in the next decades [2]. HBV causes various forms 
of infection, ranging from an asymptomatic carrier status 
to liver cirrhosis (LC) and life-threatening hepatocellular 
carcinoma (HCC) [1]. Important factors influencing 
disease progression include the patient’s age, duration 
of HBV infection, and host-virus interactions. HBV has 
evolved various mechanisms to evade both innate and 
adaptive immune responses in order to establish persistent 
infections [3]. 
Currently, nucleos(t)ide analogues and Peg-
Interferon alpha are the main classes of antivirals to 
treat chronic hepatitis B (CHB) [4,5]. IFN-α mediates 
signal transduction by binding to its receptors. Tyrosine 
phosphorylation of signal transducer and activator of 
transcription 1 (STAT1) and STAT2 leads to the formation 
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of transcriptional complexes, which translocate to the 
nucleus and activate expression of certain genes [6]. 
IFN-stimulated gene factor 3 (ISGF3) is composed of 
phosphorylated forms of STAT1, STAT2 and interferon 
regulatory factor 9 (IRF9). This complex binds to 
interferon (IFN)-stimulated response elements (ISREs) 
located in the promoters of interferon-stimulated genes 
(ISGs) [6]. Among ISGs, the human ISG15 is a 15 kDa 
protein encoded by ISG15 located on chromosome 
1p36.33 (OMIM# 147571) [7]. ISG15 is a strongly 
induced protein in various cellular processes [8,9]. 
It exists in free and/or conjugated forms (ISGlation), 
covalently conjugated to protein targets via consecutive 
action of conjugating enzymes such as ubiquitin activating 
E1 (UbE1L), E2-conjugating enzyme (UbcH8) and E3 
ligases. The ubiquitin-specific protease 18 (USP18), which 
has deconjugating protease functions, cleaves ISG15’s 
substrates and removes ISG15 (deISGylation) from ISG15 
conjugates [8]. 
Several studies have indicated that aberration of 
cell signaling in the ISG15 pathway perturbates ISG15 
regulation and causes malignant transformation of 
various human cancers [10-14]. ISG15 overexpression in 
liver tumor tissue is associated with pathology and poor 
outcome of HCC patients [12,13]. ISG15 plays also a 
role in the response to many viral infections [9,15-18]. A 
recent study has shown that knockdown of ISG15 results 
in suppression of hepatitis C virus (HCV) replication 
in vitro by promoting the IFN response, suggesting 
involvement of ISG15 in regulating HCV replication 
[19,20]. Furthermore, patients who respond favorably to 
IFN treatment of hepatitis C have low expression levels 
of ISG15 and its conjugates in the liver compared to 
non-responders [21,22]. So far, two studies using mouse 
models have documented the role of ISG15 in HBV 
pathogenesis. They concluded that mice injected with 
murine IFN-α expression plasmid along with HBV had 
higher expression levels of ISG15 [23], and an ISG15-
deconjugating enzyme (USP18) reduced expression is 
associated with rapid HBV clearance [24]. However, the 
functional role of ISG15 in the HBV replication cycle, 
immune response and clinical progression of HBV-related 
liver diseases remains poorly understood. We investigated 
possible ISG15 associations, of ISG15 serum levels and 
ISG15 expression with outcomes of HBV infection and 
progression of HBV-related diseases.
RESULTS
Study participants
Baseline characteristics of the clinically well-
characterized 766 HBV patients and of the 223 healthy 
controls (HCs) are given in Table 1. The median age of 
patients increased according to the progression of disease 
(P < 0.001). ALT, AST, total bilirubin and direct bilirubin 
levels as well as HBV loads were higher among CHB 
patients compared to other subgroups (P < 0.0001). As 
expected, albumin and prothrombin levels and platelet 
counts were lower in LC patients compared to the other 
patient groups (P < 0.0001). AFP levels were higher in 
HCC patients compared to the CHB and LC subgroups (P 
< 0.0001). Of the 36 HCC patients who underwent surgery, 
32 were males and most patients (27/36, 75%) were aged 
between 40-60 years. According to Barcelona Clinic Liver 
Cancer (BCLC) staging [25], 25/36 (69%) HCC patients 
were in stage A and 11/36 (31%) HCC patients in stage B. 
Table 1: Characteristics HBV patients segregated according to clinical presentation and healthy controls
Characteristics CHB (n = 262) LC (n = 241) HCC (n = 263) HC (n = 223)
Age (years) 42 [18-82] 54 [18-84] 58 [18-81] 37 [18-69]
Male (%) 74.5 83.7 92.2 66.4
AST (IU/L) 49 [14-7700] ‡ β 75 [15-1221] 60 [17-2158] <40
ALT (IU/L) 58 [9-4908] ‡ β 56 [8-1426] 46 [11-832] <40
Total bilirubin (mg/dL) 16 [6-357] ‡ β 30 [3-752] 18 [6-419] <17
Direct bilirubin (mg/dL) 5 [1-226] ‡ β 12 [1-450] 6.5 [1.2-214] <5
Albumin (g/L) 41 [23-50] 33 [20-47] ‡β 38 [22-49] >35
Prothrombin (% of standard) 87 [30-180] 54 [15-101] ‡β 80 [20-149] >70
WBC (x103/mL) 6 [3.6-13.9] 5.6 [1.7-20.5) 6 [6.6-16] 4 - 10
RBC(x106/mL) 4.8 [3.2-6.8) 3.9 [1.9-6.7) 4.5 [2.1-6.8) 4 - 9
PLT (x103/mL) 195 [19-472] 89 [18-441] ‡ β 166 [34-389] 150 -300
HBV-DNA (copies/mL) 5.8x10
5 [2x102- 8.4x1010] 
‡ β 1.8x10
4 [1.8x102- 4.7x109] 8.2x10
5[102-
3x1010] NA
AFP (IU/L) 2.9 [1.5-320] 36 [1.2-400] 196 [1.1-480] ‡ β <5
CHB, chronic hepatitis B; LC, liver cirrhosis; HCC, hepatocellular carcinoma; HC, healthy control; RBC, red blood cells; 
WBC, white blood cells; PLT, platelets. AST and ALT, aspartate and alanine amino transferase; AFP, alpha-fetoprotein; IU, 
international unit; NR, normal range, NA, not applicable. Values given are medians and ranges. (β) Kruskal-Wallis test was 
used to test differences of nonparametric data. (‡): P < 0.0001 for comparisons with other groups.
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Among all HCC patients, 17/36 (47%) had HBV infection, 
2/36 (6%) had HCV infection, and 17/36 (47%) showed 
non-HBV/HCV-related HCC (Suppl. Table 1).
Association of ISG15 rs1921 variant with HBV-
related liver diseases
The genotype frequencies of the ISG15 rs1921 
variant in HCs were in Hardy-Weinberg equilibrium (P 
= 0.166), whereas other promoter and exonic variants 
were not. Therefore, only ISG15 rs1921 was considered 
for further analyses. The genotype and allele frequencies 
in different subgroups and the association analyses are 
presented in Table 2. Genotype and allele frequencies of 
ISG15 rs1921 did not differ between HBV patients and 
controls, indicating that ISG15 rs1921 is not associated 
with HBV infection per se. However, the rs1921GA 
genotype occurred more frequently among CHB patients 
compared to the LC and HCC subgroups (LC vs. CHB, 
OR = 0.5, 95%CI = 0.3-0.8, adjusted P = 0.036; HCC vs. 
CHB, OR = 0.5, 95%CI = 0.3-0.8, adjusted P = 0.014). 
The minor allele rs1921A was more frequent in CHB than 
in HCC and LC patients (LC vs. CHB, OR = 0.6, 95%CI 
= 0.4-0.8, adjusted P = 0.003; HCC vs. CHB, OR = 0.6, 
95%CI = 0.4-0.9, adjusted P = 0.005). In a dominant 
genetic model, we also observed that minor allele rs1921A 
was associated with an increased protection against LC 
and HCC (LC vs. CHB, OR = 0.5, 95%CI = 0.3-0.7, 
adjusted P = 0.0016; HCC vs. CHB, OR = 0.5, 95%CI 
= 0.4-0.8, adjusted P = 0.003) (Table 2). These results 
indicate that rs1921A may contribute to a decreased risk 
of progression to LC and HCC in HBV infection.
In order to explore the influence of ISG15 rs1921 
on the clinical outcome of HBV-related liver disease, 
we compared clinical parameters among patients with 
different ISG15 rs1921 genotypes (GG, GA and AA). 
Pathological liver function tests as indicated by high levels 
of AST, ALT, total bilirubin, direct bilirubin and by low 
prothrombin levels were observed rather in HBV patients 
with the rs1921GG genotype (P < 0.05) (Figure 1) than 
in the other subgroups. AFP levels and viral loads were 
higher in patients with rs1921GG compared to those with 
either rs1921AA or rs1921GA. However, the difference 
was not significant (P>0.05) (Figure 1 and Suppl. Figure 
1A). 
ISG15 serum levels and HBV-related liver 
diseases
We quantified ISG15 levels in serum samples 
of 470 HBV patients and 175 healthy controls. ISG15 
serum levels were significantly lower in the control 
Figure 1: Association between ISG15 variant with clinical parameters in HBV patients. Box-plots illustrate median values 
with 25 and 75 percentiles with whiskers to 10 and 90 percentiles; P values were calculated by Kruskal-Wallis tests. AST and ALT, aspartate 
and alanine amino transferase; AFP, alpha-fetoprotein.
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group (median: 3.4 ng/ml) compared to all HBV patients 
(median: 8.1 ng/ml), and compared to the median values 
of the different subgroups (CHB, 6.5 ng/ml; LC, 12 ng/
ml; HCC 8.0 ng/ml; P < 0.0001) (Figure 2A). Among 
the HBV patients, ISG15 levels were lower in the CHB 
than in the combined LC and HCC subgroups (P = 0.008 
and 0.04; respectively) (Figure 2A, 2B). In addition, all 
LC, including HCC patients with concomitant LC, had 
significantly higher ISG15 levels than non-LC patients 
(P = 0.00083) (Figure 2C). However, ISG15 levels did 
not differ significantly between patients with and without 
HCC (HCC vs. CHB+LC: P>0.05) (Figure 2A and Suppl. 
Figure 2). These results show that ISG15 induced by HBV 
infection may play a role in progression of HBV-related 
liver diseases. 
ISG15 rs1921 variant and ISG15 serum levels
We analyzed the association of the ISG15 rs1921 
variant with ISG15 serum levels in HBV patients and 
controls. ISG15 serum levels in HBV patients with the 
genotype rs1921GG were marginally higher than those 
in HBV patients with either rs1921AA or rs1921GA 
genotypes (P = 0.089) (Suppl. Figure 1B). Among 
controls, ISG15 levels did not differ among individuals 
with the various genotypes (P>0.05).
ISG15 serum levels and viral loads
Of 766 HBV patients, 222 were available for 
analyses of the correlation between ISG15 serum levels 
and HBV-DNA viral loads. ISG15 serum levels were 
significantly higher in patients with high viral loads (viral 
loads ≥105 copies/ml) compared to patients with lower 
levels (viral loads < 105 copies/ml) (Figure 3A). In a 
simple linear regression analysis, the ISG15 serum levels 
were positively correlated with HBV-DNA loads (r = 0.28, 
P < 0.0001) (Figure 3B). High levels of HBV replication 
and LC were, in a multivariate linear regression model, 
independently associated with increased ISG15 serum 
levels (P = 0.0011 and 0.008, respectively) (Table 3).
ISG15 mRNA expression in primary HCC
We also analyzed expression of ISG15 mRNA in 
HCC tissue specimens and in adjacent non-tumor liver 
tissues retrieved from 36 primary HCC patients. The mean 
of ISG15 mRNA expression in liver tumor tissues was 
higher than in adjacent non-tumor tissues (not significant; 
Figure 4A). We examined whether ISG15 mRNA 
expression can be up-regulated during HCC development, 
however, ISG15 mRNA expression did not differ between 
stage A and stage B HCC tissues (Figure 4B). We further 
examined whether ISG15 mRNA expression is associated 
with HBV infection. ISG15 mRNA expression was 
significantly higher in HBV-related non-tumor tissues 
compared to non-HBV-related non-tumor tissues (P = 
0.016). A similar trend was observed when comparing 
HBV-related and non-HBV-related tumor tissues, but the 
difference was not significant (Figure 4C). These results 
indicate that increased expression of ISG15 in liver tissues 
is regulated by HBV infection. 
DISCUSSION
The interferon signaling pathway constitutes the 
first-line defense against viral infections. ISGs can regulate 
the host immune response, which in turn may inhibit 
viral replication [8,9,26,27]. The role of ISG15 in host 







HBV patients vs. 
HCs LC vs. CHB HCC vs. CHB HCC vs. LC




GG 161(61.5) 180(74.7) 198(75.3) 158(70.7) Reference Reference Reference Reference
GA 92(35.1) 57(23.7) 58(22.1) 56(25.2) 1.2(0.8-1.6) 0.43 0.5 (0.3-0.8) 0.006 0.5 (0.3-0.8) 0.014 0.9(0.6-1.4) 0.53
AA 9(3.4) 4(1.7) 7(2.6) 9(4.1) 0.7 (0.3-1.6) 0.89 0.4 (0.1-1.5) 0.17 0.3 (0.1-1.2) 0.12 1.9(0.5-6.7) 0.47
Allele
G 414(79) 417(86.5) 454(86.3) 416(84.9) Reference Reference Reference Reference
A 110(21) 65(13.5) 72(13.7) 74(15.1) 1.1(0.8-1.4) 0.90 0.6 (0.4-0.8) 0.003 0.6 (0.4-0.9) 0.005 1.0(0.7-1.5) 0.95
Dominant
GG 161(61.5) 180(74.7) 198(75.3) 157(70.7) Reference Reference Reference Reference
GA&AA 101(38.5) 61  (25.3) 65 (24.7) 65(29.3) 1.1(0.8-1.5) 0.62 0.5 (0.3-0.7) 0.0016 0.5 (0.3-0.8) 0.003 0.9(0.6-1.4) 0.83
Recessive
GG&GA 253(96.6) 237 (98.3) 256(97.4) 213(95.9) Reference Reference Reference Reference
AA 9(3.4) 4(1.7) 7(2.6) 9(4.1) 0.7(0.3-1.5) 0.34 0.5 (0.1-1.8) 0.25 0.6 (0.2-1.9) 0.32 1.9(0.5-68) 0.31
CHB, chronic hepatitis B; LC, liver cirrhosis; HCC, hepatocellular carcinoma; HC, healthy controls; n = numbers genotyped; 
OR, Odd Ratio. P values were calculated using binary logistic regression model adjusted for age and gender. Bold values 
reflect statistical significance.
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defense against invading viral pathogens has previously 
been documented [9,19,26,27]. ISG15 and its conjugates 
exhibit both antitumor and oncogenic properties [8,28]. 
We have investigated the role of ISG15 variants and 
ISG15 expression in the progression of HBV-related liver 
diseases and could show that the non-synonymous ISG15 
rs1921 variant, ISG15 levels and ISG15 expression are 
associated with HBV-related liver diseases.
Host genetic factors contribute to the progression 
of HBV-related liver diseases [29]. To the best of our 
knowledge, this is the first study showing an association 
of the ISG15 rs1921 variant with the clinical outcome of 
HBV-related liver diseases. The frequency of the rs1921G 
allele in different Vietnamese HBV patient subgroups 
and controls fits in the range estimated for East Asian 
of the 1000 Genomes project. The rs1921GG genotype 
and rs1921G allele are associated with progression 
of liver disease and contributes to poor laboratory 
parameters. The ISG15 rs1921 exon 2 variant harbors a 
missense mutation (S355N) and, thus, may influence gene 
expression and protein modification. ISG15 targets many 
cellular proteins, including Janus kinase 1 (JAK1), STAT1 
and ISGs via ISGlation [30], a process that can regulate 
HBV pathogenesis. However, our study failed to detect 
a significant association of ISG15 rs1921 with ISG15 
expression. Our result is similar to a recent observation 
showing that rs1921 variant had no influence on ISG15 
expression in European human immunodeficiency virus 
(HIV)-1 patients and healthy individuals [31]. It may be 
more likely that this missense variant may alter the binding 
affinity to its conjugate. Polyphen and Sift algorithms 
used for predicting functional consequences of nucleotide 
Figure 2: ISG15 serum levels in healthy individuals and in HBV patient sub-groups. HC, healthy controls; CHB, chronic 
hepatitis B; LC, liver cirrhosis; HCC, hepatocellular carcinoma; Cirrhosis: combination of patients with LC and patients with both HCC 
and LC; non-cirrhosis: combination of CHB patients and HCC patients without liver cirrhosis. (***): P < 0.0001 for comparison with other 
groups. Dot plots illustrate medians with inter-quartile range. P values were calculated by Mann-Whitney-Wilcoxon test. 
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substitutions classify this variant as “benign” and 
“tolerated”, respectively. The association may be due to 
linkage disequilibrium with another variant (a hitch-hiking 
effect). However, the effect of rs1921 on ISG15 function 
and the ISGlation process requires further clarification.
ISG15 and its ISGlation form mediate innate 
immune responses through IFNs, lipopolysaccharide and 
double-stranded RNA (dsRNA) stimulation [30]. Higher 
ISG15 serum levels in HBV patients than in healthy 
individuals and an increased ISG15 mRNA expression 
Table 3: Factors associated with ISG15 serum levels in HBV patients
Variables 
Univariate analysis Multivariate analysis 
P value P value Coefficient β 
Age 0.31 0.57 -0.0096 
Gender (male vs. female) 0.4 0.3 0.13 
HBV-DNA (log10 copies/mL) <0.0001 <0.0001 0.14 
ALT (IU/L) 0.42 0.57 -0.00013 
AST (IU/L) 0.46 0.88 -0.00003 
Albumin (g/L) 0.30 0.12 0.02 
Total Bilirubin (µmol/L) 0.13 0.8 -0.00017 
Prothrombin (% of standard) 0.0015 0.16 -0.0004 
Platelets (x103/mL) 0.47 0.11 -0.0011 
HCC vs. non-HCC 0.9 0.12 0.2 
Cirrhosis vs. non-Cirrhosis 0.00032 0.009 0.3 
ISG15 genotype (GA vs. AA) 0.55 0.77 -0.66
ISG15 genotype (GG vs. AA) 0.51 0.62 -1.08
Univariate analysis and multivariate linear regression model for independent factors to correlate ISG15 serum levels with 
clinical parameters.
Figure 3: Association of ISG15 serum levels with viral loads in HBV patients. A. Dot plots illustrate median values with 25 
and 75 percentiles with whiskers to 10 and 90 percentiles. P values were calculated by Mann-Whitney-Wilcoxon test. B. Linear regression 
analysis indicates a positive correlation between ISG15 serum levels and HBV-DNA in CHB patients. Non parametric Spearman’s rank 
correlation coefficient (r) and P values are presented.
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observed in HBV-related liver tissues compared to non-
HBV/HCV-related liver tissues demonstrate that HBV 
infection induces ISG15 expression. This is in agreement 
with the fact that the major host response to viral infection 
is the production of IFNs, which in turn stimulate ISG15 
expression. The notion of antiviral activities of both ISG15 
and ISGlation came from studies using an ISG15 knockout 
mice model [15,32]. Mice lacking ISG15 expression were 
more susceptible to influenza, sindbis and herpes simplex 
viruses [15]. Recent studies have explored the biological 
functions of ISG15 and related conjugates that can impair 
viral replication in vivo [18,32-34]. In contrast, our study 
showed that ISG15 levels were positively correlated with 
viral loads, implying a contradictory effect of ISG15 on 
antiviral activities. This is consistent with studies showing 
that ISG15 can promote HCV replication [19,35,36].
Host immune factors are essential in the immune-
pathogenesis of HBV infection through genetic and 
epigenetic modifications [37,38] and via the effects of 
cytokines [39]. An ineffective immune response against 
HBV may result in persistent virus replication and liver 
inflammation, leading to CHB, LC and HCC [39]. ISG15 
appears to act as an immune-modulator regulating the 
expression of cytokines, in particular of the IFN signalling 
pathway. Previous studies have indicated that ISG15 
upregulation leads to a blunted immune response to IFN 
signalling and contributes to a poor outcome of IFN-based 
therapy in HCV patients [19,40]. In addition, higher levels 
of ISG15 were observed in treatment failure compared to 
responders to IFN-based treatment [36,40]. Therefore, 
high levels of ISG15, combined with clinical, biochemical 
and histological analyses may be useful to predict the 
outcome of HBV-related liver disease and may help to 
identify HBV-infected individuals positively responding 
to IFN treatment.
The biological function of ISG15 promoting or 
suppressing tumor growth remains controversial [28] and 
antagonistic roles of ISG15 in tumorigenesis have been 
Figure 4: Expression of ISG15 mRNA in liver specimens from 36 primary HCC patients. Relative quantitative real-time 
PCR (qRT-PCR) analysis of ISG15 mRNA levels A. Relative ISG15 mRNA expression in tumor and adjacent non-tumor tissues. B. 
Relative ISG15 mRNA expression in tumor tissues from HCC stage A patients and HCC stage B patients according to the BCLC staging 
classification. C. Relative ISG15 mRNA expression in liver tissues from patients positive for HBV and in patients negative for both HBV 
and HCV. Data are shown as mean values with 95% confident intervals. P values are calculated by Mann-Whitney-Wilcoxon tests.
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reported [28,41,42]. Several studies have demonstrated 
that ISG15 is an oncoprotein, as ISG15 gene expression 
and its protein conjugates were found elevated in tumor 
cell lines and in various human malignancies [10,12-
14,41,43-46]. High levels of ISG15 serum protein in HCC 
patients and mRNA expression in liver tumor tissues also 
suggest that ISG15 may serve as a protumor factor. In 
contrast, other studies reported that free ISG15 has the 
potential to induce antitumor responses [47,48]. These 
discrepancies could be due to the functional differences 
of free ISG15 and ISG15 conjugates [28,42]. So far it is 
clear that ISG15 overexpression is crucial in modulating 
cell growth and in the progression of breast cancer 
[10,41]. The functional role of ISG15 in HCC, however, 
is still unclear. ISG15 overexpression is associated with 
poor clinical outcomes [12,13]. Moreover, knocking 
down ISG15 by shRNA ISG15 can lead to a remarkable 
reduction of HCC cell proliferation and migration [13]. 
Although our data indicate that ISG15 over-
expression is regulated by HBV infection and may trigger 
liver disease progression, the study has limitations. Due 
to the study design as a case-control study, ISG15 levels 
over the course of HBV infection were not assessed 
longitudinally and the causative effect of ISG15 levels 
on progression of HBV-related liver diseases could not 
conclusively be determined. HCC patients who donated 
liver tissues were in early and intermediate stages of liver 
cancer, which also might influence our results. Therefore, 
further studies in HCC patients with advanced stages 
of liver cancer are required to correlate ISG15 mRNA 
expression with cancer progression.
In conclusion, our study shows that both the ISG15 
rs1921 variant and ISG15 overexpression are associated 
with HBV-related liver diseases and indicate that ISG15 
may be a proviral factor and trigger progression of HBV-
related liver diseases.
MATERIALS AND METHODS
Study design and sample collection
We randomly recruited 766 unrelated Vietnamese 
HBV-infected patients in a case-control design at 108 
Military Central Hospital and 103 Military Hospital of the 
Vietnam Military Medical University, Hanoi, Vietnam, 
between 2012 and 2015. Patients were assigned to 
subgroups of disease based on clinical manifestations and 
liver function tests. Subgroups included chronic hepatitis 
B (CHB, n = 262), HBV-related liver cirrhosis (LC, n = 
241) and HBV-related hepatocellular carcinoma (HCC, 
n = 263). Criteria for the patient classification have been 
described previously [49]. HBV load is quantified by 
qPCR and the presence of HBsAg by ELISA. Among the 
263 HCC patients, 180 (68.4%) had concomitant LC and 
the remaining 83 patients (21.6%) did not have LC. As 
the healthy control (HC) group, we collected 223 blood 
samples from blood donors from blood bank and these 
healthy individuals were devoid of HBsAg, HCV and 
HIV infections. Neither the HCs nor HBV patients had 
a history of alcohol or drug use. Five ml of venous blood 
were collected from all participants. Serum/plasma was 
separated and stored at -80°C until further use. In addition, 
36 dyads of liver tissue specimens (tumor and adjacent 
non-tumor specimens) from HCC patients undergoing 
surgery were collected between 2013 and 2014. HCC 
was confirmed histologically and classified based on the 
Barcelona Clinic Liver Cancer (BCLC) classification [25]. 
The clinical profiles of the HCC patients and data of the 
liver tissue specimens were shown in the Suppl. Table 1. 
All specimens were frozen at -800C until use. 
Ethics statement
Informed written consent was obtained after 
explanation of the study at the time of sampling from all 
participants or from their parents if subjects were less 
than 18 years. The study was approved by the institutional 
review board of the 108 Military Central hospital and the 
103 Military Hospital of the Vietnam Military Medical 
University, Hanoi, Vietnam.
ISG15 genotyping
Genomic DNA was isolated from whole blood 
using a DNA purification kit (Qiagen, Hilden, Germany). 
The ISG15 promoter and the two exons of the gene were 
PCR amplified using specific sets of primers (Suppl. 
Table 2). PCR amplification was carried out in a 25 μl 
volume containing 1X PCR buffer, 0.2 mM dNTPs, 1 mM 
MgCl2, 0.15 mM of each primer, 1 unit of Taq polymerase 
and 50 ng of genomic DNA. Cycling conditions were 
denaturation at 95oC for 5 min, followed by 40 cycles 
of three-step cycling with denaturation (94°C, 30 sec), 
annealing (63°C, 35 sec), and extension (72°C, 45 sec) 
and final extension (72oC, 7 min). PCR products were 
purified by Exo-SAP-IT (USB, Affymetrix, USA) and 5 
µl of products were used as sequencing templates (BigDye 
terminator v.1.1 cycle sequencing kit, ABI 3130XL DNA 
sequencer; Applied Biosystems, Foster City, USA). 
Quantification of ISG15 levels by ELISA
Soluble ISG15 serum levels were assessed in 
174, 141 and 155 samples from CHB, LC and HCC 
patients, respectively and in 175 samples from HCs by 
the sandwich ISG15 ELISA kit (LifeSpan BioSciences, 
Eching, Germany, catalog number: MBS9302876-96). The 
lower detection limit was 0.5 ng/ml.
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ISG15 mRNA expression
Total RNA was extracted from 36 dyads of liver 
biopsy tissues with Trizol reagent (Life Technologies, 
California, USA). RNA was transcribed into cDNA 
(QuantiTect Reverse Transcription Kit; Qiagen, Hilden, 
Germany). Quantification of cDNA was performed 
by qRT-PCR using SYBR Green PCR mix (Bioline, 
Luckenwalde, Germany). All reactions were performed in 
duplicate (LightCycler®480 real-time PCR system; Roche, 
Basel, Switzerland). The glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) gene was used as the reference 
gene. The specific primers used for evaluating the relative 
expression of ISG15 mRNA were presented in Suppl. 
Table 2. Thermal cycling conditions were 2 min (95°C) 
followed by 45 cycles of (95°C, 5 sec), annealing (58°C, 
10 sec) and extension (72°C, 20 sec). Reaction specificity 
was confirmed by melting curve and electrophoresis 
analyses. Calculation of normalized gene expression was 
based on the ∆∆CT method. The fold change in ISG15 
mRNA was normalized against the expressed GAPDH 
reference gene and adjusted to the calibration sample [50].
Statistical and genetic analyses
Statistical analyses were performed using R 
version 3.1.2 (http://www.r-project.org) and GraphPad 
Prism 6 (http://www.graphpad.com). Hardy-Weinberg 
equilibrium deviations were calculated according to the 
Guo & Thompson approach by using R software. We 
applied binary logistic regression models adjusted for 
age and gender to determine ISG15 associations with 
HBV-related liver diseases in co-dominant, dominant and 
recessive models. Univariate analysis and a multivariate 
linear regression model for independent factors were used 
to correlate ISG15 serum levels with clinical parameters. 
Adjusted odds ratios (OR) with 95% confidence intervals 
(CI) were calculated. Chi-square tests were used to test for 
differences of categorical variables and Mann-Whitney-
Wilcoxon and Kruskal-Wallis tests were applied to 
compare quantitative variables. Significance was set at a 
value of P < 0.05.
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Suppl. Table 1: Characteristics of 36 HCC patients  
Characteristics n (%) 
Age (years)  
< 40  3/36 (8.3) 
40 - 60 27/36 (75) 
> 60 6/36 (16.7) 
Gender  
Male  32/36 (89) 
Female  4/36 (11) 
Etiology  
HBV 17/36 (47) 
HCV 2/36 (6) 
Non-HBV/HCV 17/36 (47) 
BCLC staging Classification  
Stage A  25/36 (69) 
Stage B  11/36 (31) 
Stage C and D 0/ 36 (0) 
Clinical parameters Median (Range) 




/ml) 211 [153 - 461] 
AST (IU/ml) 52 [21 - 415] 
ALT (IU/ml) 66.5 [17 - 242] 
Total Bilirubin (µmol/l) 27.8 [8.9 - 315] 
Direct Bilirubin (µmol/l) 6.7 [1 - 178] 
Prothrombin (% of standard) 93 [75 - 125] 
Protein (g/l) 73 [62 - 78] 
Allbumin (g/l) 40 [32 - 48]  
Abbreviation: BCLC: Barcelona Clinic Liver Cancer; HCC: hepatocellular carcinoma; AFP: Alpha feto 
protein; PLT: platelets; AST and ALT: aspartate and alanine amino transferase; IU: international unit; 




Suppl. Table 2: Primers used for this study 
 
 
Primer Sequence Application Fragment length 
ISG15_Pr_F 5'- GAG GCT GAG GTG AGA GGA TC -3'  
ISG15 promoter genotyping 715 bp 
ISG15_Pr_R 5'- GAG GGA GAC GAA AAT TGG CTG -3'  
ISG15_E1_F 5'- CAG TGC CTT GTG TGT GGT GG -3' 
ISG15 exon1 genotyping 578 bp 
ISG15_E1_R 5'- GAT GCT GGT GGA GGC CCT TAG -3' 
ISG15_Exp_F  5'- GAG AGG CAG CGA ACT CAT CT -3' 
ISG15 mRNA expression 157 bp 
ISG15_Exp_R 5'- CTT CAG CTC TGA CAC CGA CA -3' 
GADPH_F  5'-TGC ACC ACC AAC TGC TTA GC-3' 
ISG15 mRNA expression 87 bp 
GADPH_R 5'-GGC ATG GAC TGT GGT CAT GAG-3' 
 
 Suppl. Figure 1:  Association of viral loads and ISG15 serum levels with ISG15 rs1921G/A 
variant.  
Box-plots illustrate medians with 25 and 75 percentiles with whiskers to 10 and 90 percentiles; P 
values were calculated by Krusskal-Wallis-Wilcoxon test. 
 
 
Suppl. Figure 2:  Distribution of ISG15 serum levels in HCC and non-HCC patients.  
Scatter dot plots illustrate medians with 25 and 75 percentiles with whiskers to 10 and 90 
































































































3. DISCUSSION  
Hepatitis B can lead to several liver disease phenotypes, ranging from asymptomatic 
carrier status and chronic infections to life-threatening hepatocellular carcinoma. The 
factors influencing such liver disease progression are modulated by various host and 
viral factors.  This thesis describes how HEV superinfection in HBV patients may 
influence HBV disease and its course in liver disease progression. Also, 
investigations were carried out to determine the contribution of host candidate genes 
in the JAK/STAT signaling pathway to HBV susceptibility and its clinical course. 
3.1. Hepatitis E virus superinfection in HBV patients 
It is well known that HBV co-infection with HIV, HDV, and HCV contribute to a poor 
clinical outcome (Kruse et al. 2014; Kumar et al. 2008c; Rajbhandari et al. 2016; 
Wedemeyer et al. 2010). In Vietnam, HBV prevalence is documented to be greater 
than 10% in the population (Nguyen. 2012), and thus poses a significant health 
burden. Similar to other comorbidities, HEV superinfections also contribute to the 
HBV clinical outcome. However, only limited knowledge exists on the prevalence of 
HEV infection and its consequence in HBV related liver diseases in Vietnam. My 
current thesis aims to bridge this gap, thereby providing actual data on the burden 
of HEV infection.  
3.1.1 HEV infection in Vietnamese population 
The seroprevalence of  HEV in general populations and blood donors vary from one 
geographical setting to another (Boutrouille et al. 2007; Cleland et al. 2013; Guo et 
al. 2010; Petrovic et al. 2014; Pittaras et al. 2014; Ren et al. 2013) and this also 
depends on the performance of the immunoassay used (Abravanel et al. 2014; 
Mansuy et al. 2011). Several reports have raised concerns about the importance of 
HEV infection. The results from our study show a prevalence of 31% and 5% for anti-
HEV IgG and IgM respectively, in healthy Vietnamese individuals. Anti-HEV IgG 
positivity was considerably higher than previously reported in rural areas of Vietnam 
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(Hau et al. 1999). This difference might be due to the applied ELISA assays. 
Differences in social and demographic features may also affect seroprevalences 
(Hau et al. 1999; Mansuy et al. 2011). However, our results are in agreement with 
studies in Chinese blood donors, where anti-HEV IgG and IgM prevalences were 
about 30% and 1%, respectively (Guo et al. 2010; Ren et al. 2014). Until a decade 
ago, hepatitis E infection was thought to be restricted to Asian countries and 
European travelers returning from endemic areas. However, it is now well 
established that HEV is also endemic in Europe. Indeed, several studies have shown 
lower anti-HEV IgG prevalences of 3% to 17% occur among most European 
populations (Adlhoch et al. 2016; Beale et al. 2011; Boutrouille et al. 2007; Gallian 
et al. 2014; Juhl et al. 2014; Pittaras et al. 2014; Ren et al. 2014). HEV 
seroprevalences were, however, exceptionally high in southern France and 
Denmark (Christensen et al. 2008; Mansuy et al. 2011; Mansuy et al. 2016).  
Prevalences of anti-HEV IgG and IgM in hepatitis B patients were 45% and 12%, 
respectively. The HEV seroprevalence in our patient group was different from other 
reports on HBV, HCV, and HIV infections (Atiq et al. 2009; Bayram et al. 2007; Feldt 
et al. 2013; Hamid et al. 2002). Anti-HEV IgG prevalences in American and Turkish 
chronic HBV patients were 8% and 14% respectively (Atiq et al. 2009; Bayram et al. 
2007). Our results show that HBV patients might be at risk for an HEV infection 
(Hamid et al. 2002). HEV superinfection in HIV patients and the development of 
chronic hepatitis E has also been described (Dalton et al. 2009). A recent study 
reported a seroprevalence of anti-HEV IgG in Cameroon (14%) and Ghana (45%) 
(Feldt et al. 2013). However, no contribution of HEV infection to liver pathology was 
detected. The HEV seroprevalence in our study group was significantly associated 
with age, both in HBV patients and controls, indicating cumulative exposure to HEV. 





3.1.2 HEV superinfection and HBV clinical outcome.  
Although most people infected with HEV are asymptomatic, the outcome of HEV 
superinfection in HBV patients generally appears more severe (Cheng et al. 2013; 
Marion-Audibert et al. 2010; Monga et al. 2004). Our results show high levels of liver 
enzymes and bilirubin and low levels of albumin, prothrombin, and platelet counts in 
the serum of HBV patients coinfected with HEV. In contrast, an earlier report 
suggested that chronic HBV infections may remain inactive during HEV-HBV 
coinfections (Cheng et al. 2013), however, we found higher HBV-DNA loads in 
coinfected patients. Biochemical and serological tests indicate that HEV 
superinfection contribute to inflammation and liver failure. HBV-DNA loads were 
lower in HBV patients with previous HEV infection compared to those currently 
infected or with no infection, suggesting that host immune responses control HBV 
replication. HBsAg positive individuals had a poorer prognosis following HEV 
superinfection (Chow et al. 2014; Wu et al. 2013). 
HEV infection had been reported to be associated with the development and 
progression of LC (Gerolami et al. 2008; Kumar et al. 2008b; Marion-Audibert et al. 
2010), but the mechanisms of LC induction are not clear. Previous studies have 
demonstrated that HEV infections are correlated with underlying LC and progression 
of chronic hepatitis B. The association of an HEV superinfection with abnormal levels 
of bilirubin, albumin, and prothrombin supports the fact that HEV superinfections 
contribute to the severity of HBV infections. Although the difference was not 
significant, the prevalence of anti-HEV antibodies were higher among patients with 
HBV-related HCC. A HEV-induced tumorigenesis cannot be excluded.  
3.2. SOCS3 and ISG15 in HBV-related liver diseases 
3.2.1. SOCS3 promoter variants and methylation  
The negative regulator SOCS3 (suppressor of cytokine signaling-3) is a key player 
in the modulation of the JAK/STAT signaling that regulate several inflammatory 
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cytokines such as IL6 and IL16 (Yoshimura et al. 2007b) and is involved in infectious 
diseases and cancers (Persico et al. 2008; Yoshimura et al. 2012). Additionally, gene 
silencing mediated by aberrant methylation of CpG islands in the SOCS3 promoter 
frequently occurs in malignancies (He et al. 2003; Niwa et al. 2005). In this current 
thesis, I investigated the association of SOCS3 promoter variants with the 
progression of HBV-related liver diseases and explored the association of SOCS3 
methylation with HBV-induced HCC. We demonstrated that the SOCS3 promoter 
variants are associated with HBV infection and HBV-related liver diseases. SOCS3 
mRNA expression was higher in infected tumor tissues than non-tumor tissues. The 
aberrant methylation of the CpG islands in the SOCS3 promoter is associated with 
relatively low mRNA expression in tumor tissues. 
SOCS3 promoter variants and HBV-related liver diseases 
This first study reports on the association of SOCS3 variants with HBV susceptibility 
and progression of HBV-related liver diseases. We have demonstrated that infection 
and the progression of HBV-related liver diseases are associated with 
rs111033850T/C and rs12953258C/A variants. In particular, the variant 
rs111033850T/C shows a heterozygous advantage in HBV susceptibility, but might 
be a risk factor for disease progression. The contribution of the derived allele 
rs111033850C to a higher risk of HCC in CHB patients is through the gene dose 
manner. In studies on hepatitis C, the rs4969170AA genotype was associated with 
antiviral IFN-α resistance with increased SOCS3 expression in HCV patients 
(Persico et al. 2008; Zheng et al. 2013). The rs4969170A/G mutation was associated 
with HCV treatment-induced neutropenia and thrombocytopenia in antiviral therapy 
with pegylated interferon alpha (Vidal et al. 2012). The rs4969170A/G polymorphism 
was associated with clinical features and prognosis of HCC after surgical treatment 
(Jiang et al. 2015). Our results support earlier findings that SOCS3 polymorphisms 
affect liver disease progression by regulating the SOCS3 protein expression, and 
thus down-regulate the JAK/STAT signaling. 
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In this study, we showed that HBV-DNA loads are associated with the SOCS3 
promoter polymorphisms rs111033850T/C and rs12953258C/A. The HBV-DNA load 
is an essential and independent risk factor for liver disease progression in CHB 
patients (Chen et al. 2009; Zacharakis et al. 2008). HBV replication is regulated by 
many host factors (Levrero et al. 2009b). Previous studies have shown that the 
control of HBV replication is regulated by JAK/STAT signaling induced by the 
Interferon responses (Du et al. 2014; Koeberlein et al. 2010; Robek et al. 2004). 
IFNs play a vital role in controlling HBV viral replication (Koziel. 1999b) and SOCS3 
protein involved in the JAK-STAT pathway, is one such host factor that can suppress 
interferon responses (Kubo et al. 2003). Therefore, SOCS3 promoter polymorphisms 
might contribute to HBV multiplication by modulation of IFN signaling.  
Cytokines play a central role in cell to cell communication and are required for the 
defense against hepatitis viruses (Koziel. 1999b). A previous study has 
demonstrated that the HCV core protein impairs IFN-α-induced signal transduction 
via induction of SOCS3 expression (Bode et al. 2003) and thereby influencing the 
outcome of antiviral therapy (Persico et al. 2007). An intense expression of SOCS3 
in liver tissues was strongly associated with severity of hepatic inflammation in CHB 
patients (Du et al. 2014; Koeberlein et al. 2010). In accordance, a high SOCS3 
expression in liver tissues was observed in HBV compared to non-HBV patients. 
These results indicate that HBV can induce SOCS3 expression, which in turn inhibits 
IFN signaling transduction resulting in the progression of liver diseases and failure 
of IFN treatment of HBV infection (Du et al. 2014).  
SOCS3 promoter hypermethylation and HCC development 
HCC development commonly results from chronic liver injury, inflammation, and 
cirrhosis caused by HBV infection. However, the interaction between HBV and 
SOCS3 in infected hepatocytes is not well understood. DNA hypermethylation in the 
promoter region can lead to the silence of SOCS3 in HCC (Niwa et al. 2005; Zhang 
et al. 2015b). In agreement with previous studies, our results indicated that aberrant 
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methylation in the SOCS3 promoter region can be detected more frequently in tumor 
tissues compared to adjacent non-tumor tissues. Hypermethylation status in the 
SOCS3 promoter region is an important factor for HCC development. However, 
SOCS3 mRNA expression in tumor and adjacent non-tumor tissues was not 
significantly different, indicating that other factors such as acetylation, 
phosphorylation, and microRNAs may also be involved in the regulation of SOCS3 
expression during progression of liver diseases (Boosani et al. 2015). In addition, 
both SOCS3 methylation status and intensity were similar in tissue samples (tumor 
and non-tumor) from patients with and without HBV infection. This suggests that 
HBV may not enhance DNA methylation of host genes in infected hepatocytes. 
However, further studies are needed to verify this observation. 
Although our data indicate that SOCS3 expression is associated with HBV infection 
and may be involved in the progression of HBV-related liver diseases, the study has 
a number of limitations. A limited number of HCC tumor and non-tumor tissues were 
utilized. Due to the study design as a case-control study, SOCS3 expression over 
the course of HBV infection were not assessed longitudinally and therefore the 
causative effect of SOCS3 expression on progression of HBV-related liver diseases 
could not be conclusively determined. The insufficiency of some clinical and 
laboratory parameters such as HBV serology tests and HBV genotypes may weaken 
the findings indicating the crucial role of SOCS3 in the immune response to HBV 
infection and the disease outcomes. 
3.2.2. The role of ISG15 in the progression of liver diseases. 
The interferon signaling pathway forms the first-line defense against viral infections. 
ISGs can regulate the host immune response, which in turn may restrain viral 
replication (Campbell et al. 2013a; Harty et al. 2009; Jeon et al. 2010b; Skaug and 
Chen. 2010). The role of ISG15 in host defense against invading viral pathogens has 
formerly been documented (Broering et al. 2010; Campbell and Lenschow. 2013a; 
Harty et al. 2009; Skaug and Chen. 2010). ISG15 and its conjugates display both 
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antitumor and oncogenic features (Andersen et al. 2006b; Jeon et al. 2010b). We 
have investigated the role of ISG15 variants and ISG15 expression in the 
progression of HBV-related liver diseases and showed that both the ISG15 rs1921 
variant polymorphisms and ISG15 overexpression are associated with HBV-related 
liver diseases and suggest that ISG15 may be a proviral factor and trigger 
progression of HBV-related liver diseases. 
ISG15 rs1921 variant and HBV-related liver diseases 
Host genetic factors influence the progression of HBV-related liver diseases (Tong 
and Revill. 2016). To the best of our knowledge, this is the first study showing an 
association of the ISG15 rs1921 variant with the clinical outcome of HBV-related liver 
diseases. The rs1921GG genotype and rs1921G allele are associated with 
progression of liver disease. The ISG15 rs1921 exon 2 variant harbors a missense 
mutation (S355N) and, thus, may affect gene expression and protein modification. 
ISG15 targets many cellular proteins, including JAK1, STAT1 and ISGs through 
ISGlation (Sadler et al. 2008), a process that can regulate HBV pathogenesis. 
However, our study could not detect any association of ISG15 rs1921 with ISG15 
expression. A recent study also drew the same conclusion that rs1921 had no 
influence on ISG15 expression in HIV-1 patients (Scagnolari et al. 2016). It is most 
likely that this missense variant alters the binding affinity to its conjugate. However, 
the effect of rs1921 on ISG15 function and the ISGlation process requires further 
clarification. 
Overexpression of ISG15 and clinical liver disease outcomes 
ISG15 and its ISGlation form mediate innate immune responses through IFNs, 
lipopolysaccharide and dsRNA stimulation (Sadler and Williams. 2008). Higher 
ISG15 serum levels in HBV patients than in healthy individuals and an increased 
ISG15 mRNA expression observed in HBV-related liver tissues compared to non-
HBV/HCV-related liver tissues demonstrate that HBV infection triggers ISG15 
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expression. This is in accordance with the fact that the major host response to viral 
infection is the production of IFNs, which in turn stimulate ISG15 expression. The 
notion of antiviral activities of both ISG15 and ISGlation came from studies using an 
ISG15 knockout mice model (Lenschow et al. 2007; Werneke et al. 2011). Mice 
lacking ISG15 expression were more susceptible to influenza, sindbis, and herpes 
simplex viruses (Lenschow et al. 2007). Recent studies have explored the biological 
functions of ISG15 and related conjugates that can impair viral replication in vivo 
(Malakhova et al. 2008; Okumura et al. 2006; Okumura et al. 2008; Werneke et al. 
2011). In contrast, our study showed that ISG15 levels were positively associated 
with high viral loads, implying an opposing effect of ISG15 on antiviral activities. This 
is consistent with studies showing that ISG15 can promote HCV replication (Broering 
et al. 2016; Broering et al. 2010; Chen et al. 2010). 
Host immune factors are important in the immune-pathogenesis of HBV infection 
through genetic and epigenetic modifications (Koumbi et al. 2015; Tong et al. 2014a) 
and via the effects of cytokines (Li et al. 2016). An unsuccessful immune response 
against HBV may result in persistent virus replication and liver inflammation, leading 
to CHB, LC and HCC (Li et al. 2016). ISG15 appears to act as an immune-modulator, 
regulating the expression of cytokines, in particular of the IFN signaling pathway. 
Earlier studies have indicated that ISG15 upregulation results in a reduced immune 
response to IFN signaling and contributes to a poor outcome of IFN-based therapy 
in HCV patients (Broering et al. 2010; Chen et al. 2005). In addition, higher levels of 
ISG15 were observed in treatment failure compared to responders to IFN-based 
treatment (Chen et al. 2005; Chen et al. 2010). Consequently, levels of ISG15 
combined with clinical, biochemical, and histological analyses may be useful to 
predict the outcome of HBV-related liver disease and may help to evaluate the 
response of HBV-infected individuals to IFN treatment. 
The biological function of ISG15 in enhancing or suppressing tumor growth remains 
controversial (Andersen and Hassel. 2006b) although antagonistic roles of ISG15 in 
tumorigenesis have been documented (Andersen and Hassel. 2006b; Burks et al. 
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2014; Desai. 2015b). Several studies have shown that ISG15 is an oncoprotein, as 
ISG15 gene expression and its protein conjugates were found elevated in tumor cell 
lines and in various human malignancies (Andersen et al. 2006a; Bektas et al. 2008; 
Burks et al. 2014; Desai et al. 2006; Kiessling et al. 2009; Li et al. 2014; Qiu et al. 
2015; Satake et al. 2010; Wood et al. 2012). High serum ISG15 levels in HCC 
patients and mRNA expression in liver tumor tissues also suggest that ISG15 may 
serve as a protumor factor. In contrast, other studies reported that free ISG15 has 
the potential to induce antitumor responses (Burks et al. 2015; D'Cunha et al. 1996). 
These differences could be due to the functional differences of free ISG15 and 
ISG15 conjugates (Andersen and Hassel. 2006b; Desai. 2015b). So far it is clear 
that an intense ISG15 expression is vital in modulating cell growth and in the 
progression of breast cancer (Bektas et al. 2008; Burks et al. 2014). The functional 
role of ISG15 in HCC, however, is still unclear. ISG15 overexpression is associated 
with poor clinical outcomes (Li et al. 2014; Qiu et al. 2015). Moreover, knocking down 
ISG15 by shRNA ISG15 can lead to a remarkable reduction of HCC cell proliferation 
and migration (Li et al. 2014).  
Although our data suggest that ISG15 over-expression is modulated by HBV 
infection and may induce liver disease progression, the study has some limitations. 
Due to the study design as a case-control study, levels of ISG15 over the course of 
HBV infection were not measured and the causative effect of ISG15 levels on 
progression of HBV-related liver diseases was not decisively assessed. HCC 
patients who donated liver tissues were in early and intermediate stages of liver 
cancer, which might have also affected our results. Therefore, additional studies in 
HCC patients with advanced stages of liver cancer are needed to associate ISG15 
mRNA expression with cancer progression. 
In conclusion, viral hepatitis caused by HBV remains a critical public health concern. 
Worldwide, more than 2 billion people are affected during their lifetime, and 350-400 
million people are chronically infected. Chronic cases can develop into severe forms 
of liver diseases such as LC and HCC. The clinical course and pathogenesis of HBV-
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related liver diseases are multifactorial and essentially influenced by the coinfection 
with other viruses and host factors. My dissertation has explored the impact of HEV 
superinfections and the role of human genetic and epigenetic factors in the 
JAK/STAT pathway-related genes towards susceptibility to HBV infection and the 
outcome of HBV-associated liver diseases. The findings in the first publication reflect 
high endemicity of HEV infection in Vietnam, a country where HBV is also heavily 
endemic. High prevalences of HEV superinfection in all clinically classified HBV 
patients is also reported. Findings of this study also support that HEV plays an 
undesirable role in liver disease progression in HBV-infected patients, especially in 
liver cirrhosis patients. The findings extracted from the second and third publication 
have demonstrated for the first time that variants of SOCS3 and ISG15 genes 
(SOCS3 rs111033850, SOCS3 rs12953258 and ISG15 rs1921), relating to 
JAK/STAT signaling pathway, play a critical role in HBV susceptibility and liver 
disease outcomes. Moreover, the expression of SOCS3 and ISG15 at the mRNA 
and protein level is also associated with liver disease progression in HBV-infected 
patients. In addition to the importance of genetics, the role of epigenetics reveals 
that SOCS3 promoter hypermethylation stimulates HCC development. Taken 
together, this dissertation provides an increased understanding about how host 
genetic factors might influence the HBV liver diseases and how another hepatitis 





Although the introduction of the Hepatitis B virus (HBV) vaccine has significantly 
reduced mortality and morbidity in many parts of the world, few pockets of high 
endemicity still remains in South-East Asia and in Sub-Saharan Africa. Despite, 
Vietnam initiated universal immunization for hepatitis B for infants in 2003, the rates 
of chronically infected patients with hepatitis B remains high with an estimated 
prevalence of >10%. The clinical course of HBV infection is influenced by both host 
and viral factors. In this thesis, I utilized a cohort of patients well characterized for 
clinical HBV infections, including acute and chronic hepatitis B, liver cirrhosis, and 
hepatocellular carcinoma. In chapter one of my thesis, I investigated 1318 
Vietnamese HBV patients to elucidate if superinfection by other hepatitis viruses 
exists in this study population. In particular, I studied the HEV seroprevalences in 
patients with HBV and characterized specific HEV isolates at the molecular level to 
understand the consequences of HEV superinfections on the clinical course of HBV 
infections. This study showed that HEV may aggravate the clinical outcome of HBV 
infection. In chapter two of my thesis, I studied the contribution of negative regulator 
suppressor of cytokine signaling-3 (SOCS3) promoter variants in HBV disease. I 
genotyped 878 HBV patients and 272 healthy controls for SOCS3 promoter variants. 
SOCS3 promoter hyper methylation in HBV tumor tissues was examined by bisulfite 
sequencing and mRNA expression was quantified in tumor and non-tumor tissues. 
The results revealed that SOCS3 promoter variants are associated with HBV 
susceptibility and SOCS3 hypermethylation stimulates HCC development. 
Additionally in chapter 2, investigations were carried out to associate Interferon-
stimulated gene 15 (ISG15) polymorphisms, ISG15 serum levels, and relative mRNA 
expression with HBV-related liver diseases. ISG15 exon2 variant rs1921 was 
associated with HBV susceptibility. ISG15 serum levels were higher among HBV 
patients and were positively correlated with HBV-DNA loads. ISG15 mRNA 
expression was increased in HBV patients. The results reveal that ISG15 appears to 
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be a proviral factor involved in HBV replication and triggers the progression of HBV-
related liver diseases.  
Taken together, this dissertation serves as a basis to understand the association of 
host and viral factors with HBV susceptibility and subsequent clinical outcomes of 

















5. ZUSAMMENFASSUNG  
Trotz der Einführung eines effektiven Hepatitis-B-Virus (HBV) Impfstoffs, der 
weltweit die Mortalität und Morbidität einer HBV-Infektion signifikant reduziert hat, 
gibt es dennoch einige Regionen, insbesondere Südostasien und Sub-Sahara 
Afrika, in denen HBV-Infektionen hoch endemisch sind. Obwohl Vietnam im Jahr 
2003 eine generelle Immunisierung gegen Hepatitis B für Säuglinge und Jugendliche 
eingeführt hat, ist in diesem Land die Rate von chronisch HBV-Infizierten mit einer 
geschätzten HBV-Prävalenz von >10% noch immer hoch. Bekannt ist, dass der 
klinische Verlauf einer HBV Infektion sowohl von Wirt- als auch viralen Faktoren 
beeinflusst wird. Um dies weiter zu untersuchen wurde in der vorliegenden 
Doktorarbeit Proben von einer gut charakterisierten Kohorte von Patienten mit HBV-
Infektion eingesetzt, die Patienten mit akuter und chronischer Hepatitis B, 
Leberzirrhose und hepatozellulärem Karzinom einschloss. In Kapitel 1 der 
vorliegenden Dissertation wurden Proben von 1318 vietnamesischen HBV-
infizierten Patienten untersucht, um zu klären, ob Superinfektionen mit anderen 
Hepatitisviren in dieser Studienpopulation auftreten. Im Einzelnen wurde die 
Hepatitis E Virus (HEV) Seroprävalenz in den HBV-positiven Patienten analysiert. 
Spezifische HEV-Stränge wurden weiter molekular-genetisch charakterisiert um die 
Auswirkung einer HEV-Superinfektion auf den klinischen Verlauf einer HBV-
Infektion besser zu verstehen. Diese Studie zeigte, dass HEV den klinischen Verlauf 
einer HBV-Infektion verschlimmern kann. In Kapitel 2 dieser Arbeit wurde der Beitrag 
von negative regulator suppressor of cytokine signaling-3 (SOCS3) 
Promotorvarianten auf den Verlauf einer HBV-Infektion analysiert. Dazu wurden 
SOCS3 Promotorvarianten, isoliert aus 878 HBV-positive Patienten und 272 
gesunden Kontrollindividuen, näher charakterisiert. SOCS3 Promotor-
Hypermethylierung in Tumorgewebe von HBV-positiven Patienten wurde mittels Bi-
Sulfit-Sequenzierung analysiert und zudem die SOCS3 mRNA-Expression in Tumor 
und Nicht-Tumorgewebe dieser Patienten quantifiziert. Die Ergebnisse dieser 
Untersuchungen zeigten, dass SOCS3 Promotorvarianten mit der HBV-
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Suszeptibilität assoziiert waren und SOCS3 Promotor-Hypermethylierung die HCC 
Entwicklung stimulierte. Zusätzlich dazu wurde in Kapitel 2 weiterführende 
Experimente durchgeführt, die eine Assoziation von Interferon-stimulated gene 15 
(ISG15)-Polymorphismen, ISG15 Serumspiegel und relativer ISG15 mRNA 
Expression mit HBV-bedingten Leberentzündungen aufdecken sollten. Hierbei 
zeigte sich, dass die ISG15 exon2 Variante rs1921 mit der HBV-Suszeptibilität 
assoziiert war und ISG15 Serumspiegel in HBV-positiven Patienten höher und 
positiv korreliert mit der HBV-DNA Viruslast waren. Zudem war die ISG15 mRNA 
Expression in HBV-positiven Patienten erhöht. Die Ergebnisse belegten, dass ISG15 
ein proviraler Faktor ist, der bei die HBV-Replikationskontrolle involviert ist und die 
Progression HBV-bedingter Leberentzündungen triggert.   
Zusammenfassend bildet die vorliegende Dissertation eine Grundlage für das 
bessere Verständnis essentieller Assoziationen von Wirt- und viralen Faktoren mit 





Abravanel F, Lhomme S, Chapuy-Regaud S, Mansuy J M, Muscari F, Sallusto F, 
Rostaing L, Kamar N, and Izopet J (2014) Hepatitis E virus reinfections in solid-
organ-transplant recipients can evolve into chronic infections. J Infect. Dis 209: 
1900-1906. 
Adlhoch C, Avellon A, Baylis S A, Ciccaglione A R, Couturier E, de Sousa R, Epstein 
J, Ethelberg S, Faber M, Feher A, Ijaz S, Lange H, Mandakova Z, Mellou K, 
Mozalevskis A, Rimhanen-Finne R, Rizzi V, Said B, Sundqvist L, Thornton L, Tosti 
M E, van Pelt W, Aspinall E, Domanovic D, Severi E, Takkinen J, and Dalton H R 
(2016) Hepatitis E virus: Assessment of the epidemiological situation in humans in 
Europe, 2014/15. J Clin Virol 82: 9-16. 
Aggarwal R (2013) Hepatitis E: clinical presentation in disease-endemic areas and 
diagnosis. Semin Liver Dis 33: 30-40. 
Akira S, Uematsu S, and Takeuchi O (2006) Pathogen recognition and innate 
immunity. Cell 124: 783-801. 
Al-Qahtani A, Khalak H G, Alkuraya F S, Al-hamoudi W, Alswat K, Al Balwi M A, Al 
A, I, Sanai F M, and Abdo A A (2013) Genome-wide association study of chronic 
hepatitis B virus infection reveals a novel candidate risk allele on 11q22.3. 
J.Med.Genet. 50: 725-732. 
Allweiss L, and Dandri M (2016) Experimental in vitro and in vivo models for the 
study of human hepatitis B virus infection. J.Hepatol. 64: S17-S31. 
Andersen J B, Aaboe M, Borden E C, Goloubeva O G, Hassel B A, and Orntoft T F 
(2006a) Stage-associated overexpression of the ubiquitin-like protein, ISG15, in 
bladder cancer. Br. J. Cancer 94: 1465-1471. 
Andersen J B, and Hassel B A (2006b) The interferon regulated ubiquitin-like protein, 
ISG15, in tumorigenesis: friend or foe? Cytokine Growth Factor Rev 17: 411-421. 
Arends J E, Ghisetti V, Irving W, Dalton H R, Izopet J, Hoepelman A I, and Salmon 
D (2014) Hepatitis E: An emerging infection in high income countries. J Clin Virol 59: 
81-88. 
Atiq M, Shire N J, Barrett A, Rouster S D, Sherman K E, and Shata M T (2009) 
Hepatitis E virus antibodies in patients with chronic liver disease. Emerg. Infect. Dis 
15: 479-481. 
Banks M, Bendall R, Grierson S, Heath G, Mitchell J, and Dalton H (2004) Human 
and porcine hepatitis E virus strains, United Kingdom. Emerg Infect Dis 10: 953-955. 
 86 
 
Barnaba V, Valesini G, Levrero M, Zaccari C, Van D A, Falco M, Musca A, and 
Balsano F (1985) Immunoregulation of the in vitro anti-HBs antibody synthesis in 
chronic HBsAg carriers and in recently boosted anti-hepatitis B vaccine recipients. 
Clin.Exp.Immunol. 60: 259-266. 
Bayram A, Eksi F, Mehli M, and Sozen E (2007) Prevalence of hepatitis E virus 
antibodies in patients with chronic hepatitis B and chronic hepatitis C. Intervirology 
50: 281-286. 
Beale M A, Tettmar K, Szypulska R, Tedder R S, and Ijaz S (2011) Is there evidence 
of recent hepatitis E virus infection in English and North Welsh blood donors? Vox 
Sang 100: 340-342. 
Bektas N, Noetzel E, Veeck J, Press M F, Kristiansen G, Naami A, Hartmann A, 
Dimmler A, Beckmann M W, Knuchel R, Fasching P A, and Dahl E (2008) The 
ubiquitin-like molecule interferon-stimulated gene 15 (ISG15) is a potential 
prognostic marker in human breast cancer. Breast Cancer Res 10: R58. 
Bertoletti A, and Naoumov N V (2003) Translation of immunological knowledge into 
better treatments of chronic hepatitis B. J.Hepatol. 39: 115-124. 
Bile K, Isse A, Mohamud O, Allebeck P, Nilsson L, Norder H, Mushahwar I K, and 
Magnius L O (1994) Contrasting roles of rivers and wells as sources of drinking water 
on attack and fatality rates in a hepatitis E epidemic in Somalia. Am J Trop Med Hyg 
51: 466-474. 
Blumberg B S, ALTER H J, and VISNICH S (1965) A "NEW" ANTIGEN IN 
LEUKEMIA SERA. JAMA 191: 541-546. 
Blumberg B S, Gerstley B J, Hungerford D A, London W T, and Sutnick A I (1967) A 
serum antigen (Australia antigen) in Down's syndrome, leukemia, and hepatitis. 
Ann.Intern.Med. 66: 924-931. 
Bocher W O, Herzog-Hauff S, Herr W, Heermann K, Gerken G, Meyer Zum 
Buschenfelde K H, and Lohr H F (1996) Regulation of the neutralizing anti-hepatitis 
B surface (HBs) antibody response in vitro in HBs vaccine recipients and patients 
with acute or chronic hepatitis B virus (HBV) infection. Clin.Exp.Immunol. 105: 52-
58. 
Bode J G, Ludwig S, Ehrhardt C, Albrecht U, Erhardt A, Schaper F, Heinrich P C, 
and Haussinger D (2003) IFN-alpha antagonistic activity of HCV core protein 
involves induction of suppressor of cytokine signaling-3. FASEB J 17: 488-490. 
Boehme K W, and Compton T (2004) Innate sensing of viruses by toll-like receptors. 
J.Virol. 78: 7867-7873. 
 87 
 
Boosani C S, and Agrawal D K (2015) Methylation and microRNA-mediated 
epigenetic regulation of SOCS3. Mol. Biol. Rep 42: 853-872. 
Bose P D, Das B C, Hazam R K, Kumar A, Medhi S, and Kar P (2014) Evidence of 
extrahepatic replication of hepatitis E virus in human placenta. J Gen Virol 95: 1266-
1271. 
Bose P D, Das B C, Kumar A, Gondal R, Kumar D, and Kar P (2011) High viral load 
and deregulation of the progesterone receptor signaling pathway: association with 
hepatitis E-related poor pregnancy outcome. J Hepatol 54: 1107-1113. 
Boutrouille A, Bakkali-Kassimi L, Cruciere C, and Pavio N (2007) Prevalence of anti-
hepatitis E virus antibodies in French blood donors. J Clin. Microbiol 45: 2009-2010. 
Broering R, Trippler M, Werner M, Real C I, Megger D A, Bracht T, Schweinsberg V, 
Sitek B, Eisenacher M, Meyer H E, Baba H A, Weber F, Hoffmann A C, Gerken G, 
and Schlaak J F (2016) Hepatic expression of proteasome subunit alpha type-6 is 
upregulated during viral hepatitis and putatively regulates the expression of ISG15 
ubiquitin-like modifier, a proviral host gene in hepatitis C virus infection. J. Viral 
Hepat. 
Broering R, Zhang X, Kottilil S, Trippler M, Jiang M, Lu M, Gerken G, and Schlaak J 
F (2010) The interferon stimulated gene 15 functions as a proviral factor for the 
hepatitis C virus and as a regulator of the IFN response. Gut 59: 1111-1119. 
Burks J, Reed R E, and Desai S D (2014) ISGylation governs the oncogenic function 
of Ki-Ras in breast cancer. Oncogene 33: 794-803. 
Burks J, Reed R E, and Desai S D (2015) Free ISG15 triggers an antitumor immune 
response against breast cancer: a new perspective. Oncotarget 6: 7221-7231. 
Campbell J A, and Lenschow D J (2013a) Emerging roles for immunomodulatory 
functions of free ISG15. J. Interferon Cytokine Res 33: 728-738. 
Campbell J A, and Lenschow D J (2013b) Emerging roles for immunomodulatory 
functions of free ISG15. J.Interferon Cytokine Res. 33: 728-738. 
Carow B, and Rottenberg M E (2014) SOCS3, a Major Regulator of Infection and 
Inflammation. Front Immunol. 5: 58. 
CDC (2015). Epidemiology and Prevention of Vaccine-Preventable Diseases 
(www.cdc.gov/vaccines/pubs/pinkbook/hepb.html). 
Chang J J, and Lewin S R (2007) Immunopathogenesis of hepatitis B virus infection. 
Immunol.Cell Biol. 85: 16-23. 
 88 
 
Chang M H (2006) Impact of hepatitis B vaccination on hepatitis B disease and 
nucleic acid testing in high-prevalence populations. J.Clin.Virol. 36 Suppl 1: S45-
S50. 
Chang S W, Fann C S, Su W H, Wang Y C, Weng C C, Yu C J, Hsu C L, Hsieh A R, 
Chien R N, Chu C M, and Tai D I (2014) A genome-wide association study on chronic 
HBV infection and its clinical progression in male Han-Taiwanese. PLoS.One. 9: 
e99724. 
Chen C J, and Yang H I (2011) Natural history of chronic hepatitis B REVEALed. 
J.Gastroenterol.Hepatol. 26: 628-638. 
Chen C J, Yang H I, and Iloeje U H (2009) Hepatitis B virus DNA levels and outcomes 
in chronic hepatitis B. Hepatology 49: S72-S84. 
Chen L, Borozan I, Feld J, Sun J, Tannis L L, Coltescu C, Heathcote J, Edwards A 
M, and McGilvray I D (2005) Hepatic gene expression discriminates responders and 
nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 
128: 1437-1444. 
Chen L, Sun J, Meng L, Heathcote J, Edwards A M, and McGilvray I D (2010) ISG15, 
a ubiquitin-like interferon-stimulated gene, promotes hepatitis C virus production in 
vitro: implications for chronic infection and response to treatment. J. Gen. Virol 91: 
382-388. 
Cheng S H, Mai L, Zhu F Q, Pan X F, Sun H X, Cao H, Shu X, Ke W M, Li G, and 
Xu Q H (2013) Influence of chronic HBV infection on superimposed acute hepatitis 
E. World J Gastroenterol 19: 5904-5909. 
Chisari F V, and Ferrari C (1995) Hepatitis B virus immunopathogenesis. 
Annu.Rev.Immunol. 13: 29-60. 
Chow C W, Tsang S W, Tsang O T, Leung V K, Fung K S, Luk W K, and Chau T N 
(2014) Comparison of acute hepatitis E infection outcome in patients with and 
without chronic hepatitis B infection: a 10 year retrospective study in three regional 
hospitals in Hong Kong. J Clin. Virol 60: 4-10. 
Christensen P B, Engle R E, Hjort C, Homburg K M, Vach W, Georgsen J, and 
Purcell R H (2008) Time trend of the prevalence of hepatitis E antibodies among 
farmers and blood donors: a potential zoonosis in Denmark. Clin. Infect. Dis 47: 
1026-1031. 
Cleland A, Smith L, Crossan C, Blatchford O, Dalton H R, Scobie L, and Petrik J 
(2013) Hepatitis E virus in Scottish blood donors. Vox Sang 105: 283-289. 
 89 
 
Colonna M, Krug A, and Cella M (2002) Interferon-producing cells: on the front line 
in immune responses against pathogens. Curr Opin Immunol 14: 373-379. 
Cossart Y E, and Field A M (1970) Virus-like particles in serum of patients with 
Australia-antigen-associated hepatitis. Lancet 1: 848. 
D'Cunha J, Jr K E, Haas A L, Truitt R L, and Borden E C (1996) Immunoregulatory 
properties of ISG15, an interferon-induced cytokine. Proc. Natl. Acad. Sci. U. S. A 
93: 211-215. 
Dalton H R, Bendall R, Ijaz S, and Banks M (2008) Hepatitis E: an emerging infection 
in developed countries. Lancet Infect Dis 8: 698-709. 
Dalton H R, Bendall R P, Keane F E, Tedder R S, and Ijaz S (2009) Persistent 
carriage of hepatitis E virus in patients with HIV infection. N. Engl. J Med 361: 1025-
1027. 
Dalton H R, Hunter J G, and Bendall R P (2013) Hepatitis E. Curr Opin Infect Dis 26: 
471-478. 
Dandri M, and Locarnini S (2012) New insight in the pathobiology of hepatitis B virus 
infection. Gut 61 Suppl 1: i6-17. 
Dane D S, Cameron C H, and Briggs M (1970) Virus-like particles in serum of 
patients with Australia-antigen-associated hepatitis. Lancet 1: 695-698. 
Debing Y, Gisa A, Dallmeier K, Pischke S, Bremer B, Manns M, Wedemeyer H, 
Suneetha P V, and Neyts J (2014) A mutation in the hepatitis E virus RNA 
polymerase promotes its replication and associates with ribavirin treatment failure in 
organ transplant recipients. Gastroenterology 147: 1008-1011 e1007; quiz e1015-
1006. 
Desai S D (2015a) ISG15: A double edged sword in cancer. Oncoimmunology. 4: 
e1052935. 
Desai S D (2015b) ISG15: A double edged sword in cancer. Oncoimmunology 4: 
e1052935. 
Desai S D, Haas A L, Wood L M, Tsai Y C, Pestka S, Rubin E H, Saleem A, Nur-E-
Kamal, and Liu L F (2006) Elevated expression of ISG15 in tumor cells interferes 
with the ubiquitin/26S proteasome pathway. Cancer Res 66: 921-928. 
Donnelly M C, Scobie L, Crossan C L, Dalton H, Hayes P C, and Simpson K J (2017) 
Review article: hepatitis E-a concise review of virology, epidemiology, clinical 
presentation and therapy. Aliment Pharmacol Ther 46: 126-141. 
 90 
 
Donnelly R P, and Kotenko S V (2010) Interferon-lambda: a new addition to an old 
family. J.Interferon Cytokine Res. 30: 555-564. 
Du L Y, Cui Y L, Chen E Q, Cheng X, Liu L, and Tang H (2014) Correlation between 
the suppressor of cytokine signaling-1 and 3 and hepatitis B virus: possible roles in 
the resistance to interferon treatment. Virol. J 11: 51. 
Dunn C, Brunetto M, Reynolds G, Christophides T, Kennedy P T, Lampertico P, Das 
A, Lopes A R, Borrow P, Williams K, Humphreys E, Afford S, Adams D H, Bertoletti 
A, and Maini M K (2007) Cytokines induced during chronic hepatitis B virus infection 
promote a pathway for NK cell-mediated liver damage. J.Exp.Med. 204: 667-680. 
El-Serag H B (2011) Hepatocellular carcinoma. N.Engl.J.Med. 365: 1118-1127. 
Elgouhari H M, Abu-Rajab Tamimi T I, and Carey W D (2008) Hepatitis B virus 
infection: understanding its epidemiology, course, and diagnosis. Cleve.Clin.J.Med. 
75: 881-889. 
Emerson S U, and Purcell R H (2003) Hepatitis E virus. Rev Med Virol 13: 145-154. 
Engelke M, Mills K, Seitz S, Simon P, Gripon P, Schnolzer M, and Urban S (2006) 
Characterization of a hepatitis B and hepatitis delta virus receptor binding site. 
Hepatology 43: 750-760. 
Estrabaud E, and Asselah T (2010) Interferon-stimulated gene 15: a dual activity 
during hepatitis C virus infection. Gut 59: 1017-1019. 
European Association for the Study of the Liver. Electronic address e e e, and 
European Association for the Study of the L (2017) EASL 2017 Clinical Practice 
Guidelines on the management of hepatitis B virus infection. J Hepatol. 
Fattovich G (2003) Natural history of hepatitis B. J.Hepatol. 39 Suppl 1: S50-S58. 
Fattovich G, Bortolotti F, and Donato F (2008) Natural history of chronic hepatitis B: 
special emphasis on disease progression and prognostic factors. J.Hepatol. 48: 335-
352. 
Feldt T, Sarfo F S, Zoufaly A, Phillips R O, Burchard G, van L J, Jochum J, Chadwick 
D, Awasom C, Claussen L, Drosten C, Drexler J F, and Eis-Hubinger A M (2013) 
Hepatitis E virus infections in HIV-infected patients in Ghana and Cameroon. J Clin. 
Virol 58: 18-23. 
Gallian P, Lhomme S, Piquet Y, Saune K, Abravanel F, Assal A, Tiberghien P, and 
Izopet J (2014) Hepatitis E virus infections in blood donors, France. Emerg. Infect. 
Dis 20: 1914-1917. 
 91 
 
Ganem D, and Prince A M (2004) Hepatitis B virus infection--natural history and 
clinical consequences. N.Engl.J.Med. 350: 1118-1129. 
Gao B, Wang H, Lafdil F, and Feng D (2012) STAT proteins - key regulators of anti-
viral responses, inflammation, and tumorigenesis in the liver. J Hepatol 57: 430-441. 
Gao W, Kondo Y, Shen L, Shimizu Y, Sano T, Yamao K, Natsume A, Goto Y, Ito M, 
Murakami H, Osada H, Zhang J, Issa J P, and Sekido Y (2008) Variable DNA 
methylation patterns associated with progression of disease in hepatocellular 
carcinomas. Carcinogenesis 29: 1901-1910. 
Gerolami R, Moal V, and Colson P (2008) Chronic hepatitis E with cirrhosis in a 
kidney-transplant recipient. N. Engl. J Med 358: 859-860. 
Glebe D, and Urban S (2007) Viral and cellular determinants involved in 
hepadnaviral entry. World J.Gastroenterol. 13: 22-38. 
Gonzalez Tallon A I, Moreira Vicente V, Mateos Lindemann M L, and Achecar Justo 
L M (2011) [Chronic hepatitis E in an immunocompetent patient]. Gastroenterol 
Hepatol 34: 398-400. 
Grewal P, Kamili S, and Motamed D (2014) Chronic hepatitis E in an 
immunocompetent patient: a case report. Hepatology 59: 347-348. 
Gripon P, Cannie I, and Urban S (2005) Efficient inhibition of hepatitis B virus 
infection by acylated peptides derived from the large viral surface protein. J.Virol. 79: 
1613-1622. 
Guidotti L G, and Chisari F V (2006) Immunobiology and pathogenesis of viral 
hepatitis. Annu.Rev.Pathol. 1: 23-61. 
Guidotti L G, Ishikawa T, Hobbs M V, Matzke B, Schreiber R, and Chisari F V (1996) 
Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. 
Immunity. 4: 25-36. 
Guidotti L G, Rochford R, Chung J, Shapiro M, Purcell R, and Chisari F V (1999) 
Viral clearance without destruction of infected cells during acute HBV infection. 
Science 284: 825-829. 
Guo Q S, Yan Q, Xiong J H, Ge S X, Shih J W, Ng M H, Zhang J, and Xia N S (2010) 
Prevalence of hepatitis E virus in Chinese blood donors. J Clin. Microbiol 48: 317-
318. 
H.C.Thomas, S.M.Lemon, and A.J.Zuckerman (2013). Structure and molecular 
virology. In Viral hepatitis (Wiley Blackwell), pp. 65-80. 
 92 
 
Hadziyannis S J (2011) Natural history of chronic hepatitis B in Euro-Mediterranean 
and African countries. J.Hepatol. 55: 183-191. 
Hamid S S, Atiq M, Shehzad F, Yasmeen A, Nissa T, Salam A, Siddiqui A, and Jafri 
W (2002) Hepatitis E virus superinfection in patients with chronic liver disease. 
Hepatology 36: 474-478. 
Harty R N, Pitha P M, and Okumura A (2009) Antiviral activity of innate immune 
protein ISG15. J. Innate. Immun 1: 397-404. 
Hau C H, Hien T T, Tien N T, Khiem H B, Sac P K, Nhung V T, Larasati R P, Laras 
K, Putri M P, Doss R, Hyams K C, and Corwin A L (1999) Prevalence of enteric 
hepatitis A and E viruses in the Mekong River delta region of Vietnam. Am. J Trop. 
Med. Hyg 60: 277-280. 
He B, You L, Uematsu K, Zang K, Xu Z, Lee A Y, Costello J F, McCormick F, and 
Jablons D M (2003) SOCS-3 is frequently silenced by hypermethylation and 
suppresses cell growth in human lung cancer. Proc. Natl. Acad. Sci. U. S. A 100: 
14133-14138. 
Herman J G, and Baylin S B (2003) Gene silencing in cancer in association with 
promoter hypermethylation. N.Engl.J.Med. 349: 2042-2054. 
Hernandez-Vargas H, Lambert M P, Le Calvez-Kelm F, Gouysse G, McKay-Chopin 
S, Tavtigian S V, Scoazec J Y, and Herceg Z (2010) Hepatocellular carcinoma 
displays distinct DNA methylation signatures with potential as clinical predictors. 
PLoS.One. 5: e9749. 
Hu Z, Liu Y, Zhai X, Dai J, Jin G, Wang L, Zhu L, Yang Y, Liu J, Chu M, Wen J, Xie 
K, Du G, Wang Q, Zhou Y, Cao M, Liu L, He Y, Wang Y, Zhou G, Jia W, Lu J, Li S, 
Liu J, Yang H, Shi Y, Zhou W, and Shen H (2013) New loci associated with chronic 
hepatitis B virus infection in Han Chinese. Nat.Genet. 45: 1499-1503. 
Jammeh S, Tavner F, Watson R, Thomas H C, and Karayiannis P (2008) Effect of 
basal core promoter and pre-core mutations on hepatitis B virus replication. 
J.Gen.Virol. 89: 901-909. 
Jeon Y J, Yoo H M, and Chung C H (2010a) ISG15 and immune diseases. 
Biochim.Biophys.Acta 1802: 485-496. 
Jeon Y J, Yoo H M, and Chung C H (2010b) ISG15 and immune diseases. Biochim. 
Biophys. Acta 1802: 485-496. 
Jiang B G, Yang Y, Liu H, Gu F M, Yang Y, Zhao L H, Yuan S X, Wang R Y, Zhang 
J, and Zhou W P (2015) SOCS3 Genetic Polymorphism Is Associated With Clinical 
 93 
 
Features and Prognosis of Hepatocellular Carcinoma Patients Receiving 
Hepatectomy. Medicine (Baltimore) 94: e1344. 
Jiang D K, Sun J, Cao G, Liu Y, Lin D, Gao Y Z, Ren W H, Long X D, Zhang H, Ma 
X P, Wang Z, Jiang W, Chen T Y, Gao Y, Sun L D, Long J R, Huang H X, Wang D, 
Yu H, Zhang P, Tang L S, Peng B, Cai H, Liu T T, Zhou P, Liu F, Lin X, Tao S, Wan 
B, Sai-Yin H X, Qin L X, Yin J, Liu L, Wu C, Pei Y, Zhou Y F, Zhai Y, Lu P X, Tan A, 
Zuo X B, Fan J, Chang J, Gu X, Wang N J, Li Y, Liu Y K, Zhai K, Zhang H, Hu Z, Liu 
J, Yi Q, Xiang Y, Shi R, Ding Q, Zheng W, Shu X O, Mo Z, Shugart Y Y, Zhang X J, 
Zhou G, Shen H, Zheng S L, Xu J, and Yu L (2013) Genetic variants in STAT4 and 
HLA-DQ genes confer risk of hepatitis B virus-related hepatocellular carcinoma. 
Nat.Genet. 45: 72-75. 
Jiang R, Tan Z, Deng L, Chen Y, Xia Y, Gao Y, Wang X, and Sun B (2011) 
Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3. 
Hepatology 54: 900-909. 
Juhl D, Baylis S A, Blumel J, Gorg S, and Hennig H (2014) Seroprevalence and 
incidence of hepatitis E virus infection in German blood donors. Transfusion 54: 49-
56. 
Kadowaki N, and Liu Y J (2002) Natural type I interferon-producing cells as a link 
between innate and adaptive immunity. Hum Immunol 63: 1126-1132. 
Kakimi K, Guidotti L G, Koezuka Y, and Chisari F V (2000) Natural killer T cell 
activation inhibits hepatitis B virus replication in vivo. J.Exp.Med. 192: 921-930. 
Kakimi K, Lane T E, Wieland S, Asensio V C, Campbell I L, Chisari F V, and Guidotti 
L G (2001) Blocking chemokine responsive to gamma-2/interferon (IFN)-gamma 
inducible protein and monokine induced by IFN-gamma activity in vivo reduces the 
pathogenetic but not the antiviral potential of hepatitis B virus-specific cytotoxic T 
lymphocytes. J.Exp.Med. 194: 1755-1766. 
Kamar N, Bendall R, Legrand-Abravanel F, Xia N S, Ijaz S, Izopet J, and Dalton H 
R (2012) Hepatitis E. Lancet 379: 2477-2488. 
Kamar N, Dalton H R, Abravanel F, and Izopet J (2014) Hepatitis E virus infection. 
Clin Microbiol Rev 27: 116-138. 
Kamar N, Mansuy J M, Cointault O, Selves J, Abravanel F, Danjoux M, Otal P, 
Esposito L, Durand D, Izopet J, and Rostaing L (2008) Hepatitis E virus-related 
cirrhosis in kidney- and kidney-pancreas-transplant recipients. Am J Transplant 8: 
1744-1748. 




Khuroo M S, Kamili S, and Khuroo M S (2009) Clinical course and duration of viremia 
in vertically transmitted hepatitis E virus (HEV) infection in babies born to HEV-
infected mothers. J Viral Hepat 16: 519-523. 
Kiessling A, Hogrefe C, Erb S, Bobach C, Fuessel S, Wessjohann L, and Seliger B 
(2009) Expression, regulation and function of the ISGylation system in prostate 
cancer. Oncogene 28: 2606-2620. 
Kim Y J, Kim H Y, Lee J H, Yu S J, Yoon J H, Lee H S, Kim C Y, Cheong J Y, Cho 
S W, Park N H, Park B L, Namgoong S, Kim L H, Cheong H S, and Shin H D (2013) 
A genome-wide association study identified new variants associated with the risk of 
chronic hepatitis B. Hum.Mol.Genet. 22: 4233-4238. 
Koeberlein B, zur H A, Bektas N, Zentgraf H, Chin R, Nguyen L T, Kandolf R, Torresi 
J, and Bock C T (2010) Hepatitis B virus overexpresses suppressor of cytokine 
signaling-3 (SOCS3) thereby contributing to severity of inflammation in the liver. 
Virus Res 148: 51-59. 
Koumbi L, and Karayiannis P (2015) The Epigenetic Control of Hepatitis B Virus 
Modulates the Outcome of Infection. Front Microbiol 6: 1491. 
Koyama S, Ishii K J, Coban C, and Akira S (2008) Innate immune response to viral 
infection. Cytokine 43: 336-341. 
Koziel M J (1999a) Cytokines in viral hepatitis. Semin.Liver Dis. 19: 157-169. 
Koziel M J (1999b) Cytokines in viral hepatitis. Semin. Liver Dis 19: 157-169. 
Kruse R L, Kramer J R, Tyson G L, Duan Z, Chen L, El-Serag H B, and Kanwal F 
(2014) Clinical outcomes of hepatitis B virus coinfection in a United States cohort of 
hepatitis C virus-infected patients. Hepatology 60: 1871-1878. 
Kubo M, Hanada T, and Yoshimura A (2003) Suppressors of cytokine signaling and 
immunity. Nat. Immunol 4: 1169-1176. 
Kumar M, Sarin S K, Hissar S, Pande C, Sakhuja P, Sharma B C, Chauhan R, and 
Bose S (2008a) Virologic and histologic features of chronic hepatitis B virus-infected 
asymptomatic patients with persistently normal ALT. Gastroenterology 134: 1376-
1384. 
Kumar M, Sharma B C, and Sarin S K (2008b) Hepatitis E virus as an etiology of 
acute exacerbation of previously unrecognized asymptomatic patients with hepatitis 
B virus-related chronic liver disease. J Gastroenterol. Hepatol 23: 883-887. 
Kumar R, Singla V, and Kacharya S (2008c) Impact and management of hepatitis B 
and hepatitis C virus co-infection in HIV patients. Trop Gastroenterol 29: 136-147. 
 95 
 
Larrubia J R, Benito-Martinez S, Miquel-Plaza J, Sanz-de-Villalobos E, Gonzalez-
Mateos F, and Parra T (2009) Cytokines - their pathogenic and therapeutic role in 
chronic viral hepatitis. Rev.Esp.Enferm.Dig. 101: 343-351. 
Lee G H, Tan B H, Teo E C, Lim S G, Dan Y Y, Wee A, Aw P P, Zhu Y, Hibberd M 
L, Tan C K, Purdy M A, and Teo C G (2016) Chronic Infection With Camelid Hepatitis 
E Virus in a Liver Transplant Recipient Who Regularly Consumes Camel Meat and 
Milk. Gastroenterology 150: 355-357 e353. 
Leistner C M, Gruen-Bernhard S, and Glebe D (2008) Role of glycosaminoglycans 
for binding and infection of hepatitis B virus. Cell Microbiol. 10: 122-133. 
Lenschow D J (2010) Antiviral Properties of ISG15. Viruses 2: 2154-2168. 
Lenschow D J, Lai C, Frias-Staheli N, Giannakopoulos N V, Lutz A, Wolff T, Osiak 
A, Levine B, Schmidt R E, Garcia-Sastre A, Leib D A, Pekosz A, Knobeloch K P, 
Horak I, and Virgin H W (2007) IFN-stimulated gene 15 functions as a critical antiviral 
molecule against influenza, herpes, and Sindbis viruses. Proc. Natl. Acad. Sci. U. S. 
A 104: 1371-1376. 
Levrero M, Pollicino T, Petersen J, Belloni L, Raimondo G, and Dandri M (2009a) 
Control of cccDNA function in hepatitis B virus infection. J.Hepatol. 51: 581-592. 
Levrero M, Pollicino T, Petersen J, Belloni L, Raimondo G, and Dandri M (2009b) 
Control of cccDNA function in hepatitis B virus infection. J. Hepatol 51: 581-592. 
Levy D E, and Inghirami G (2006) STAT3: a multifaceted oncogene. 
Proc.Natl.Acad.Sci.U.S.A 103: 10151-10152. 
Lhomme S, Marion O, Abravanel F, Chapuy-Regaud S, Kamar N, and Izopet J 
(2016) Hepatitis E Pathogenesis. Viruses 8. 
Li B, Liu W, Wang L, Li M, Wang J, Huang L, Huang P, and Yuan Y (2010) CpG 
island methylator phenotype associated with tumor recurrence in tumor-node-
metastasis stage I hepatocellular carcinoma. Ann.Surg.Oncol. 17: 1917-1926. 
Li C, Wang J, Zhang H, Zhu M, Chen F, Hu Y, Liu H, and Zhu H (2014) Interferon-
stimulated gene 15 (ISG15) is a trigger for tumorigenesis and metastasis of 
hepatocellular carcinoma. Oncotarget 5: 8429-8441. 
Li S, Qian J, Yang Y, Zhao W, Dai J, Bei J X, Foo J N, McLaren P J, Li Z, Yang J, 
Shen F, Liu L, Yang J, Li S, Pan S, Wang Y, Li W, Zhai X, Zhou B, Shi L, Chen X, 
Chu M, Yan Y, Wang J, Cheng S, Shen J, Jia W, Liu J, Yang J, Wen Z, Li A, Zhang 
Y, Zhang G, Luo X, Qin H, Chen M, Wang H, Jin L, Lin D, Shen H, He L, de Bakker 
P I, Wang H, Zeng Y X, Wu M, Hu Z, Shi Y, Liu J, and Zhou W (2012) GWAS 
 96 
 
identifies novel susceptibility loci on 6p21.32 and 21q21.3 for hepatocellular 
carcinoma in chronic hepatitis B virus carriers. PLoS.Genet. 8: e1002791. 
Li X, Liu X, Tian L, and Chen Y (2016) Cytokine-Mediated Immunopathogenesis of 
Hepatitis B Virus Infections. Clin. Rev. Allergy Immunol 50: 41-54. 
Lin T M, Chen C J, Wu M M, Yang C S, Chen J S, Lin C C, Kwang T Y, Hsu S T, Lin 
S Y, and Hsu L C (1989) Hepatitis B virus markers in Chinese twins. Anticancer Res. 
9: 737-741. 
Liu J, and Fan D (2007) Hepatitis B in China. Lancet 369: 1582-1583. 
Lo K J, Tsai Y T, Lee S D, Yeh C L, Wang J Y, Chiang B N, Wu T C, Yeh P S, 
Goudeau A, Coursaget P, and . (1985) Combined passive and active immunization 
for interruption of perinatal transmission of hepatitis B virus in Taiwan. 
Hepatogastroenterology 32: 65-68. 
Lok A S (2002) Chronic hepatitis B. N.Engl.J.Med. 346: 1682-1683. 
Lok A S, Heathcote E J, and Hoofnagle J H (2001a) Management of hepatitis B: 
2000--summary of a workshop. Gastroenterology 120: 1828-1853. 
Lok A S, and McMahon B J (2001b) Chronic hepatitis B. Hepatology 34: 1225-1241. 
Lok A S, and McMahon B J (2007) Chronic hepatitis B. Hepatology 45: 507-539. 
Lou C, Du Z, Yang B, Gao Y, Wang Y, and Fang S (2009) Aberrant DNA methylation 
profile of hepatocellular carcinoma and surgically resected margin. Cancer Sci. 100: 
996-1004. 
Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair 
T, Aggarwal R, Ahn S Y, Alvarado M, Anderson H R, Anderson L M, Andrews K G, 
Atkinson C, Baddour L M, Barker-Collo S, Bartels D H, Bell M L, Benjamin E J, 
Bennett D, Bhalla K, Bikbov B, Bin A A, Birbeck G, Blyth F, Bolliger I, Boufous S, 
Bucello C, Burch M, Burney P, Carapetis J, Chen H, Chou D, Chugh S S, Coffeng L 
E, Colan S D, Colquhoun S, Colson K E, Condon J, Connor M D, Cooper L T, 
Corriere M, Cortinovis M, de Vaccaro K C, Couser W, Cowie B C, Criqui M H, Cross 
M, Dabhadkar K C, Dahodwala N, De L D, Degenhardt L, Delossantos A, Denenberg 
J, Des Jarlais D C, Dharmaratne S D, Dorsey E R, Driscoll T, Duber H, Ebel B, Erwin 
P J, Espindola P, Ezzati M, Feigin V, Flaxman A D, Forouzanfar M H, Fowkes F G, 
Franklin R, Fransen M, Freeman M K, Gabriel S E, Gakidou E, Gaspari F, Gillum R 
F, Gonzalez-Medina D, Halasa Y A, Haring D, Harrison J E, Havmoeller R, Hay R J, 
Hoen B, Hotez P J, Hoy D, Jacobsen K H, James S L, Jasrasaria R, Jayaraman S, 
Johns N, Karthikeyan G, Kassebaum N, Keren A, Khoo J P, Knowlton L M, 
Kobusingye O, Koranteng A, Krishnamurthi R, Lipnick M, Lipshultz S E, Ohno S L, 
Mabweijano J, MacIntyre M F, Mallinger L, March L, Marks G B, Marks R, Matsumori 
 97 
 
A, Matzopoulos R, Mayosi B M, McAnulty J H, McDermott M M, McGrath J, Mensah 
G A, Merriman T R, Michaud C, Miller M, Miller T R, Mock C, Mocumbi A O, Mokdad 
A A, Moran A, Mulholland K, Nair M N, Naldi L, Narayan K M, Nasseri K, Norman P, 
O'Donnell M, Omer S B, Ortblad K, Osborne R, Ozgediz D, Pahari B, Pandian J D, 
Rivero A P, Padilla R P, Perez-Ruiz F, Perico N, Phillips D, Pierce K, Pope C A, III, 
Porrini E, Pourmalek F, Raju M, Ranganathan D, Rehm J T, Rein D B, Remuzzi G, 
Rivara F P, Roberts T, De Leon F R, Rosenfeld L C, Rushton L, Sacco R L, Salomon 
J A, Sampson U, Sanman E, Schwebel D C, Segui-Gomez M, Shepard D S, Singh 
D, Singleton J, Sliwa K, Smith E, Steer A, Taylor J A, Thomas B, Tleyjeh I M, Towbin 
J A, Truelsen T, Undurraga E A, Venketasubramanian N, Vijayakumar L, Vos T, 
Wagner G R, Wang M, Wang W, Watt K, Weinstock M A, Weintraub R, Wilkinson J 
D, Woolf A D, Wulf S, Yeh P H, Yip P, Zabetian A, Zheng Z J, Lopez A D, Murray C 
J, AlMazroa M A, and Memish Z A (2012) Global and regional mortality from 235 
causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the 
Global Burden of Disease Study 2010. Lancet 380: 2095-2128. 
Lu L, Li C, and Hagedorn C H (2006) Phylogenetic analysis of global hepatitis E virus 
sequences: genetic diversity, subtypes and zoonosis. Rev Med Virol 16: 5-36. 
Lucifora J, Arzberger S, Durantel D, Belloni L, Strubin M, Levrero M, Zoulim F, Hantz 
O, and Protzer U (2011) Hepatitis B virus X protein is essential to initiate and 
maintain virus replication after infection. J.Hepatol. 55: 996-1003. 
Lutgehetmann M, Mancke L V, Volz T, Helbig M, Allweiss L, Bornscheuer T, Pollok 
J M, Lohse A W, Petersen J, Urban S, and Dandri M (2012) Humanized chimeric 
uPA mouse model for the study of hepatitis B and D virus interactions and preclinical 
drug evaluation. Hepatology 55: 685-694. 
Maini M K, Boni C, Lee C K, Larrubia J R, Reignat S, Ogg G S, King A S, Herberg 
J, Gilson R, Alisa A, Williams R, Vergani D, Naoumov N V, Ferrari C, and Bertoletti 
A (2000) The role of virus-specific CD8(+) cells in liver damage and viral control 
during persistent hepatitis B virus infection. J.Exp.Med. 191: 1269-1280. 
Maini M K, Boni C, Ogg G S, King A S, Reignat S, Lee C K, Larrubia J R, Webster 
G J, McMichael A J, Ferrari C, Williams R, Vergani D, and Bertoletti A (1999) Direct 
ex vivo analysis of hepatitis B virus-specific CD8(+) T cells associated with the 
control of infection. Gastroenterology 117: 1386-1396. 
Malakhova O A, and Zhang D E (2008) ISG15 inhibits Nedd4 ubiquitin E3 activity 
and enhances the innate antiviral response. J. Biol. Chem 283: 8783-8787. 
Mansuy J M, Bendall R, Legrand-Abravanel F, Saune K, Miedouge M, Ellis V, Rech 
H, Destruel F, Kamar N, Dalton H R, and Izopet J (2011) Hepatitis E virus antibodies 
in blood donors, France. Emerg. Infect. Dis 17: 2309-2312. 
 98 
 
Mansuy J M, Gallian P, Dimeglio C, Saune K, Arnaud C, Pelletier B, Morel P, 
Legrand D, Tiberghien P, and Izopet J (2016) A nationwide survey of hepatitis E viral 
infection in French blood donors. Hepatology 63: 1145-1154. 
Mansuy J M, Legrand-Abravanel F, Calot J P, Peron J M, Alric L, Agudo S, Rech H, 
Destruel F, and Izopet J (2008) High prevalence of anti-hepatitis E virus antibodies 
in blood donors from South West France. J Med Virol 80: 289-293. 
Marion-Audibert A M, Tesse S, Graillot E, Phelip G, Radenne S, Duperret S, Durieux 
M, Rode A, Mabrut J Y, Souquet J C, and Nicand E (2010) Lethal acute HEV 
superinfection on hepatitis B cirrhosis. Gastroenterol. Clin. Biol 34: 334-336. 
Matsuura K, Isogawa M, and Tanaka Y (2016) Host genetic variants influencing the 
clinical course of hepatitis B virus infection. J.Med.Virol. 88: 371-379. 
Mbarek H, Ochi H, Urabe Y, Kumar V, Kubo M, Hosono N, Takahashi A, Kamatani 
Y, Miki D, Abe H, Tsunoda T, Kamatani N, Chayama K, Nakamura Y, and Matsuda 
K (2011) A genome-wide association study of chronic hepatitis B identified novel risk 
locus in a Japanese population. Hum.Mol.Genet. 20: 3884-3892. 
McMahon B J (2009) The natural history of chronic hepatitis B virus infection. 
Hepatology 49: S45-S55. 
Meier A, Mehrle S, Weiss T S, Mier W, and Urban S (2013) Myristoylated PreS1-
domain of the hepatitis B virus L-protein mediates specific binding to differentiated 
hepatocytes. Hepatology 58: 31-42. 
Meng X J (2010) Hepatitis E virus: animal reservoirs and zoonotic risk. Vet Microbiol 
140: 256-265. 
Mikeska T, and Craig J M (2014) DNA methylation biomarkers: cancer and beyond. 
Genes (Basel) 5: 821-864. 
Monga R, Garg S, Tyagi P, and Kumar N (2004) Superimposed acute hepatitis E 
infection in patients with chronic liver disease. Indian J Gastroenterol 23: 50-52. 
Moribe T, Iizuka N, Miura T, Kimura N, Tamatsukuri S, Ishitsuka H, Hamamoto Y, 
Sakamoto K, Tamesa T, and Oka M (2009) Methylation of multiple genes as 
molecular markers for diagnosis of a small, well-differentiated hepatocellular 
carcinoma. Int.J.Cancer 125: 388-397. 
Nair V P, Anang S, Subramani C, Madhvi A, Bakshi K, Srivastava A, Shalimar, Nayak 
B, Ranjith Kumar C T, and Surjit M (2016) Endoplasmic Reticulum Stress Induced 
Synthesis of a Novel Viral Factor Mediates Efficient Replication of Genotype-1 
Hepatitis E Virus. PLoS Pathog 12: e1005521. 
 99 
 
Navaneethan U, Al Mohajer M, and Shata M T (2008) Hepatitis E and pregnancy: 
understanding the pathogenesis. Liver Int 28: 1190-1199. 
Nguyen V T (2012) Hepatitis B infection in Vietnam: current issues and future 
challenges. Asia Pac.J.Public Health 24: 361-373. 
Nishida N, Sawai H, Kashiwase K, Minami M, Sugiyama M, Seto W K, Yuen M F, 
Posuwan N, Poovorawan Y, Ahn S H, Han K H, Matsuura K, Tanaka Y, Kurosaki M, 
Asahina Y, Izumi N, Kang J H, Hige S, Ide T, Yamamoto K, Sakaida I, Murawaki Y, 
Itoh Y, Tamori A, Orito E, Hiasa Y, Honda M, Kaneko S, Mita E, Suzuki K, Hino K, 
Tanaka E, Mochida S, Watanabe M, Eguchi Y, Masaki N, Murata K, Korenaga M, 
Mawatari Y, Ohashi J, Kawashima M, Tokunaga K, and Mizokami M (2014) New 
susceptibility and resistance HLA-DP alleles to HBV-related diseases identified by a 
trans-ethnic association study in Asia. PLoS.One. 9: e86449. 
Nishida N, Sawai H, Matsuura K, Sugiyama M, Ahn S H, Park J Y, Hige S, Kang J 
H, Suzuki K, Kurosaki M, Asahina Y, Mochida S, Watanabe M, Tanaka E, Honda M, 
Kaneko S, Orito E, Itoh Y, Mita E, Tamori A, Murawaki Y, Hiasa Y, Sakaida I, 
Korenaga M, Hino K, Ide T, Kawashima M, Mawatari Y, Sageshima M, Ogasawara 
Y, Koike A, Izumi N, Han K H, Tanaka Y, Tokunaga K, and Mizokami M (2012) 
Genome-wide association study confirming association of HLA-DP with protection 
against chronic hepatitis B and viral clearance in Japanese and Korean. PLoS.One. 
7: e39175. 
Niwa Y, Kanda H, Shikauchi Y, Saiura A, Matsubara K, Kitagawa T, Yamamoto J, 
Kubo T, and Yoshikawa H (2005) Methylation silencing of SOCS-3 promotes cell 
growth and migration by enhancing JAK/STAT and FAK signalings in human 
hepatocellular carcinoma. Oncogene 24: 6406-6417. 
Okumura A, Lu G, Pitha-Rowe I, and Pitha P M (2006) Innate antiviral response 
targets HIV-1 release by the induction of ubiquitin-like protein ISG15. Proc. Natl. 
Acad. Sci. U. S. A 103: 1440-1445. 
Okumura A, Pitha P M, and Harty R N (2008) ISG15 inhibits Ebola VP40 VLP 
budding in an L-domain-dependent manner by blocking Nedd4 ligase activity. Proc. 
Natl. Acad. Sci. U. S. A 105: 3974-3979. 
Oliviero B, Cerino A, Varchetta S, Paudice E, Pai S, Ludovisi S, Zaramella M, 
Michelone G, Pugnale P, Negro F, Barnaba V, and Mondelli M U (2011) Enhanced 
B-cell differentiation and reduced proliferative capacity in chronic hepatitis C and 
chronic hepatitis B virus infections. J.Hepatol. 55: 53-60. 
Ott J J, Stevens G A, Groeger J, and Wiersma S T (2012) Global epidemiology of 
hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and 
endemicity. Vaccine 30: 2212-2219. 
 100 
 
Ozen C, Yildiz G, Dagcan A T, Cevik D, Ors A, Keles U, Topel H, and Ozturk M 
(2013) Genetics and epigenetics of liver cancer. N.Biotechnol. 30: 381-384. 
Parvez M K, and Al-Dosari M S (2015) Evidence of MAPK-JNK1/2 activation by 
hepatitis E virus ORF3 protein in cultured hepatoma cells. Cytotechnology 67: 545-
550. 
Peng G, Li S, Wu W, Sun Z, Chen Y, and Chen Z (2008) Circulating CD4+ CD25+ 
regulatory T cells correlate with chronic hepatitis B infection. Immunology 123: 57-
65. 
Persico M, Capasso M, Persico E, Svelto M, Russo R, Spano D, Croce L, La M, V, 
Moschella F, Masutti F, Torella R, Tiribelli C, and Iolascon A (2007) Suppressor of 
cytokine signaling 3 (SOCS3) expression and hepatitis C virus-related chronic 
hepatitis: Insulin resistance and response to antiviral therapy. Hepatology 46: 1009-
1015. 
Persico M, Capasso M, Russo R, Persico E, Croce L, Tiribelli C, and Iolascon A 
(2008) Elevated expression and polymorphisms of SOCS3 influence patient 
response to antiviral therapy in chronic hepatitis C. Gut 57: 507-515. 
Petersen J, Dandri M, Mier W, Lutgehetmann M, Volz T, von W F, Haberkorn U, 
Fischer L, Pollok J M, Erbes B, Seitz S, and Urban S (2008) Prevention of hepatitis 
B virus infection in vivo by entry inhibitors derived from the large envelope protein. 
Nat.Biotechnol. 26: 335-341. 
Petrovic T, Lupulovic D, Jimenez de O N, Vojvodic S, Blazquez A B, Escribano-
Romero E, Martin-Acebes M A, Potkonjak A, Milosevic V, Lazic S, and Saiz J C 
(2014) Prevalence of hepatitis E virus (HEV) antibodies in Serbian blood donors. J 
Infect. Dev. Ctries 8: 1322-1327. 
Phillips S, Chokshi S, Riva A, Evans A, Williams R, and Naoumov N V (2010) CD8(+) 
T cell control of hepatitis B virus replication: direct comparison between cytolytic and 
noncytolytic functions. J.Immunol. 184: 287-295. 
Pischke S, Hardtke S, Bode U, Birkner S, Chatzikyrkou C, Kauffmann W, Bara C L, 
Gottlieb J, Wenzel J, Manns M P, and Wedemeyer H (2013) Ribavirin treatment of 
acute and chronic hepatitis E: a single-centre experience. Liver Int 33: 722-726. 
Pischke S, Stiefel P, Franz B, Bremer B, Suneetha P V, Heim A, Ganzenmueller T, 
Schlue J, Horn-Wichmann R, Raupach R, Darnedde M, Scheibner Y, Taubert R, 
Haverich A, Manns M P, Wedemeyer H, and Bara C L (2012) Chronic hepatitis e in 
heart transplant recipients. Am J Transplant 12: 3128-3133. 
Pittaras T, Valsami S, Mavrouli M, Kapsimali V, Tsakris A, and Politou M (2014) 
Seroprevalence of hepatitis E virus in blood donors in Greece. Vox Sang. 
 101 
 
Platanias L C (2005) Mechanisms of type-I- and type-II-interferon-mediated 
signalling. Nat.Rev.Immunol. 5: 375-386. 
Qiu X, Hong Y, Yang D, Xia M, Zhu H, Li Q, Xie H, Wu Q, Liu C, and Zuo C (2015) 
ISG15 as a novel prognostic biomarker for hepatitis B virus-related hepatocellular 
carcinoma. Int. J. Clin. Exp. Med 8: 17140-17150. 
Rajbhandari R, Jun T, Khalili H, Chung R T, and Ananthakrishnan A N (2016) 
HBV/HIV coinfection is associated with poorer outcomes in hospitalized patients with 
HBV or HIV. J Viral Hepat 23: 820-829. 
Rakyan V K, Down T A, Balding D J, and Beck S (2011) Epigenome-wide association 
studies for common human diseases. Nat.Rev.Genet. 12: 529-541. 
Rehermann B, and Nascimbeni M (2005) Immunology of hepatitis B virus and 
hepatitis C virus infection. Nat.Rev.Immunol. 5: 215-229. 
Ren F, Zhao C, Wang L, Wang Z, Gong X, Song M, Zhuang H, Huang Y, Shan H, 
Wang J, Liu Q, Ness P, Nelson K E, and Wang Y (2013) Hepatitis E virus 
seroprevalence and molecular study among blood donors in China. Transfusion. 
Ren F, Zhao C, Wang L, Wang Z, Gong X, Song M, Zhuang H, Huang Y, Shan H, 
Wang J, Liu Q, Ness P, Nelson K E, and Wang Y (2014) Hepatitis E virus 
seroprevalence and molecular study among blood donors in China. Transfusion 54: 
910-917. 
Robek M D, Boyd B S, Wieland S F, and Chisari F V (2004) Signal transduction 
pathways that inhibit hepatitis B virus replication. Proc. Natl. Acad. Sci. U. S. A 101: 
1743-1747. 
S.Mauss, T.Berg, J.Rockstroh, C.Sarrazin, and H.Wedemeyer (2015). Hepatitis B. 
In Hepatology - A Clinical Textbook (Flying), pp. 36-49. 
Sadler A J, and Williams B R (2008) Interferon-inducible antiviral effectors. Nat. Rev. 
Immunol 8: 559-568. 
Sarin S K, Kumar M, Lau G K, Abbas Z, Chan H L, Chen C J, Chen D S, Chen H L, 
Chen P J, Chien R N, Dokmeci A K, Gane E, Hou J L, Jafri W, Jia J, Kim J H, Lai C 
L, Lee H C, Lim S G, Liu C J, Locarnini S, Al M M, Mohamed R, Omata M, Park J, 
Piratvisuth T, Sharma B C, Sollano J, Wang F S, Wei L, Yuen M F, Zheng S S, and 
Kao J H (2016) Asian-Pacific clinical practice guidelines on the management of 
hepatitis B: a 2015 update. Hepatol.Int. 10: 1-98. 
Satake H, Tamura K, Furihata M, Anchi T, Sakoda H, Kawada C, Iiyama T, Ashida 
S, and Shuin T (2010) The ubiquitin-like molecule interferon-stimulated gene 15 is 
overexpressed in human prostate cancer. Oncol. Rep 23: 11-16. 
 102 
 
Scagnolari C, Monteleone K, Selvaggi C, Pierangeli A, D'Ettorre G, Mezzaroma I, 
Turriziani O, Gentile M, Vullo V, and Antonelli G (2016) ISG15 expression correlates 
with HIV-1 viral load and with factors regulating T cell response. Immunobiology 221: 
282-290. 
Schaefer S (2007) Hepatitis B virus taxonomy and hepatitis B virus genotypes. World 
J.Gastroenterol. 13: 14-21. 
Schuch A, Hoh A, and Thimme R (2014) The role of natural killer cells and CD8(+) 
T cells in hepatitis B virus infection. Front Immunol. 5: 258. 
Schultz U, Grgacic E, and Nassal M (2004) Duck hepatitis B virus: an invaluable 
model system for HBV infection. Adv.Virus Res. 63: 1-70. 
Schulze A, Gripon P, and Urban S (2007) Hepatitis B virus infection initiates with a 
large surface protein-dependent binding to heparan sulfate proteoglycans. 
Hepatology 46: 1759-1768. 
Schweitzer A, Horn J, Mikolajczyk R T, Krause G, and Ott J J (2015) Estimations of 
worldwide prevalence of chronic hepatitis B virus infection: a systematic review of 
data published between 1965 and 2013. Lancet 386: 1546-1555. 
Scobie L, and Dalton H R (2013) Hepatitis E: source and route of infection, clinical 
manifestations and new developments. J Viral Hepat 20: 1-11. 
Shen J, Wang S, Zhang Y J, Kappil M, Wu H C, Kibriya M G, Wang Q, Jasmine F, 
Ahsan H, Lee P H, Yu M W, Chen C J, and Santella R M (2012) Genome-wide DNA 
methylation profiles in hepatocellular carcinoma. Hepatology 55: 1799-1808. 
Sherlock S (1970) Progress report: hepatitis-associated (Australia) antigen. Gut 11: 
185-188. 
Shuai Z, Leung M W, He X, Zhang W, Yang G, Leung P S, and Eric G M (2016) 
Adaptive immunity in the liver. Cell Mol.Immunol. 13: 354-368. 
Skaug B, and Chen Z J (2010) Emerging role of ISG15 in antiviral immunity. Cell 
143: 187-190. 
Smith D B, Simmonds P, International Committee on Taxonomy of Viruses 
Hepeviridae Study G, Jameel S, Emerson S U, Harrison T J, Meng X J, Okamoto H, 
Van der Poel W H, and Purdy M A (2014) Consensus proposals for classification of 
the family Hepeviridae. J Gen Virol 95: 2223-2232. 
Smith D B, Simmonds P, Izopet J, Oliveira-Filho E F, Ulrich R G, Johne R, Koenig 
M, Jameel S, Harrison T J, Meng X J, Okamoto H, Van der Poel W H, and Purdy M 
 103 
 
A (2016) Proposed reference sequences for hepatitis E virus subtypes. J Gen Virol 
97: 537-542. 
Sprengers D, van der Molen R G, Kusters J G, De Man R A, Niesters H G, Schalm 
S W, and Janssen H L (2006) Analysis of intrahepatic HBV-specific cytotoxic T-cells 
during and after acute HBV infection in humans. J.Hepatol. 45: 182-189. 
Sridhar S, Teng J L L, Chiu T H, Lau S K P, and Woo P C Y (2017) Hepatitis E Virus 
Genotypes and Evolution: Emergence of Camel Hepatitis E Variants. Int J Mol Sci 
18. 
Stoop J N, van der Molen R G, Baan C C, van der Laan L J, Kuipers E J, Kusters J 
G, and Janssen H L (2005) Regulatory T cells contribute to the impaired immune 
response in patients with chronic hepatitis B virus infection. Hepatology 41: 771-778. 
Stroffolini T, Gaeta G B, and Mele A (2007) AASLD Practice Guidelines on chronic 
hepatitis B and HBV infection in Italy. Hepatology 46: 608-609. 
Takahashi M, Nishizawa T, Sato H, Sato Y, Jirintai, Nagashima S, and Okamoto H 
(2011) Analysis of the full-length genome of a hepatitis E virus isolate obtained from 
a wild boar in Japan that is classifiable into a novel genotype. J Gen Virol 92: 902-
908. 
Terrault N A, Bzowej N H, Chang K M, Hwang J P, Jonas M M, and Murad M H 
(2016) AASLD guidelines for treatment of chronic hepatitis B. Hepatology 63: 261-
283. 
Teshale E H, Howard C M, Grytdal S P, Handzel T R, Barry V, Kamili S, Drobeniuc 
J, Okware S, Downing R, Tappero J W, Bakamutumaho B, Teo C G, Ward J W, 
Holmberg S D, and Hu D J (2010) Hepatitis E epidemic, Uganda. Emerg Infect Dis 
16: 126-129. 
Thimme R, Wieland S, Steiger C, Ghrayeb J, Reimann K A, Purcell R H, and Chisari 
F V (2003) CD8(+) T cells mediate viral clearance and disease pathogenesis during 
acute hepatitis B virus infection. J.Virol. 77: 68-76. 
Thursz M, Yee L, and Khakoo S (2011) Understanding the host genetics of chronic 
hepatitis B and C. Semin.Liver Dis. 31: 115-127. 
Tischoff I, Hengge U R, Vieth M, Ell C, Stolte M, Weber A, Schmidt W E, and 
Tannapfel A (2007) Methylation of SOCS-3 and SOCS-1 in the carcinogenesis of 
Barrett's adenocarcinoma. Gut 56: 1047-1053. 
Tong H, Bock C T, and Velavan T P (2014a) Genetic insights on host and hepatitis 
B virus in liver diseases. Mutat. Res. Rev. Mutat. Res 762: 65-75. 
 104 
 
Tong H, Bock C T, and Velavan T P (2014b) Genetic insights on host and hepatitis 
B virus in liver diseases. Mutat.Res.Rev.Mutat.Res. 762: 65-75. 
Tong S, and Revill P (2016) Overview of hepatitis B viral replication and genetic 
variability. J.Hepatol. 64: S4-S16. 
Trepo C, Chan H L, and Lok A (2014) Hepatitis B virus infection. Lancet 384: 2053-
2063. 
Um T H, Kim H, Oh B K, Kim M S, Kim K S, Jung G, and Park Y N (2011) Aberrant 
CpG island hypermethylation in dysplastic nodules and early HCC of hepatitis B 
virus-related human multistep hepatocarcinogenesis. J.Hepatol. 54: 939-947. 
van Tong H, Hoan N X, Wang B, Wedemeyer H, Bock C T, and Velavan T P (2016a) 
Hepatitis E Virus Mutations: Functional and Clinical Relevance. EBioMedicine 11: 
31-42. 
van Tong H, Hoan N X, Wang B, Wedemeyer H, Bock C T, and Velavan T P (2016b) 
Hepatitis E Virus Mutations: Functional and Clinical Relevance. EBioMedicine. 
Vidal F, Lopez-Dupla M, Laguno M, Veloso S, Mallolas J, Murillas J, Cifuentes C, 
Gallart L, Auguet T, Samperiz G, Payeras A, Hernandez P, Arnedo M, Gatell J M, 
and Richart C (2012) Pharmacogenetics of efficacy and safety of HCV treatment in 
HCV-HIV coinfected patients: significant associations with IL28B and SOCS3 gene 
variants. PLoS. One 7: e47725. 
Villeneuve J P (2005) The natural history of chronic hepatitis B virus infection. 
J.Clin.Virol. 34 Suppl 1: S139-S142. 
Vollenweider R, and Lennert K (1983) Plasmacytoid T-cell clusters in non-specific 
lymphadenitis. Virchows Arch B Cell Pathol Incl Mol Pathol 44: 1-14. 
Wake M S, and Watson C J (2015) STAT3 the oncogene - still eluding therapy? 
FEBS J. 282: 2600-2611. 
Watashi K, Urban S, Li W, and Wakita T (2014) NTCP and beyond: opening the door 
to unveil hepatitis B virus entry. Int.J.Mol.Sci. 15: 2892-2905. 
Webster G J, Reignat S, Maini M K, Whalley S A, Ogg G S, King A, Brown D, Amlot 
P L, Williams R, Vergani D, Dusheiko G M, and Bertoletti A (2000) Incubation phase 
of acute hepatitis B in man: dynamic of cellular immune mechanisms. Hepatology 
32: 1117-1124. 
Wedemeyer H, and Manns M P (2010) Epidemiology, pathogenesis and 
management of hepatitis D: update and challenges ahead. Nat Rev Gastroenterol 
Hepatol 7: 31-40. 
 105 
 
Wedemeyer H, Pischke S, and Manns M P (2012) Pathogenesis and treatment of 
hepatitis e virus infection. Gastroenterology 142: 1388-1397 e1381. 
Wenzel J J, Preiss J, Schemmerer M, Huber B, Plentz A, and Jilg W (2011) Detection 
of hepatitis E virus (HEV) from porcine livers in Southeastern Germany and high 
sequence homology to human HEV isolates. J Clin Virol 52: 50-54. 
Werneke S W, Schilte C, Rohatgi A, Monte K J, Michault A, Arenzana-Seisdedos F, 
Vanlandingham D L, Higgs S, Fontanet A, Albert M L, and Lenschow D J (2011) 
ISG15 is critical in the control of Chikungunya virus infection independent of UbE1L 
mediated conjugation. PLoS. Pathog 7: e1002322. 
WHO (2001). Introduction of hepatitis B vaccine into childhood immunization 
services: management guidelines, including information for health works and 
parents.  (Geneva). 
WHO (2015). Hepatitis B. 
WHO (2016). Hepatitis E: Fact sheet. 
WHO (2017). Global hepatitis report, 2017. 
Woo P C, Lau S K, Teng J L, Cao K Y, Wernery U, Schountz T, Chiu T H, Tsang A 
K, Wong P C, Wong E Y, and Yuen K Y (2016) New Hepatitis E Virus Genotype in 
Bactrian Camels, Xinjiang, China, 2013. Emerg Infect Dis 22: 2219-2221. 
Wood L M, Pan Z K, Seavey M M, Muthukumaran G, and Paterson Y (2012) The 
ubiquitin-like protein, ISG15, is a novel tumor-associated antigen for cancer 
immunotherapy. Cancer Immunol. Immunother 61: 689-700. 
Wu C H, Ho C M, Tsai J H, Sun H Y, Hu R H, and Lee P H (2017) First Case 
Genotype 4 Hepatitis E Infection After a Liver Transplant. Exp Clin Transplant 15: 
228-230. 
Wu T, Huang S J, Zhu F C, Zhang X F, Ai X, Yan Q, Wang Z Z, Yang C L, Jiang H 
M, Liu X H, Guo M, Du H L, Ng M H, Zhang J, and Xia N S (2013) Immunogenicity 
and safety of hepatitis E vaccine in healthy hepatitis B surface antigen positive 
adults. Hum. Vaccin. Immunother 9: 2474-2479. 
Xu D, Fu J, Jin L, Zhang H, Zhou C, Zou Z, Zhao J M, Zhang B, Shi M, Ding X, Tang 
Z, Fu Y X, and Wang F S (2006) Circulating and liver resident CD4+CD25+ 
regulatory T cells actively influence the antiviral immune response and disease 
progression in patients with hepatitis B. J.Immunol. 177: 739-747. 
Xu X, Shang Q, Chen X, Nie W, Zou Z, Huang A, Meng M, Jin L, Xu R, Zhang J Y, 
Fu J, Wang L, Tang Z, Xie Y, Yang X, Zhang Z, and Wang F S (2015) Reversal of 
 106 
 
B-cell hyperactivation and functional impairment is associated with HBsAg 
seroconversion in chronic hepatitis B patients. Cell Mol.Immunol. 12: 309-316. 
Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z, Huang Y, Qi Y, Peng B, Wang H, Fu 
L, Song M, Chen P, Gao W, Ren B, Sun Y, Cai T, Feng X, Sui J, and Li W (2012) 
Sodium taurocholate cotransporting polypeptide is a functional receptor for human 
hepatitis B and D virus. Elife. 1: e00049. 
Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z, Huang Y, Qi Y, Peng B, Wang H, Fu 
L, Song M, Chen P, Gao W, Ren B, Sun Y, Cai T, Feng X, Sui J, and Li W (2014) 
Sodium taurocholate cotransporting polypeptide is a functional receptor for human 
hepatitis B and D virus. Elife. 3. 
Yang P L, Althage A, Chung J, Maier H, Wieland S, Isogawa M, and Chisari F V 
(2010) Immune effectors required for hepatitis B virus clearance. 
Proc.Natl.Acad.Sci.U.S.A 107: 798-802. 
Yang Y, Zheng B, Han Q, Zhang C, Tian Z, and Zhang J (2016) Targeting blockage 
of STAT3 inhibits hepatitis B virus-related hepatocellular carcinoma. Cancer 
Biol.Ther. 17: 449-456. 
Yasukawa H, Ohishi M, Mori H, Murakami M, Chinen T, Aki D, Hanada T, Takeda 
K, Akira S, Hoshijima M, Hirano T, Chien K R, and Yoshimura A (2003) IL-6 induces 
an anti-inflammatory response in the absence of SOCS3 in macrophages. 
Nat.Immunol. 4: 551-556. 
Yong W S, Hsu F M, and Chen P Y (2016) Profiling genome-wide DNA methylation. 
Epigenetics.Chromatin. 9: 26. 
Yoshimura A, Naka T, and Kubo M (2007a) SOCS proteins, cytokine signalling and 
immune regulation. Nat.Rev.Immunol. 7: 454-465. 
Yoshimura A, Naka T, and Kubo M (2007b) SOCS proteins, cytokine signalling and 
immune regulation. Nat. Rev. Immunol 7: 454-465. 
Yoshimura A, Suzuki M, Sakaguchi R, Hanada T, and Yasukawa H (2012) SOCS, 
Inflammation, and Autoimmunity. Front Immunol 3: 20. 
Yu H, Kortylewski M, and Pardoll D (2007) Crosstalk between cancer and immune 
cells: role of STAT3 in the tumour microenvironment. Nat.Rev.Immunol. 7: 41-51. 
Yu H, Pardoll D, and Jove R (2009) STATs in cancer inflammation and immunity: a 
leading role for STAT3. Nat.Rev.Cancer 9: 798-809. 
Zacharakis G, Koskinas J, Kotsiou S, Tzara F, Vafeiadis N, Papoutselis M, Maltezos 
E, Sivridis E, and Papoutselis K (2008) The role of serial measurement of serum 
 107 
 
HBV DNA levels in patients with chronic HBeAg(-) hepatitis B infection: association 
with liver disease progression. A prospective cohort study. J. Hepatol 49: 884-891. 
Zhang J, Shih J W, and Xia N S (2015a) Long-term efficacy of a hepatitis E vaccine. 
N Engl J Med 372: 2265-2266. 
Zhang X, You Q, Zhang X, and Chen X (2015b) SOCS3 Methylation Predicts a Poor 
Prognosis in HBV Infection-Related Hepatocellular Carcinoma. Int. J. Mol. Sci 16: 
22662-22675. 
Zhao Y, Xue F, Sun J, Guo S, Zhang H, Qiu B, Geng J, Gu J, Zhou X, Wang W, 
Zhang Z, Tang N, He Y, Yu J, and Xia Q (2014) Genome-wide methylation profiling 
of the different stages of hepatitis B virus-related hepatocellular carcinoma 
development in plasma cell-free DNA reveals potential biomarkers for early detection 
and high-risk monitoring of hepatocellular carcinoma. Clin.Epigenetics. 6: 30. 
Zheng Y Y, Wang L F, Fan X H, Wu C H, Huo N, Lu H Y, Xu X Y, and Wei L (2013) 
Association of suppressor of cytokine signalling 3 polymorphisms with insulin 
resistance in patients with chronic hepatitis C. J. Viral Hepat 20: 273-280. 
Zhong S, Tang M W, Yeo W, Liu C, Lo Y M, and Johnson P J (2002) Silencing of 
GSTP1 gene by CpG island DNA hypermethylation in HBV-associated 












7. DECLARATION OF CONTRIBUTIONS  
We hereby declare that the doctoral dissertation entitled “Hepatitis E virus 
superinfection and human SOCS3 and ISG15 in hepatitis B-related liver 
diseases” submitted to the members of the PhD Board at the Faculty of Medicine, 
University of Tuebingen is a record of an original work done by Dr. Xuan Hoan 
Nghiem and co-authors at the Institute of Tropical Medicine, University of Tuebingen.  
Three publications (Publication 1: EBioMedicine. 2015 Nov 11;2(12):2080-6. PMID: 
26844288; Publication 2: Oncotarget. 2017 Mar 7;8(10):17127-17139. PMID: 
28179578; Publication 3: Oncotarget. 2016 Oct 18;7(42):67777-67787. PMID: 
27626177) accomplished by Dr. Xuan Hoan Nghiem as the first author lay as the 
backbone of his doctoral dissertation. We declare that Dr. Xuan Hoan Nghiem have 
substantially contributed to all three manuscripts with respect to study design, 
sampling procedures, patient’s recruitment, experimental design, data analyses and 
writing of the manuscript. We also state individually the contribution of of all the co-
authors in each study as following, 
Contributions of PhD candidate and other co-authors 
Publication 1: Nghiem Xuan Hoan, Hoang Van Tong, Nicole Hecht, Bui Tien Sy, 
and Patrick Marcinek contributed to performing of the experiments. Le Huu Song, 
Nguyen Linh Toan, Peter G Kremsner, C- Thomas Bock and Thirumalaisamy P 
Velavan contributed to materials and reagents. C- Thomas Bock and 
Thirumalaisamy P Velavan designed the study. Nghiem Xuan Hoan, Le Huu Song 
and Nguyen Linh Toan recruited patients and collected samples. Nghiem Xuan Hoan 
and Hoang Van Tong performed statistical analyses. Nghiem Xuan Hoan, Hoang 
Van Tong, C- Thomas Bock and Thirumalaisamy P Velavan wrote the manuscript. 
Christian G Meyer and Jens Kurreck contributed to the revision. 
Publication 2: Nghiem Xuan Hoan, Hoang Van Tong, C- Thomas Bock, Heiner 
Wedemeyer and Thirumalaisamy P Velavan designed the study and wrote the 
 109 
 
manuscript.  Nghiem Xuan Hoan, Hoang Van Tong, and Dao Phuong Giang 
performed the experiments. Nghiem Xuan Hoan and Hoang Van Tong performed 
the statistical analyses and interpreted data. Nghiem Xuan Hoan, Le Huu Song and 
Nguyen Linh Toan, Bui Khac Cuong recruited patients and collected samples. Peter 
G Kremsner and Thirumalaisamy P Velavan contributed to materials and reagents.  
Publication 3: Nghiem Xuan Hoan, Hoang Van Tong, C- Thomas Bock, and 
Thirumalaisamy P Velavan designed the study. Nghiem Xuan Hoan, Hoang Van 
Tong and Dao Phuong Giang performed the experiments. Nghiem Xuan Hoan, 
Hoang Van Tong, Christian G Meyer and Thirumalaisamy P Velavan performed the 
statistical analyses and interpreted the data. Nghiem Xuan Hoan, Dao Phuong 
Giang, Le Huu Song and Nguyen Linh Toan are involved in patient recruitment. C- 
Thomas Bock, Peter G Kremsner and Thirumalaisamy P Velavan contributed to 
study materials and consumables. Nghiem Xuan Hoan, Hoang Van Tong, Christian 








First and foremost, I would like to thank Prof. Peter G. Kremsner for giving me an 
opportunity to work at the Institute of Tropical Medicine, University of Tübingen (ITM-
UKT). I am heartily thankful to PD. Dr. Thirumalaisamy P Velavan. He encouraged 
me to improve my scientific skills and helped me to deal with all my research 
problems. I really appreciate you for your continuous support.  Thank you Prof. Dr. 
Le Huu Song and Prof. Dr. Nguyen Linh Toan for recommending me to start my 
doctoral thesis in Tübingen and I am grateful for all your support. A very special 
thanks goes to the doctoral committee members, Prof. Dr. C. Thomas Bock and Prof. 
Dr. Ruben R. Plentz for your valuable time and guidance. A special thanks goes to 
Prof. Dr. Christian Meyer for his constructive criticisms on my manuscripts. My 
sincere thanks go to my colleague Dr. Hoang Van Tong for his valuable suggestions, 
practical advises, and for contributions related to my work. I would like to thank my 
colleague Dr. Patrick Marcinek for all your helps and support during my initial PhD 
life. Furthermore, I thank to all colleagues and staffs, working in the ITM-UKT for 
their assistance offered every time, when needed. It was memorable to work with 
you during my PhD years. I am highly indebted to my beloved wife Dao Phuong 
Giang for her constant forbearance, unconditional support and being there for me 
when needed. My special thanks and all my love go to my dearest family, including 
my parents, my parents-in-law, my older and younger sisters for their understanding, 
fortitude, and taking care my little boys: Nghiem Hoang Minh and Nghiem Quang 
Vinh. I sincerely thank all staffs of the 108 Military Central hospital, Hanoi for your 
continued support. I sincerely apologize to those, whom I might have missed to 
acknowledge here due to space constraint.  
 
 
Xuan Hoan Nghiem  
 111 
 
9. CURRICULUM VITAE 
Personal and contact Information 
Full name:   Xuan Hoan Nghiem 
Date of birth:  May 19th, 1983  
Place of birth:  Hanoi, Vietnam  
Gender:   Male  
Nationality:   Vietnam  
Marital status:  Married and two children 
Language:   English (working knowledge), Vietnamese (native)  
Address:  Eberhard-Karls University, Institute of Tropical Medicine, 
Wilhelmstr. 27 
D- 72074 Tübingen, Germany  
Tel:    0049-7071 2982197 (Office)  
Email:   nghiemxuanhoan@108-icid.com   
 
Education background   
2001-2007:   Hanoi Medical University, Vietnam; Medical Doctor  




2007 - 12/2013:  Medical Doctor in Institute of clinical infectious diseases in Tran 
Hung Dao hospital, Hanoi, Vietnam.  
03/2014 - 03/2015:  Molecular biology trainee in Institute of Tropical Medicine 
                                Eberhard Karls Universität Tübingen, Germany  
04/2015 - to date:    PhD student - Institute of Tropical Medicine - Faculty of 
Medicine Eberhard Karls Universität Tübingen, Germany  
 
Research interests 
▪ Infectious diseases, Viral hepatitis infection, Clinical course, diagnostics, 




Presentations in conference proceedings 
 
1. Nghiem Xuan Hoan, Hoang Van Tong, Dao Phuong Giang, Nguyen Linh Toan, 
Le Huu Song, C.-Thomas Bock, Peter G Kremsner, Thirumalaisamy P Velavan. 
Functional variants and aberrant Methylation in the SOCS3 promoter region 
influence the progression of HBV-related liver diseases. The International Liver 
Congress 51th. 13-17th April 2016 in Barcelona, Spain. (Peer-reviewed, poster 
presentation. Journal of Hepatology). 
 
2. Hoang Van Tong, Nghiem Xuan Hoan, Dao Phuong Giang, Nguyen Linh Toan, 
Le Huu Song, C.-Thomas Bock, Peter G Kremsner, Thirumalaisamy P Velavan. 
Interferon-stimulated gene 15 in HBV infection and progression of HBV-related 
liver diseases. The International Liver Congress 51th. 13-17th April 2016 in 
Barcelona, Spain. (Peer-reviewed, poster presentation. Journal of Hepatology). 
 
3. Nghiem X. Hoan, Hoang Van Tong, Nicole Hecht, Bui Tien Sy, Patrick Marcinek, 
Christian G. Meyer, Le Huu Song, Nguyen Linh Toan, Jens Kurreck, Peter G. 
Kremsner, C-Thomas Bock, Thirumalaisamy P. Velavan. Hepatitis E Virus 
Superinfection and Clinical Progression in Hepatitis B Patients. Grad School Day 
at the Interfaculty Graduate School of Infection Biology and Microbiology (IGIM). 
12th February 2016 in Tuebingen, Germany (Oral Presentation). 
 
4. Hoang V. Tong, Nghiem Xuan Hoan, Adam Clark, Franziska Gerlach, Nguyen 
Linh Toan, Le Huu Song, C.-Thomas Bock, Peter G Kremsner, Thirumalaisamy 
P Velavan. JAK/STAT signaling pathway and susceptibility to hepato]it is B virus 
infection and related liver diseases. The International Liver Congress 50th. 13-
17th April 2016 in Vienna, Austria. (Peer-reviewed, poster presentation. Journal 
of Hepatology). 
 
5. Hoang V. Tong, Le Huu Song, Nghiem Xuan Hoan, Bui Khac Cuong, Bui Tien 
Sy, Ho Anh Son, Do Quyet, Vu Quoc Binh, Peter G Kremsner, Claus Thomas 
Bock, Thirumalaisamy P Velavan and Nguyen Linh Toan. Soluble MICB protein 
levels and platelet counts during hepatitis B virus infection and response to 
hepatocellular carcinoma treatment. HCC Summit. 13-16th February 2014 in 











https://www.ncbi.nlm.nih.gov/pubmed/?term=Hoan+NX   
(*Shared first authors) 
 
1. Sy BT*, Hoan NX*, Tong HV*, Meyer CG, Toan NL, Song LH, Bock CT, Velavan 
TP. Genetic variants of interferon regulatory factor 5 associated with chronic 
hepatitis B infection. World J Gastroenterol 2017; In press 
2. Amorima LM, Tong HV, Hoan NX, Vargas LB, Enilze Maria de Souza Fonseca 
Ribeiroa, Petzl-Erler LM, Angelica B.W. Boldt, Toan NL, Song LH, Velavan TP, 
August DG. KIR-HLA distribution in a Vietnamese population from Hanoi. Human 
Immunology; Accepted 24.11.2017. 
3. Adedoja A, Hoan NX, van Tong H, Adukpo S, Tijani DB, Akanbi AA 2nd, Meyer 
CG, Ojurongbe O, Velavan TP. Differential contribution of interleukin-10 promoter 
variants in malaria and schistosomiasis mono- and co-infections among Nigerian 
children. Trop Med Int Health. 2017 Nov 13.  
4. Nguyen HM, Sy BT, Trung NT, Hoan NX, Wedemeyer H, Velavan TP, Bock CT. 
Prevalence and genotype distribution of hepatitis delta virus among chronic 
hepatitis B carriers in Central Vietnam. PLoS One. 2017 Apr 12;12(4):e0175304. 
5. Hoan NX, Van Tong H, Giang DP, Cuong BK, Toan NL, Wedemeyer H, Bock 
CT, Kremsner PG, Song LH, Velavan TP. SOCS3 promoter variants and 
hypermethylation influence the progression of HBV-related liver diseases. 
Oncotarget. 2017 Mar 7;8(10):17127-17139. 
6. Hoan NX, Khuyen N, Binh MT, Giang DP, Van Tong H, Hoan PQ, Trung NT, Anh 
DT, Toan NL, Meyer CG, Kremsner PG, Velavan TP, Song LH. Vitamin D 
deficiency influences the clinical course of Hepatitis B virus - related liver 
diseases. BMC Infect Dis. 2016 Sep 23;16(1):507. 
7. Hoan NX, Van Tong H, Giang DP, Toan NL, Meyer CG, Bock CT, Kremsner PG, 
Song LH, Velavan TP. Interferon-stimulated gene 15 in hepatitis B-related liver 
diseases. Oncotarget. 2016 Sep 10. doi: 10.18632/oncotarget.11955. 
8. Van Tong H, Hoan NX, Wang B, Wedemeyer H, Bock CT, Velavan TP. Hepatitis 
E Virus Mutations: Functional and Clinical Relevance. EBioMedicine. 2016 
Sep;11:31-42.  
9. Hoan NX, Tong HV, Hecht N, Sy BT, Marcinek P, Meyer CG, Song le H, Toan 
NL, Kurreck J, Kremsner PG, Bock CT, Velavan TP. Hepatitis E Virus 
Superinfection and Clinical Progression in Hepatitis B Patients. EBioMedicine. 
2015 Nov 11;2(12): 2080-6.  
 114 
 
10. Tong HV, Song le H, Hoan NX, Cuong BK, Sy BT, Son HA, Quyet D, Binh VQ, 
Kremsner PG, Bock CT, Velavan TP, Toan NL. Soluble MICB protein levels and 
platelet counts during hepatitis B virus infection and response to hepatocellular 
carcinoma treatment. BMC Infect Dis. 2015 Jan 23;15:25. 
11.  Clark A, Gerlach F, Tong HV, Hoan NX, Song le H, Toan NL, Bock CT, Kremsner 
PG, Velavan TP. A trivial role of STAT4 variant in chronic hepatitis B induced 
hepatocellular carcinoma. Infect Genet Evol. 2013 Aug;18:257-61. 
 
 
